{
  "matching_results": 573322,
  "results": [
    {
      "id": "whP0A780LzRsIyExeVEqvaVLpqapkIPqYGl7LCBhjSePDnM0t6l9xvB9-bScTycM",
      "result_metadata": {
        "score": 21.166258
      },
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar",
            "relevance": 0.33,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AwardWinner"
              ],
              "name": "Jaguar Cars",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Land Rover",
            "relevance": 0.33,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AutomobileCompany",
                "AwardWinner"
              ],
              "name": "Land Rover",
              "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Farnell Guiseley",
            "relevance": 0.33,
            "type": "Company"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0,
            "label": "neutral"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Land Rover",
              "keywords": [
                {
                  "text": "Land Rover"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                }
              ]
            },
            "sentence": "Jaguar to join Land Rover at Farnell Guiseley",
            "action": {
              "verb": {
                "text": "join",
                "tense": "future"
              },
              "text": "to join",
              "normalized": "to join"
            }
          }
        ],
        "concepts": [
          {
            "text": "Land Rover",
            "relevance": 0.939327,
            "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
          },
          {
            "text": "British Leyland",
            "relevance": 0.862212,
            "dbpedia_resource": "http://dbpedia.org/resource/British_Leyland"
          },
          {
            "text": "Jaguar Cars",
            "relevance": 0.851992,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
          },
          {
            "text": "Tata Motors",
            "relevance": 0.814216,
            "dbpedia_resource": "http://dbpedia.org/resource/Tata_Motors"
          },
          {
            "text": "Ford Motor Company",
            "relevance": 0.774161,
            "dbpedia_resource": "http://dbpedia.org/resource/Ford_Motor_Company"
          },
          {
            "text": "Jaguar AJ-V8 engine",
            "relevance": 0.73994,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_AJ-V8_engine"
          },
          {
            "text": "Jaguar Land Rover",
            "relevance": 0.73653,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
          }
        ],
        "categories": [
          {
            "score": 0.997279,
            "label": "/automotive and vehicles/vehicle brands/land rover"
          }
        ],
        "relations": [
          {
            "type": "locatedAt",
            "sentence": "Jaguar to join Land Rover at Farnell Guiseley",
            "score": 0.785462,
            "arguments": [
              {
                "text": "Land Rover",
                "location": [
                  15,
                  25
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "Land Rover"
                  }
                ]
              },
              {
                "text": "Farnell Guiseley",
                "location": [
                  29,
                  45
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "Farnell Guiseley"
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "Land Rover",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.995976,
            "count": 1
          },
          {
            "text": "Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.899735,
            "count": 1
          },
          {
            "text": "Farnell Guiseley",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.461522,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-18T23:45:06Z",
      "url": "https://www.entirelyyorkshire.co.uk/news/finance/leeds/jaguar-to-join-land-rover-at-farnell-guiseley2975",
      "host": "entirelyyorkshire.co.uk",
      "text": "At the time Robert Forrester, Vertu’s chief executive, described the deal as the “most significant moment” since the company’s acquisition of Bristol Street Motors kick-started its growth.",
      "main_image_url": "https://www.entirely.media/NewsImages/guisely-upload-8479-art.jpg",
      "country": "GB",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-17T00:00:00Z",
      "enriched_text": {
        "entities": [
          {
            "count": 2,
            "sentiment": {
              "score": 0.918674,
              "label": "positive"
            },
            "text": "Farnell Land Rover Guiseley",
            "relevance": 0.890359,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0.753957,
              "label": "positive"
            },
            "text": "Farnell Guiseley",
            "relevance": 0.795495,
            "type": "Company"
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0.777304,
              "label": "positive"
            },
            "text": "Land Rover",
            "relevance": 0.714025,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AutomobileCompany",
                "AwardWinner"
              ],
              "name": "Land Rover",
              "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.745512,
              "label": "positive"
            },
            "text": "Jaguar Land Rover",
            "relevance": 0.708623,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Jaguar Land Rover",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
            }
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0.908807,
              "label": "positive"
            },
            "text": "Jaguar",
            "relevance": 0.613112,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AwardWinner"
              ],
              "name": "Jaguar Cars",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Albert Farnell",
            "relevance": 0.436073,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.213349,
              "label": "positive"
            },
            "text": "Guiseley",
            "relevance": 0.326634,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ],
              "name": "Guiseley",
              "dbpedia_resource": "http://dbpedia.org/resource/Guiseley"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Farnell Group",
            "relevance": 0.324879,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.647519,
              "label": "positive"
            },
            "text": "Farnell",
            "relevance": 0.320168,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.68867,
              "label": "positive"
            },
            "text": "Steve Whitaker",
            "relevance": 0.279898,
            "type": "Person"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.667874,
              "label": "positive"
            },
            "text": "Stephen Whitaker",
            "relevance": 0.246975,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Vertu Motors",
            "relevance": 0.235475,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Vertu Motors",
              "dbpedia_resource": "http://dbpedia.org/resource/Vertu_Motors"
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.217948,
              "label": "positive"
            },
            "text": "Head of Business",
            "relevance": 0.213903,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.38102,
              "label": "positive"
            },
            "text": "Vertu",
            "relevance": 0.190565,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Vertu",
              "dbpedia_resource": "http://dbpedia.org/resource/Vertu"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.337939,
              "label": "positive"
            },
            "text": "Mike Simms",
            "relevance": 0.17963,
            "type": "Person",
            "disambiguation": {
              "subtype": [],
              "name": "Mike Simms",
              "dbpedia_resource": "http://dbpedia.org/resource/Mike_Simms"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jatinder Aujla",
            "relevance": 0.178554,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Bradford",
            "relevance": 0.172363,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "AdministrativeDivision",
                "EnglishMetropolitanBorough",
                "City"
              ],
              "name": "City of Bradford",
              "dbpedia_resource": "http://dbpedia.org/resource/City_of_Bradford"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Operations director",
            "relevance": 0.16763,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "General Sales Manager",
            "relevance": 0.165325,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Bristol Street Motors",
            "relevance": 0.163857,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.326219,
              "label": "positive"
            },
            "text": "Ryan Flynn",
            "relevance": 0.16366,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "West Yorkshire",
            "relevance": 0.158603,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.439728,
              "label": "positive"
            },
            "text": "Robert Forrester",
            "relevance": 0.157625,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.38102,
              "label": "positive"
            },
            "text": "chief executive",
            "relevance": 0.14613,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "20 years",
            "relevance": 0.113304,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0.905169,
            "label": "positive"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Land Rover",
              "keywords": [
                {
                  "text": "Land Rover"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                }
              ]
            },
            "sentence": "Jaguar to join Land Rover at Farnell Guiseley",
            "action": {
              "verb": {
                "text": "join",
                "tense": "future"
              },
              "text": "to join",
              "normalized": "to join"
            }
          },
          {
            "subject": {
              "text": "Farnell Land Rover Guiseley",
              "keywords": [
                {
                  "text": "Farnell Land Rover"
                },
                {
                  "text": "Guiseley"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "sentence": " Following a £4 million refurbishment Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand.",
            "object": {
              "text": "its offering",
              "keywords": [
                {
                  "text": "offering"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "expand",
                "tense": "present"
              },
              "text": "is expanding",
              "normalized": "be expand"
            }
          },
          {
            "subject": {
              "text": "The site",
              "keywords": [
                {
                  "text": "site"
                }
              ]
            },
            "sentence": " The site has undergone a significant redevelopment and now features a 10-car showroom, designed to showcase new products, in addition to state-of-the-art servicing technology.",
            "object": {
              "text": "undergone a significant redevelopment",
              "keywords": [
                {
                  "text": "significant redevelopment"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "The site",
              "keywords": [
                {
                  "text": "site"
                }
              ]
            },
            "sentence": " The site has undergone a significant redevelopment and now features a 10-car showroom, designed to showcase new products, in addition to state-of-the-art servicing technology.",
            "object": {
              "text": "a significant redevelopment",
              "keywords": [
                {
                  "text": "significant redevelopment"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "undergo",
                "tense": "past"
              },
              "text": "has undergone",
              "normalized": "have undergo"
            }
          },
          {
            "subject": {
              "text": "The site",
              "keywords": [
                {
                  "text": "site"
                }
              ]
            },
            "sentence": " The site has undergone a significant redevelopment and now features a 10-car showroom, designed to showcase new products, in addition to state-of-the-art servicing technology.",
            "object": {
              "text": "a 10-car showroom, designed to showcase new products, in addition to state-of-the-art servicing technology",
              "keywords": [
                {
                  "text": "state-of-the-art servicing technology"
                },
                {
                  "text": "10-car showroom"
                },
                {
                  "text": "new products"
                },
                {
                  "text": "addition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "feature",
                "tense": "present"
              },
              "text": "features",
              "normalized": "feature"
            }
          },
          {
            "subject": {
              "text": "Operations director Jatinder Aujla",
              "keywords": [
                {
                  "text": "director Jatinder Aujla"
                }
              ],
              "entities": [
                {
                  "type": "JobTitle",
                  "text": "Operations director"
                },
                {
                  "type": "Person",
                  "text": "Jatinder Aujla"
                }
              ]
            },
            "sentence": " Operations director Jatinder Aujla said: “This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "object": {
              "text": "This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand",
              "keywords": [
                {
                  "text": "incredibly exciting time"
                },
                {
                  "text": "Jaguar Land Rover"
                },
                {
                  "text": "Farnell division"
                },
                {
                  "text": "West Yorkshire"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell"
                },
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                },
                {
                  "type": "Location",
                  "text": "West Yorkshire",
                  "disambiguation": {
                    "subtype": [
                      "City"
                    ]
                  }
                },
                {
                  "type": "Company",
                  "text": "Jaguar Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Company"
                    ],
                    "name": "Jaguar Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "say",
                "tense": "past"
              },
              "text": "said",
              "normalized": "say"
            }
          },
          {
            "subject": {
              "text": "the Farnell division",
              "keywords": [
                {
                  "text": "Farnell division"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell"
                }
              ]
            },
            "sentence": " Operations director Jatinder Aujla said: “This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "object": {
              "text": "with Land Rover",
              "keywords": [
                {
                  "text": "Land Rover"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "link",
                "tense": "past"
              },
              "text": "linked",
              "normalized": "link"
            }
          },
          {
            "subject": {
              "text": "The Jaguar Land Rover brands",
              "keywords": [
                {
                  "text": "Jaguar Land Rover"
                },
                {
                  "text": "brands"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Company"
                    ],
                    "name": "Jaguar Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
                  }
                }
              ]
            },
            "sentence": " “The Jaguar Land Rover brands have seen considerable growth over the last few years and epitomise style and luxury and our retail sites reflect this.",
            "object": {
              "text": "seen considerable growth over the last few years and epitomise style and luxury",
              "keywords": [
                {
                  "text": "considerable growth"
                },
                {
                  "text": "epitomise style"
                },
                {
                  "text": "luxury"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "have",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "The Jaguar Land Rover brands",
              "keywords": [
                {
                  "text": "Jaguar Land Rover"
                },
                {
                  "text": "brands"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Company"
                    ],
                    "name": "Jaguar Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
                  }
                }
              ]
            },
            "sentence": " “The Jaguar Land Rover brands have seen considerable growth over the last few years and epitomise style and luxury and our retail sites reflect this.",
            "object": {
              "text": "considerable growth",
              "keywords": [
                {
                  "text": "considerable growth"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "see",
                "tense": "past"
              },
              "text": "have seen",
              "normalized": "have see"
            }
          },
          {
            "subject": {
              "text": "this"
            },
            "sentence": " “The Jaguar Land Rover brands have seen considerable growth over the last few years and epitomise style and luxury and our retail sites reflect this.",
            "object": {
              "text": "epitomise style and luxury and our retail sites",
              "keywords": [
                {
                  "text": "luxury"
                },
                {
                  "text": "epitomise style"
                },
                {
                  "text": "retail sites"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "reflect",
                "tense": "present"
              },
              "text": "reflect",
              "normalized": "reflect"
            }
          },
          {
            "subject": {
              "text": "We"
            },
            "sentence": " We are looking towards future opportunities for further growth and the creation of career opportunities for talented people across many disciplines.",
            "object": {
              "text": "towards future opportunities for further growth and the creation of career opportunities",
              "keywords": [
                {
                  "text": "future opportunities"
                },
                {
                  "text": "career opportunities"
                },
                {
                  "text": "growth"
                },
                {
                  "text": "creation"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "look",
                "tense": "present"
              },
              "text": "are looking",
              "normalized": "be look"
            }
          },
          {
            "subject": {
              "text": "We"
            },
            "sentence": " We are looking towards future opportunities for further growth and the creation of career opportunities for talented people across many disciplines.",
            "object": {
              "text": "people",
              "keywords": [
                {
                  "text": "people"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "talented",
                "tense": "past"
              },
              "text": "talented",
              "normalized": "talented"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " “Bringing Jaguar to Guiseley to sit alongside Land Rover is very rewarding and reflects our confidence in both the brand and the local area.”",
            "object": {
              "text": "to Guiseley",
              "keywords": [
                {
                  "text": "Guiseley"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Bringing",
                "tense": "present"
              },
              "text": "Bringing",
              "normalized": "Bringing"
            }
          },
          {
            "subject": {
              "text": "Bringing Jaguar to Guiseley",
              "keywords": [
                {
                  "text": "Guiseley"
                },
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                },
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "sentence": " “Bringing Jaguar to Guiseley to sit alongside Land Rover is very rewarding and reflects our confidence in both the brand and the local area.”",
            "object": {
              "text": "alongside Land Rover",
              "keywords": [
                {
                  "text": "alongside Land Rover"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "sit",
                "tense": "future"
              },
              "text": "to sit",
              "normalized": "to sit"
            }
          },
          {
            "subject": {
              "text": "Bringing Jaguar to Guiseley to sit alongside Land Rover",
              "keywords": [
                {
                  "text": "alongside Land Rover"
                },
                {
                  "text": "Guiseley"
                },
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                },
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                },
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                }
              ]
            },
            "sentence": " “Bringing Jaguar to Guiseley to sit alongside Land Rover is very rewarding and reflects our confidence in both the brand and the local area.”",
            "object": {
              "text": "very rewarding"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Steve Whitaker",
              "keywords": [
                {
                  "text": "Steve Whitaker"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Steve Whitaker"
                }
              ]
            },
            "sentence": " Steve Whitaker, who is local to the Guiseley area, and has more than 20 years’ experience in the motor retail sector oversees the site.",
            "object": {
              "text": "local to the Guiseley area",
              "keywords": [
                {
                  "text": "Guiseley area"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Guiseley",
                  "disambiguation": {
                    "subtype": [
                      "CityTown",
                      "City"
                    ],
                    "name": "Guiseley",
                    "dbpedia_resource": "http://dbpedia.org/resource/Guiseley"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Steve Whitaker, who is local",
              "keywords": [
                {
                  "text": "Steve Whitaker"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Steve Whitaker"
                }
              ]
            },
            "sentence": " Steve Whitaker, who is local to the Guiseley area, and has more than 20 years’ experience in the motor retail sector oversees the site.",
            "object": {
              "text": "more than 20 years’ experience in the motor retail sector oversees the site",
              "keywords": [
                {
                  "text": "motor retail sector"
                },
                {
                  "text": "experience"
                },
                {
                  "text": "site"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "20 years"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "He",
              "entities": [
                {
                  "type": "Person",
                  "text": "Steve Whitaker"
                }
              ]
            },
            "sentence": " He said: “This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom.",
            "object": {
              "text": "This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom",
              "keywords": [
                {
                  "text": "Farnell Guiseley"
                },
                {
                  "text": "new Jaguar cars"
                },
                {
                  "text": "fantastic endorsement"
                },
                {
                  "text": "redeveloped showroom"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Guiseley"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "say",
                "tense": "past"
              },
              "text": "said",
              "normalized": "say"
            }
          },
          {
            "subject": {
              "text": "It"
            },
            "sentence": " “It will also enable us to showcase a range of electric vehicles from the plug-in Land Rover hybrid to the multiple award-winning Jaguar I-Pace.",
            "object": {
              "text": "us to showcase a range of electric vehicles from the plug-in Land Rover hybrid to the multiple award-winning Jaguar I-Pace",
              "keywords": [
                {
                  "text": "plug-in Land Rover"
                },
                {
                  "text": "multiple award-winning Jaguar"
                },
                {
                  "text": "electric vehicles"
                },
                {
                  "text": "range"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "enable",
                "tense": "future"
              },
              "text": "will also enable",
              "normalized": "will also enable"
            }
          },
          {
            "subject": {
              "text": "I"
            },
            "sentence": " “I am certain that Jaguar customers will enjoy the fantastic facilities, and of course the exemplary customer service they expect from a premium retailer.",
            "object": {
              "text": "certain that Jaguar customers will enjoy the fantastic facilities",
              "keywords": [
                {
                  "text": "Jaguar customers"
                },
                {
                  "text": "fantastic facilities"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "am",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The Farnell Group",
              "keywords": [
                {
                  "text": "Farnell Group"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Group"
                }
              ]
            },
            "sentence": " The Farnell Group was founded in 1882 by Albert Farnell as a shop selling pushbikes.",
            "object": {
              "text": "founded in 1882 by Albert Farnell",
              "keywords": [
                {
                  "text": "Albert Farnell"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Albert Farnell"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "by Albert Farnell",
              "keywords": [
                {
                  "text": "Albert Farnell"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Albert Farnell"
                }
              ]
            },
            "sentence": " The Farnell Group was founded in 1882 by Albert Farnell as a shop selling pushbikes.",
            "object": {
              "text": "The Farnell Group",
              "keywords": [
                {
                  "text": "Farnell Group"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Group"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "found",
                "tense": "past"
              },
              "text": "was founded",
              "normalized": "be found"
            }
          },
          {
            "subject": {
              "text": "He",
              "entities": [
                {
                  "type": "Person",
                  "text": "Albert Farnell"
                }
              ]
            },
            "sentence": " He went on to stock the first motorised Rover pedal cycles and in 1904 built an ancestor of the first Rover car.",
            "object": {
              "text": "the first motorised Rover pedal cycles",
              "keywords": [
                {
                  "text": "Rover pedal cycles"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "stock",
                "tense": "future"
              },
              "text": "to stock",
              "normalized": "to stock"
            }
          },
          {
            "subject": {
              "text": "He",
              "entities": [
                {
                  "type": "Person",
                  "text": "Albert Farnell"
                }
              ]
            },
            "sentence": " He went on to stock the first motorised Rover pedal cycles and in 1904 built an ancestor of the first Rover car.",
            "object": {
              "text": "Rover pedal cycles",
              "keywords": [
                {
                  "text": "Rover pedal cycles"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "motorise",
                "tense": "past"
              },
              "text": "motorised",
              "normalized": "motorise"
            }
          },
          {
            "subject": {
              "text": "The Guiseley site",
              "keywords": [
                {
                  "text": "Guiseley site"
                }
              ]
            },
            "sentence": " The Guiseley site was built in 1984 and the company’s head office relocated from Bradford.",
            "object": {
              "text": "built"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The Guiseley site",
              "keywords": [
                {
                  "text": "Guiseley site"
                }
              ]
            },
            "sentence": " The Guiseley site was built in 1984 and the company’s head office relocated from Bradford.",
            "action": {
              "verb": {
                "text": "build",
                "tense": "past"
              },
              "text": "was built",
              "normalized": "be build"
            }
          },
          {
            "subject": {
              "text": "the company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " The Guiseley site was built in 1984 and the company’s head office relocated from Bradford.",
            "object": {
              "text": "head office relocated from Bradford",
              "keywords": [
                {
                  "text": "Bradford"
                },
                {
                  "text": "head office"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Bradford",
                  "disambiguation": {
                    "subtype": [
                      "AdministrativeDivision",
                      "EnglishMetropolitanBorough",
                      "City"
                    ],
                    "name": "City of Bradford",
                    "dbpedia_resource": "http://dbpedia.org/resource/City_of_Bradford"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "Vertu Motors",
              "keywords": [
                {
                  "text": "Vertu Motors"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Vertu Motors",
                  "disambiguation": {
                    "subtype": [],
                    "name": "Vertu Motors",
                    "dbpedia_resource": "http://dbpedia.org/resource/Vertu_Motors"
                  }
                }
              ]
            },
            "sentence": " Vertu Motors acquired the business in 2013.",
            "object": {
              "text": "the business",
              "keywords": [
                {
                  "text": "business"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "acquire",
                "tense": "past"
              },
              "text": "acquired",
              "normalized": "acquire"
            }
          },
          {
            "subject": {
              "text": "Robert Forrester, Vertu’s chief executive,",
              "keywords": [
                {
                  "text": "Robert Forrester"
                },
                {
                  "text": "Vertu"
                },
                {
                  "text": "chief executive"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Robert Forrester"
                },
                {
                  "type": "Company",
                  "text": "Vertu",
                  "disambiguation": {
                    "subtype": [
                      "Company"
                    ],
                    "name": "Vertu",
                    "dbpedia_resource": "http://dbpedia.org/resource/Vertu"
                  }
                },
                {
                  "type": "JobTitle",
                  "text": "chief executive"
                }
              ]
            },
            "sentence": " At the time Robert Forrester, Vertu’s chief executive, described the deal as the “most significant moment” since the company’s acquisition of Bristol Street Motors kick-started its growth.",
            "object": {
              "text": "the deal",
              "keywords": [
                {
                  "text": "deal"
                }
              ],
              "entities": []
            },
            "action": {
              "verb": {
                "text": "describe",
                "tense": "past"
              },
              "text": "described",
              "normalized": "describe"
            }
          },
          {
            "subject": {
              "text": "the company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " At the time Robert Forrester, Vertu’s chief executive, described the deal as the “most significant moment” since the company’s acquisition of Bristol Street Motors kick-started its growth.",
            "object": {
              "text": "acquisition of Bristol Street Motors kick-started its growth",
              "keywords": [
                {
                  "text": "Bristol Street Motors"
                },
                {
                  "text": "acquisition"
                },
                {
                  "text": "growth"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Bristol Street Motors"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "the company’s acquisition of Bristol Street Motors",
              "keywords": [
                {
                  "text": "Bristol Street Motors"
                },
                {
                  "text": "acquisition"
                },
                {
                  "text": "company"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Bristol Street Motors"
                }
              ]
            },
            "sentence": " At the time Robert Forrester, Vertu’s chief executive, described the deal as the “most significant moment” since the company’s acquisition of Bristol Street Motors kick-started its growth.",
            "object": {
              "text": "its growth",
              "keywords": [
                {
                  "text": "growth"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "kick-started",
                "tense": "past"
              },
              "text": "kick-started",
              "normalized": "kick-started"
            }
          }
        ],
        "concepts": [
          {
            "text": "Land Rover",
            "relevance": 0.967706,
            "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
          },
          {
            "text": "Jaguar Cars",
            "relevance": 0.945319,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
          },
          {
            "text": "Tata Motors",
            "relevance": 0.903547,
            "dbpedia_resource": "http://dbpedia.org/resource/Tata_Motors"
          },
          {
            "text": "Jaguar Land Rover",
            "relevance": 0.71288,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
          },
          {
            "text": "British Leyland",
            "relevance": 0.60416,
            "dbpedia_resource": "http://dbpedia.org/resource/British_Leyland"
          },
          {
            "text": "Ford Motor Company",
            "relevance": 0.596571,
            "dbpedia_resource": "http://dbpedia.org/resource/Ford_Motor_Company"
          },
          {
            "text": "Coventry",
            "relevance": 0.55061,
            "dbpedia_resource": "http://dbpedia.org/resource/Coventry"
          },
          {
            "text": "British Motor Holdings",
            "relevance": 0.514989,
            "dbpedia_resource": "http://dbpedia.org/resource/British_Motor_Holdings"
          },
          {
            "text": "Rover Company",
            "relevance": 0.5084,
            "dbpedia_resource": "http://dbpedia.org/resource/Rover_Company"
          },
          {
            "text": "Jaguar AJ-V8 engine",
            "relevance": 0.49525,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_AJ-V8_engine"
          },
          {
            "text": "Jaguar",
            "relevance": 0.479434,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar"
          },
          {
            "text": "BMW",
            "relevance": 0.470073,
            "dbpedia_resource": "http://dbpedia.org/resource/BMW"
          },
          {
            "text": "Sales",
            "relevance": 0.444047,
            "dbpedia_resource": "http://dbpedia.org/resource/Sales"
          },
          {
            "text": "Land Rover Series",
            "relevance": 0.43871,
            "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover_Series"
          },
          {
            "text": "Motor vehicle manufacturers of the United Kingdom",
            "relevance": 0.436967,
            "dbpedia_resource": "http://dbpedia.org/resource/Motor_vehicle_manufacturers_of_the_United_Kingdom"
          },
          {
            "text": "Customer service",
            "relevance": 0.429804,
            "dbpedia_resource": "http://dbpedia.org/resource/Customer_service"
          },
          {
            "text": "Gaydon",
            "relevance": 0.427765,
            "dbpedia_resource": "http://dbpedia.org/resource/Gaydon"
          },
          {
            "text": "Austin Rover Group",
            "relevance": 0.425836,
            "dbpedia_resource": "http://dbpedia.org/resource/Austin_Rover_Group"
          }
        ],
        "categories": [
          {
            "score": 0.999822,
            "label": "/automotive and vehicles/vehicle brands/land rover"
          }
        ],
        "relations": [
          {
            "type": "locatedAt",
            "sentence": "Jaguar to join Land Rover at Farnell Guiseley 956 VIEWS Following a £4 million refurbishment Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand.",
            "score": 0.559415,
            "arguments": [
              {
                "text": "Farnell Land Rover Guiseley",
                "location": [
                  93,
                  120
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Farnell Land Rover Guiseley"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  178,
                  184
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "\"It will also enable us to showcase a range of electric vehicles from the plug-in Land Rover hybrid to the multiple award-winning Jaguar I-Pace.",
            "score": 0.485233,
            "arguments": [
              {
                "text": "us",
                "location": [
                  1350,
                  1352
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "our"
                  }
                ]
              },
              {
                "text": "vehicles",
                "location": [
                  1385,
                  1393
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "vehicles"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "\"I am certain that Jaguar customers will enjoy the fantastic facilities, and of course the exemplary customer service they expect from a premium retailer.",
            "score": 0.579286,
            "arguments": [
              {
                "text": "customers",
                "location": [
                  1500,
                  1509
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "customers"
                  }
                ]
              },
              {
                "text": "facilities",
                "location": [
                  1535,
                  1545
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "facilities"
                  }
                ]
              }
            ]
          },
          {
            "type": "foundedOn",
            "sentence": "The Farnell Group was founded in 1882 by Albert Farnell as a shop selling pushbikes.",
            "score": 0.670195,
            "arguments": [
              {
                "text": "Farnell Group",
                "location": [
                  1633,
                  1646
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Farnell Group",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "1882",
                "location": [
                  1662,
                  1666
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "1882",
                    "disambiguation": {
                      "subtype": [
                        "Starting"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "The Guiseley site was built in 1984 and the company's head office relocated from Bradford.",
            "score": 0.424842,
            "arguments": [
              {
                "text": "head office",
                "location": [
                  1881,
                  1892
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "head office"
                  }
                ]
              },
              {
                "text": "company",
                "location": [
                  1871,
                  1878
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "retailer"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The Guiseley site was built in 1984 and the company's head office relocated from Bradford.",
            "score": 0.387591,
            "arguments": [
              {
                "text": "head office",
                "location": [
                  1881,
                  1892
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "head office"
                  }
                ]
              },
              {
                "text": "Bradford",
                "location": [
                  1908,
                  1916
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Bradford"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Vertu Motors acquired the business in 2013.",
            "score": 0.909061,
            "arguments": [
              {
                "text": "Vertu Motors",
                "location": [
                  1918,
                  1930
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Vertu Motors"
                  }
                ]
              },
              {
                "text": "acquired",
                "location": [
                  1931,
                  1939
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "Vertu Motors acquired the business in 2013.",
            "score": 0.980871,
            "arguments": [
              {
                "text": "business",
                "location": [
                  1944,
                  1952
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Business",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "acquired",
                "location": [
                  1931,
                  1939
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Vertu Motors acquired the business in 2013.",
            "score": 0.982429,
            "arguments": [
              {
                "text": "2013",
                "location": [
                  1956,
                  1960
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "2013"
                  }
                ]
              },
              {
                "text": "acquired",
                "location": [
                  1931,
                  1939
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.847201,
            "arguments": [
              {
                "text": "Robert Forrester",
                "location": [
                  1974,
                  1990
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Robert Forrester"
                  }
                ]
              },
              {
                "text": "described",
                "location": [
                  2017,
                  2026
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "described"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.630917,
            "arguments": [
              {
                "text": "chief executive",
                "location": [
                  2000,
                  2015
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Robert Forrester"
                  }
                ]
              },
              {
                "text": "Vertu",
                "location": [
                  1992,
                  1997
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Vertu Motors"
                  }
                ]
              }
            ]
          },
          {
            "type": "productOf",
            "sentence": "Jaguar to join Land Rover at Farnell Guiseley 956 VIEWS Following a £4 million refurbishment Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand.",
            "score": 0.706671,
            "arguments": [
              {
                "text": "Jaguar",
                "location": [
                  178,
                  184
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Jaguar"
                  }
                ]
              },
              {
                "text": "its",
                "location": [
                  134,
                  137
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Farnell Guiseley",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.578131,
            "arguments": [
              {
                "text": "company",
                "location": [
                  2079,
                  2086
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "retailer"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2089,
                  2100
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.548967,
            "arguments": [
              {
                "text": "company",
                "location": [
                  2079,
                  2086
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "retailer"
                  }
                ]
              },
              {
                "text": "Bristol Street Motors",
                "location": [
                  2104,
                  2125
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Bristol Street Motors"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.842876,
            "arguments": [
              {
                "text": "Bristol Street Motors",
                "location": [
                  2104,
                  2125
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Bristol Street Motors"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2089,
                  2100
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Photo Caption: L to R: Stephen Whitaker - Head of Business, Mike Simms - General Sales Manager, Ryan Flynn - Service Manager \"This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom\" Stephen Whitaker - Head of Business 956  Discover the best Industry News & Opinion on Entirely RECOMMENDED FOR YOU ON ENTIRELY FINANCE",
            "score": 0.792268,
            "arguments": [
              {
                "text": "Stephen Whitaker - Head",
                "location": [
                  2174,
                  2197
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Stephen Whitaker - Head"
                  }
                ]
              },
              {
                "text": "Business",
                "location": [
                  2201,
                  2209
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Business"
                  }
                ]
              }
            ]
          },
          {
            "type": "colleague",
            "sentence": "Photo Caption: L to R: Stephen Whitaker - Head of Business, Mike Simms - General Sales Manager, Ryan Flynn - Service Manager \"This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom\" Stephen Whitaker - Head of Business 956  Discover the best Industry News & Opinion on Entirely RECOMMENDED FOR YOU ON ENTIRELY FINANCE",
            "score": 0.454396,
            "arguments": [
              {
                "text": "General Sales Manager",
                "location": [
                  2224,
                  2245
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Ryan Flynn"
                  }
                ]
              },
              {
                "text": "Mike Simms",
                "location": [
                  2211,
                  2221
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mike Simms"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Photo Caption: L to R: Stephen Whitaker - Head of Business, Mike Simms - General Sales Manager, Ryan Flynn - Service Manager \"This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom\" Stephen Whitaker - Head of Business 956  Discover the best Industry News & Opinion on Entirely RECOMMENDED FOR YOU ON ENTIRELY FINANCE",
            "score": 0.695947,
            "arguments": [
              {
                "text": "Stephen Whitaker - Head",
                "location": [
                  2395,
                  2418
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Stephen Whitaker - Head"
                  }
                ]
              },
              {
                "text": "Business",
                "location": [
                  2422,
                  2430
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Business",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The site has undergone a significant redevelopment and now features a 10-car showroom, designed to showcase new products, in addition to state-of-the-art servicing technology.",
            "score": 0.368507,
            "arguments": [
              {
                "text": "car",
                "location": [
                  265,
                  268
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "vehicles"
                  }
                ]
              },
              {
                "text": "showroom",
                "location": [
                  269,
                  277
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "showroom"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "He said: \"This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom.",
            "score": 0.68915,
            "arguments": [
              {
                "text": "cars",
                "location": [
                  1282,
                  1286
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "vehicles"
                  }
                ]
              },
              {
                "text": "showroom",
                "location": [
                  1319,
                  1327
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "showroom"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Operations director Jatinder Aujla said: \"This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "score": 0.996507,
            "arguments": [
              {
                "text": "Jatinder Aujla",
                "location": [
                  388,
                  402
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Jatinder Aujla"
                  }
                ]
              },
              {
                "text": "said",
                "location": [
                  403,
                  407
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "said"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "Operations director Jatinder Aujla said: \"This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "score": 0.443698,
            "arguments": [
              {
                "text": "Land Rover",
                "location": [
                  519,
                  529
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Land Rover"
                  }
                ]
              },
              {
                "text": "West Yorkshire",
                "location": [
                  533,
                  547
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "West Yorkshire"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Operations director Jatinder Aujla said: \"This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "score": 0.438926,
            "arguments": [
              {
                "text": "1948",
                "location": [
                  554,
                  558
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "1948"
                  }
                ]
              },
              {
                "text": "Jaguar Land Rover",
                "location": [
                  599,
                  616
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar Land Rover"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "\"Bringing Jaguar to Guiseley to sit alongside Land Rover is very rewarding and reflects our confidence in both the brand and the local area.",
            "score": 0.760847,
            "arguments": [
              {
                "text": "Jaguar",
                "location": [
                  933,
                  939
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar Land Rover"
                  }
                ]
              },
              {
                "text": "Land Rover",
                "location": [
                  969,
                  979
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "Land Rover"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "\" Steve Whitaker, who is local to the Guiseley area, and has more than 20 years' experience in the motor retail sector oversees the site.",
            "score": 0.691594,
            "arguments": [
              {
                "text": "Guiseley",
                "location": [
                  1101,
                  1109
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Farnell Land Rover Guiseley"
                  }
                ]
              },
              {
                "text": "area",
                "location": [
                  1110,
                  1114
                ],
                "entities": [
                  {
                    "type": "Location",
                    "text": "area"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "He said: \"This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom.",
            "score": 0.986434,
            "arguments": [
              {
                "text": "He",
                "location": [
                  1201,
                  1203
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Steve Whitaker"
                  }
                ]
              },
              {
                "text": "said",
                "location": [
                  1204,
                  1208
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "said"
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "Land Rover",
            "sentiment": {
              "score": 0.93874,
              "label": "positive"
            },
            "relevance": 0.736142,
            "count": 3
          },
          {
            "text": "Operations director Jatinder Aujla",
            "sentiment": {
              "score": 0.970823,
              "label": "positive"
            },
            "relevance": 0.713969,
            "count": 1
          },
          {
            "text": "Farnell Guiseley",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.702708,
            "count": 1
          },
          {
            "text": "refurbishment Farnell Land Rover Guiseley",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.631047,
            "count": 1
          },
          {
            "text": "fantastic endorsement of Farnell Guiseley",
            "sentiment": {
              "score": 0.891537,
              "label": "positive"
            },
            "relevance": 0.580962,
            "count": 2
          },
          {
            "text": "time Robert Forrester",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.56765,
            "count": 1
          },
          {
            "text": "prestigious Jaguar brand",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.566762,
            "count": 1
          },
          {
            "text": "West Yorkshire",
            "sentiment": {
              "score": 0.907781,
              "label": "positive"
            },
            "relevance": 0.559851,
            "count": 1
          },
          {
            "text": "local area",
            "sentiment": {
              "score": 0.967059,
              "label": "positive"
            },
            "relevance": 0.556437,
            "count": 1
          },
          {
            "text": "10-car showroom",
            "sentiment": {
              "score": 0.970823,
              "label": "positive"
            },
            "relevance": 0.555656,
            "count": 1
          },
          {
            "text": "significant moment",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.549504,
            "count": 1
          },
          {
            "text": "Jaguar Land Rover brand",
            "sentiment": {
              "score": 0.907781,
              "label": "positive"
            },
            "relevance": 0.54428,
            "count": 1
          },
          {
            "text": "Jaguar",
            "sentiment": {
              "score": 0.833112,
              "label": "positive"
            },
            "relevance": 0.543894,
            "count": 2
          },
          {
            "text": "General Sales Manager",
            "sentiment": {
              "score": 0.99915,
              "label": "positive"
            },
            "relevance": 0.541614,
            "count": 1
          },
          {
            "text": "Photo Caption",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.537009,
            "count": 1
          },
          {
            "text": "new products",
            "sentiment": {
              "score": 0.970823,
              "label": "positive"
            },
            "relevance": 0.535195,
            "count": 1
          },
          {
            "text": "talented people",
            "sentiment": {
              "score": 0.833112,
              "label": "positive"
            },
            "relevance": 0.525461,
            "count": 1
          },
          {
            "text": "Farnell division",
            "sentiment": {
              "score": 0.907781,
              "label": "positive"
            },
            "relevance": 0.523375,
            "count": 1
          },
          {
            "text": "Steve Whitaker",
            "sentiment": {
              "score": 0.967059,
              "label": "positive"
            },
            "relevance": 0.523201,
            "count": 1
          },
          {
            "text": "significant redevelopment",
            "sentiment": {
              "score": 0.970823,
              "label": "positive"
            },
            "relevance": 0.521508,
            "count": 1
          },
          {
            "text": "considerable growth",
            "sentiment": {
              "score": 0.833663,
              "label": "positive"
            },
            "relevance": 0.521175,
            "count": 1
          },
          {
            "text": "Jaguar Land Rover brands",
            "sentiment": {
              "score": 0.907781,
              "label": "positive"
            },
            "relevance": 0.520765,
            "count": 1
          },
          {
            "text": "site",
            "sentiment": {
              "score": 0.548387,
              "label": "positive"
            },
            "relevance": 0.520601,
            "count": 2
          },
          {
            "text": "company’s head office",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.520274,
            "count": 1
          },
          {
            "text": "new Jaguar cars",
            "sentiment": {
              "score": 0.998076,
              "label": "positive"
            },
            "relevance": 0.516444,
            "count": 2
          },
          {
            "text": "showcase",
            "sentiment": {
              "score": 0.984438,
              "label": "positive"
            },
            "relevance": 0.515914,
            "count": 2
          },
          {
            "text": "exemplary customer service",
            "sentiment": {
              "score": 0.990152,
              "label": "positive"
            },
            "relevance": 0.515129,
            "count": 1
          },
          {
            "text": "ancestor of the first Rover car",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514466,
            "count": 1
          },
          {
            "text": "range of electric vehicles",
            "sentiment": {
              "score": 0.996997,
              "label": "positive"
            },
            "relevance": 0.514414,
            "count": 1
          },
          {
            "text": "Vertu Motors",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514308,
            "count": 1
          },
          {
            "text": "Guiseley",
            "sentiment": {
              "score": 0.833112,
              "label": "positive"
            },
            "relevance": 0.511662,
            "count": 1
          },
          {
            "text": "retail sites",
            "sentiment": {
              "score": 0.745242,
              "label": "positive"
            },
            "relevance": 0.510951,
            "count": 1
          },
          {
            "text": "years’ experience",
            "sentiment": {
              "score": 0.548387,
              "label": "positive"
            },
            "relevance": 0.510318,
            "count": 1
          },
          {
            "text": "Mike Simms",
            "sentiment": {
              "score": 0.99915,
              "label": "positive"
            },
            "relevance": 0.510124,
            "count": 1
          },
          {
            "text": "motor retail sector",
            "sentiment": {
              "score": 0.548387,
              "label": "positive"
            },
            "relevance": 0.509962,
            "count": 1
          },
          {
            "text": "business",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.509903,
            "count": 1
          },
          {
            "text": "future opportunities",
            "sentiment": {
              "score": 0.790611,
              "label": "positive"
            },
            "relevance": 0.509123,
            "count": 1
          },
          {
            "text": "plug-in Land Rover hybrid",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.508822,
            "count": 1
          },
          {
            "text": "Jaguar customers",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.508324,
            "count": 1
          },
          {
            "text": "deal",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.508248,
            "count": 1
          },
          {
            "text": "name",
            "sentiment": {
              "score": 0.907781,
              "label": "positive"
            },
            "relevance": 0.508082,
            "count": 1
          },
          {
            "text": "style",
            "sentiment": {
              "score": 0.745242,
              "label": "positive"
            },
            "relevance": 0.506897,
            "count": 1
          },
          {
            "text": "showroom",
            "sentiment": {
              "score": 0.998076,
              "label": "positive"
            },
            "relevance": 0.506582,
            "count": 2
          },
          {
            "text": "award",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.505993,
            "count": 1
          },
          {
            "text": "Stephen Whitaker",
            "sentiment": {
              "score": 0.99915,
              "label": "positive"
            },
            "relevance": 0.505424,
            "count": 2
          },
          {
            "text": "addition",
            "sentiment": {
              "score": 0.970823,
              "label": "positive"
            },
            "relevance": 0.505141,
            "count": 1
          },
          {
            "text": "Farnell Group",
            "sentiment": {
              "score": 0.990152,
              "label": "positive"
            },
            "relevance": 0.504937,
            "count": 1
          },
          {
            "text": "Rover",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.504839,
            "count": 1
          },
          {
            "text": "confidence",
            "sentiment": {
              "score": 0.967059,
              "label": "positive"
            },
            "relevance": 0.504784,
            "count": 1
          },
          {
            "text": "growth",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.504467,
            "count": 1
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "e7ca4baa2956adfcb2d6eb404eefcb7d3699d811",
        "filename": "1563493506593.zip-c5e5e192406d581fde08ceeb58b4504c.xml",
        "file_type": "json"
      },
      "title": "Jaguar to join Land Rover at Farnell Guiseley",
      "forum_title": "Entirely Yorkshire"
    },
    {
      "id": "BOyJFhw3vKUHx2XBFzT246WgXqpBlfqdaLlpKfh7VHo4dKFfNgZ5W1f25RKbdLzP",
      "result_metadata": {
        "score": 20.888536
      },
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Farnell Land Rover Guiseley",
            "relevance": 0.33,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "4m",
            "relevance": 0.33,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0,
            "label": "neutral"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Farnell Land Rover Guiseley",
              "keywords": [
                {
                  "text": "Farnell Land Rover"
                },
                {
                  "text": "Guiseley"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "sentence": "Farnell Land Rover Guiseley adds Jaguar after £4m upgrade",
            "object": {
              "text": "Jaguar after £4m upgrade",
              "keywords": [
                {
                  "text": "Jaguar"
                },
                {
                  "text": "upgrade"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "4m"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "add",
                "tense": "present"
              },
              "text": "adds",
              "normalized": "add"
            }
          }
        ],
        "concepts": [
          {
            "text": "Land Rover",
            "relevance": 0.939327,
            "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
          },
          {
            "text": "British Leyland",
            "relevance": 0.862212,
            "dbpedia_resource": "http://dbpedia.org/resource/British_Leyland"
          },
          {
            "text": "Jaguar Cars",
            "relevance": 0.851992,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
          },
          {
            "text": "Tata Motors",
            "relevance": 0.814216,
            "dbpedia_resource": "http://dbpedia.org/resource/Tata_Motors"
          },
          {
            "text": "Ford Motor Company",
            "relevance": 0.774161,
            "dbpedia_resource": "http://dbpedia.org/resource/Ford_Motor_Company"
          },
          {
            "text": "Jaguar AJ-V8 engine",
            "relevance": 0.73994,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_AJ-V8_engine"
          },
          {
            "text": "Jaguar Land Rover",
            "relevance": 0.73653,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
          }
        ],
        "categories": [
          {
            "score": 0.996964,
            "label": "/automotive and vehicles/vehicle brands/land rover"
          }
        ],
        "relations": [],
        "keywords": [
          {
            "text": "Farnell Land Rover Guiseley",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.999717,
            "count": 1
          },
          {
            "text": "Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.61055,
            "count": 1
          },
          {
            "text": "upgrade",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.01593,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-18T10:30:57Z",
      "url": "https://www.am-online.com/news/dealer-news/2019/07/17/farnell-land-rover-guiseley-adds-jaguar-after-4m-upgrade",
      "host": "am-online.com",
      "text": "Farnell Land Rover Guiseley adds Jaguar after £4m upgrade Farnell Land Rover Guiseley adds Jaguar after £4m upgrade Was this article useful? Click the thumbs up > Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand following a £4 million refurbishment of its showroom facility.",
      "main_image_url": "https://amcdn.blob.core.windows.net/media/1/root/jlr-site-pic_w555_h555.jpg",
      "country": "US",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-18T08:49:00Z",
      "enriched_text": {
        "entities": [
          {
            "count": 5,
            "sentiment": {
              "score": 0.843605,
              "label": "positive"
            },
            "text": "Farnell Land Rover Guiseley",
            "relevance": 0.930967,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.615464,
              "label": "positive"
            },
            "text": "Jaguar Land Rover",
            "relevance": 0.471562,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Jaguar Land Rover",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
            }
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0.787565,
              "label": "positive"
            },
            "text": "Land Rover",
            "relevance": 0.398126,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AutomobileCompany",
                "AwardWinner"
              ],
              "name": "Land Rover",
              "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Albert Farnell",
            "relevance": 0.294425,
            "type": "Person"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.368891,
              "label": "positive"
            },
            "text": "Jaguar",
            "relevance": 0.283304,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AwardWinner"
              ],
              "name": "Jaguar Cars",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.898939,
              "label": "positive"
            },
            "text": "Farnell JLR",
            "relevance": 0.269065,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Farnell Group",
            "relevance": 0.22582,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Farnell",
            "relevance": 0.220315,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0.38102,
              "label": "positive"
            },
            "text": "Tom Sharpe",
            "relevance": 0.179771,
            "type": "Person",
            "disambiguation": {
              "subtype": [],
              "name": "Tom Sharpe",
              "dbpedia_resource": "http://dbpedia.org/resource/Tom_Sharpe"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Vertu Motors",
            "relevance": 0.1737,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Vertu Motors",
              "dbpedia_resource": "http://dbpedia.org/resource/Vertu_Motors"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.376153,
              "label": "negative"
            },
            "text": "Vertu",
            "relevance": 0.14345,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Vertu",
              "dbpedia_resource": "http://dbpedia.org/resource/Vertu"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Bradford",
            "relevance": 0.128317,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "AdministrativeDivision",
                "EnglishMetropolitanBorough",
                "City"
              ],
              "name": "City of Bradford",
              "dbpedia_resource": "http://dbpedia.org/resource/City_of_Bradford"
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "editor",
            "relevance": 0.127861,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Arch Concept",
            "relevance": 0.12781,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "AM",
            "relevance": 0.121926,
            "type": "PrintMedia"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jatinder Aujla",
            "relevance": 0.121643,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.745512,
              "label": "positive"
            },
            "text": "UK",
            "relevance": 0.121435,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "AdministrativeDivision",
                "GovernmentalJurisdiction",
                "Kingdom",
                "MeteorologicalService",
                "Country"
              ],
              "name": "United Kingdom",
              "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.606113,
              "label": "positive"
            },
            "text": "Steve Whitaker",
            "relevance": 0.120263,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "operations director",
            "relevance": 0.110721,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Bristol Street Motors",
            "relevance": 0.110449,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "West Yorkshire",
            "relevance": 0.109349,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.439728,
              "label": "positive"
            },
            "text": "Robert Forrester",
            "relevance": 0.107935,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.38102,
              "label": "positive"
            },
            "text": "chief executive",
            "relevance": 0.100265,
            "type": "JobTitle"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "4m",
            "relevance": 0.077289,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "60%",
            "relevance": 0.077289,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0.859955,
            "label": "positive"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Farnell Land Rover Guiseley",
              "keywords": [
                {
                  "text": "Farnell Land Rover"
                },
                {
                  "text": "Guiseley"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "sentence": "Farnell Land Rover Guiseley adds Jaguar after £4m upgrade Farnell Land Rover Guiseley adds Jaguar after £4m upgrade Was this article useful?",
            "object": {
              "text": "Jaguar after £4m upgrade Farnell Land Rover Guiseley adds Jaguar after £4m upgrade Was this article useful",
              "keywords": [
                {
                  "text": "upgrade Farnell Land"
                },
                {
                  "text": "Rover Guiseley"
                },
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                },
                {
                  "type": "Quantity",
                  "text": "4m"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "add",
                "tense": "present"
              },
              "text": "adds",
              "normalized": "add"
            }
          },
          {
            "subject": {
              "text": "Farnell Land Rover Guiseley",
              "keywords": [
                {
                  "text": "Farnell Land Rover"
                },
                {
                  "text": "Guiseley"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "sentence": " Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand following a £4 million refurbishment of its showroom facility.",
            "object": {
              "text": "its offering",
              "keywords": [
                {
                  "text": "offering"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "expand",
                "tense": "present"
              },
              "text": "is expanding",
              "normalized": "be expand"
            }
          },
          {
            "subject": {
              "text": "Farnell Land Rover Guiseley",
              "keywords": [
                {
                  "text": "Farnell Land Rover"
                },
                {
                  "text": "Guiseley"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "sentence": " Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand following a £4 million refurbishment of its showroom facility.",
            "object": {
              "text": "the prestigious Jaguar brand",
              "keywords": [
                {
                  "text": "prestigious Jaguar brand"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "incorporate",
                "tense": "future"
              },
              "text": "to incorporate",
              "normalized": "to incorporate"
            }
          },
          {
            "subject": {
              "text": "the prestigious Jaguar brand",
              "keywords": [
                {
                  "text": "prestigious Jaguar brand"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand following a £4 million refurbishment of its showroom facility.",
            "object": {
              "text": "a £4 million refurbishment of its showroom facility",
              "keywords": [
                {
                  "text": "showroom facility"
                },
                {
                  "text": "refurbishment"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "follow",
                "tense": "present"
              },
              "text": "following",
              "normalized": "follow"
            }
          },
          {
            "subject": {
              "text": "The Vertu Motors-owned group",
              "keywords": [
                {
                  "text": "Vertu Motors-owned group"
                }
              ]
            },
            "sentence": " The Vertu Motors-owned group’s Bradford Road site now features a 10-car showroom designed under JLR’s Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology.",
            "object": {
              "text": "Bradford Road site now features a 10-car showroom designed under JLR’s Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology",
              "keywords": [
                {
                  "text": "state-of-the-art servicing technology"
                },
                {
                  "text": "Bradford Road site"
                },
                {
                  "text": "Concept corporate identity"
                },
                {
                  "text": "JLR’s Arch"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "a 10-car showroom designed under JLR’s Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology",
              "keywords": [
                {
                  "text": "state-of-the-art servicing technology"
                },
                {
                  "text": "Concept corporate identity"
                },
                {
                  "text": "JLR’s Arch"
                },
                {
                  "text": "10-car showroom"
                }
              ]
            },
            "sentence": " The Vertu Motors-owned group’s Bradford Road site now features a 10-car showroom designed under JLR’s Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology.",
            "object": {
              "text": "The Vertu Motors-owned group’s Bradford Road site",
              "keywords": [
                {
                  "text": "Vertu Motors-owned group"
                },
                {
                  "text": "Bradford Road site"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "feature",
                "tense": "present"
              },
              "text": "features",
              "normalized": "feature"
            }
          },
          {
            "subject": {
              "text": "a 10-car showroom",
              "keywords": [
                {
                  "text": "10-car showroom"
                }
              ]
            },
            "sentence": " The Vertu Motors-owned group’s Bradford Road site now features a 10-car showroom designed under JLR’s Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology.",
            "action": {
              "verb": {
                "text": "design",
                "tense": "past"
              },
              "text": "designed",
              "normalized": "design"
            }
          },
          {
            "subject": {
              "text": "a 10-car showroom",
              "keywords": [
                {
                  "text": "10-car showroom"
                }
              ]
            },
            "sentence": " The Vertu Motors-owned group’s Bradford Road site now features a 10-car showroom designed under JLR’s Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology.",
            "object": {
              "text": "new products",
              "keywords": [
                {
                  "text": "new products"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "showcase",
                "tense": "future"
              },
              "text": "to showcase",
              "normalized": "to showcase"
            }
          },
          {
            "subject": {
              "text": "the new facility now features a Jaguar showroom for the first time",
              "keywords": [
                {
                  "text": "Jaguar showroom"
                },
                {
                  "text": "new facility"
                },
                {
                  "text": "time"
                }
              ]
            },
            "sentence": " Officially unveiled last month, the new facility now features a Jaguar showroom for the first time.",
            "action": {
              "verb": {
                "text": "unveil",
                "tense": "past"
              },
              "text": "unveiled",
              "normalized": "unveil"
            }
          },
          {
            "subject": {
              "text": "the new facility",
              "keywords": [
                {
                  "text": "new facility"
                }
              ]
            },
            "sentence": " Officially unveiled last month, the new facility now features a Jaguar showroom for the first time.",
            "object": {
              "text": "a Jaguar showroom",
              "keywords": [
                {
                  "text": "Jaguar showroom"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "feature",
                "tense": "present"
              },
              "text": "features",
              "normalized": "feature"
            }
          },
          {
            "subject": {
              "text": "Farnell JLR operations director, Jatinder Aujla,",
              "keywords": [
                {
                  "text": "Farnell JLR operations"
                },
                {
                  "text": "Jatinder Aujla"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell JLR"
                },
                {
                  "type": "JobTitle",
                  "text": "operations director"
                },
                {
                  "type": "Person",
                  "text": "Jatinder Aujla"
                }
              ]
            },
            "sentence": " Farnell JLR operations director, Jatinder Aujla, said: “This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "object": {
              "text": "This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand",
              "keywords": [
                {
                  "text": "incredibly exciting time"
                },
                {
                  "text": "Jaguar Land Rover"
                },
                {
                  "text": "Farnell division"
                },
                {
                  "text": "West Yorkshire"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell"
                },
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                },
                {
                  "type": "Location",
                  "text": "West Yorkshire",
                  "disambiguation": {
                    "subtype": [
                      "City"
                    ]
                  }
                },
                {
                  "type": "Company",
                  "text": "Jaguar Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Company"
                    ],
                    "name": "Jaguar Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "say",
                "tense": "past"
              },
              "text": "said",
              "normalized": "say"
            }
          },
          {
            "subject": {
              "text": "the Farnell division",
              "keywords": [
                {
                  "text": "Farnell division"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell"
                }
              ]
            },
            "sentence": " Farnell JLR operations director, Jatinder Aujla, said: “This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "object": {
              "text": "with Land Rover",
              "keywords": [
                {
                  "text": "Land Rover"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "link",
                "tense": "past"
              },
              "text": "linked",
              "normalized": "link"
            }
          },
          {
            "subject": {
              "text": "a name"
            },
            "sentence": " Farnell JLR operations director, Jatinder Aujla, said: “This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "object": {
              "text": "synonymous with the Jaguar Land Rover brand",
              "keywords": [
                {
                  "text": "Jaguar Land Rover"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Company"
                    ],
                    "name": "Jaguar Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "become",
                "tense": "present"
              },
              "text": "becoming",
              "normalized": "become"
            }
          },
          {
            "subject": {
              "text": "The Jaguar Land Rover brands",
              "keywords": [
                {
                  "text": "Jaguar Land Rover"
                },
                {
                  "text": "brands"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Company"
                    ],
                    "name": "Jaguar Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
                  }
                }
              ]
            },
            "sentence": " “The Jaguar Land Rover brands have seen considerable growth over the last few years and epitomise style and luxury and our retail sites reflect this.",
            "object": {
              "text": "seen considerable growth over the last few years and epitomise style and luxury",
              "keywords": [
                {
                  "text": "considerable growth"
                },
                {
                  "text": "epitomise style"
                },
                {
                  "text": "luxury"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "have",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "The Jaguar Land Rover brands",
              "keywords": [
                {
                  "text": "Jaguar Land Rover"
                },
                {
                  "text": "brands"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Company"
                    ],
                    "name": "Jaguar Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
                  }
                }
              ]
            },
            "sentence": " “The Jaguar Land Rover brands have seen considerable growth over the last few years and epitomise style and luxury and our retail sites reflect this.",
            "object": {
              "text": "considerable growth",
              "keywords": [
                {
                  "text": "considerable growth"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "see",
                "tense": "past"
              },
              "text": "have seen",
              "normalized": "have see"
            }
          },
          {
            "subject": {
              "text": "this"
            },
            "sentence": " “The Jaguar Land Rover brands have seen considerable growth over the last few years and epitomise style and luxury and our retail sites reflect this.",
            "object": {
              "text": "epitomise style and luxury and our retail sites",
              "keywords": [
                {
                  "text": "luxury"
                },
                {
                  "text": "epitomise style"
                },
                {
                  "text": "retail sites"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "reflect",
                "tense": "present"
              },
              "text": "reflect",
              "normalized": "reflect"
            }
          },
          {
            "subject": {
              "text": "We"
            },
            "sentence": " “We are looking towards future opportunities for further growth and the creation of career opportunities for talented people across many disciplines.",
            "object": {
              "text": "towards future opportunities for further growth and the creation of career opportunities",
              "keywords": [
                {
                  "text": "future opportunities"
                },
                {
                  "text": "career opportunities"
                },
                {
                  "text": "growth"
                },
                {
                  "text": "creation"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "look",
                "tense": "present"
              },
              "text": "are looking",
              "normalized": "be look"
            }
          },
          {
            "subject": {
              "text": "people",
              "keywords": [
                {
                  "text": "people"
                }
              ]
            },
            "sentence": " “We are looking towards future opportunities for further growth and the creation of career opportunities for talented people across many disciplines.",
            "object": {
              "text": "across many disciplines",
              "keywords": [
                {
                  "text": "disciplines"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "talented",
                "tense": "past"
              },
              "text": "talented",
              "normalized": "talented"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " “Bringing Jaguar to Guiseley to sit alongside Land Rover is very rewarding and reflects our confidence in both the brand and the local area.”",
            "object": {
              "text": "to Guiseley",
              "keywords": [
                {
                  "text": "Guiseley"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Bringing",
                "tense": "present"
              },
              "text": "Bringing",
              "normalized": "Bringing"
            }
          },
          {
            "subject": {
              "text": "Bringing Jaguar to Guiseley",
              "keywords": [
                {
                  "text": "Guiseley"
                },
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "sentence": " “Bringing Jaguar to Guiseley to sit alongside Land Rover is very rewarding and reflects our confidence in both the brand and the local area.”",
            "object": {
              "text": "alongside Land Rover",
              "keywords": [
                {
                  "text": "alongside Land Rover"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "sit",
                "tense": "future"
              },
              "text": "to sit",
              "normalized": "to sit"
            }
          },
          {
            "subject": {
              "text": "Bringing Jaguar to Guiseley to sit alongside Land Rover",
              "keywords": [
                {
                  "text": "alongside Land Rover"
                },
                {
                  "text": "Guiseley"
                },
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                },
                {
                  "type": "Company",
                  "text": "Land Rover",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AutomobileCompany",
                      "AwardWinner"
                    ],
                    "name": "Land Rover",
                    "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
                  }
                }
              ]
            },
            "sentence": " “Bringing Jaguar to Guiseley to sit alongside Land Rover is very rewarding and reflects our confidence in both the brand and the local area.”",
            "object": {
              "text": "very rewarding"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "diector",
              "keywords": [
                {
                  "text": "diector"
                }
              ]
            },
            "sentence": " In March JLR's UK managing diector told AM that the brands' Arch Concept dealer network CI makeover was only 60% complete, despite plans to have the scheme finished by the end of 2018.",
            "object": {
              "text": "the brands' Arch Concept dealer network CI makeover was only 60% complete",
              "keywords": [
                {
                  "text": "network CI makeover"
                },
                {
                  "text": "Arch Concept dealer"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Arch Concept"
                },
                {
                  "type": "Quantity",
                  "text": "60"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "manage",
                "tense": "present"
              },
              "text": "managing",
              "normalized": "manage"
            }
          },
          {
            "subject": {
              "text": "JLR's UK managing diector",
              "keywords": [
                {
                  "text": "UK managing diector"
                },
                {
                  "text": "JLR"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "UK",
                  "disambiguation": {
                    "subtype": [
                      "AdministrativeDivision",
                      "Country",
                      "GovernmentalJurisdiction",
                      "Kingdom",
                      "MeteorologicalService",
                      "Country"
                    ],
                    "name": "United Kingdom",
                    "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"
                  }
                }
              ]
            },
            "sentence": " In March JLR's UK managing diector told AM that the brands' Arch Concept dealer network CI makeover was only 60% complete, despite plans to have the scheme finished by the end of 2018.",
            "object": {
              "text": "CI makeover was only 60% complete, despite plans to have the scheme finished by the end of 2018",
              "keywords": [
                {
                  "text": "CI makeover"
                },
                {
                  "text": "scheme"
                },
                {
                  "text": "plans"
                },
                {
                  "text": "end"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "60"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "tell",
                "tense": "past"
              },
              "text": "told",
              "normalized": "tell"
            }
          },
          {
            "subject": {
              "text": "the brands' Arch Concept dealer network CI makeover",
              "keywords": [
                {
                  "text": "network CI makeover"
                },
                {
                  "text": "Arch Concept dealer"
                },
                {
                  "text": "brands"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Arch Concept"
                }
              ]
            },
            "sentence": " In March JLR's UK managing diector told AM that the brands' Arch Concept dealer network CI makeover was only 60% complete, despite plans to have the scheme finished by the end of 2018.",
            "object": {
              "text": "the scheme finished by the end of 2018",
              "keywords": [
                {
                  "text": "scheme"
                },
                {
                  "text": "end"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "future"
              },
              "text": "to have",
              "normalized": "to have"
            }
          },
          {
            "subject": {
              "text": "the scheme",
              "keywords": [
                {
                  "text": "scheme"
                }
              ]
            },
            "sentence": " In March JLR's UK managing diector told AM that the brands' Arch Concept dealer network CI makeover was only 60% complete, despite plans to have the scheme finished by the end of 2018.",
            "action": {
              "verb": {
                "text": "finish",
                "tense": "past"
              },
              "text": "finished",
              "normalized": "finish"
            }
          },
          {
            "subject": {
              "text": "The new site’s head of business, Steve Whitaker ,",
              "keywords": [
                {
                  "text": "Steve Whitaker"
                },
                {
                  "text": "new site"
                },
                {
                  "text": "head"
                },
                {
                  "text": "business"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Steve Whitaker"
                }
              ]
            },
            "sentence": " The new site’s head of business, Steve Whitaker , said: “This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom.",
            "object": {
              "text": "This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom",
              "keywords": [
                {
                  "text": "Farnell Guiseley"
                },
                {
                  "text": "new Jaguar cars"
                },
                {
                  "text": "fantastic endorsement"
                },
                {
                  "text": "redeveloped showroom"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Land Rover Guiseley"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "say",
                "tense": "past"
              },
              "text": "said",
              "normalized": "say"
            }
          },
          {
            "subject": {
              "text": "us"
            },
            "sentence": " “It will also enable us to showcase a range of electric vehicles from the plug-in Land Rover hybrid to the multiple award-winning Jaguar I-Pace electric vehicle (EV).",
            "object": {
              "text": "a range of electric vehicles",
              "keywords": [
                {
                  "text": "electric vehicles"
                },
                {
                  "text": "range"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "showcase",
                "tense": "future"
              },
              "text": "to showcase",
              "normalized": "to showcase"
            }
          },
          {
            "subject": {
              "text": "I"
            },
            "sentence": " “I am certain that Jaguar customers will enjoy the fantastic facilities, and of course the exemplary customer service they expect from a premium retailer.”",
            "object": {
              "text": "certain that Jaguar customers will enjoy the fantastic facilities",
              "keywords": [
                {
                  "text": "Jaguar customers"
                },
                {
                  "text": "fantastic facilities"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "am",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The Farnell Group",
              "keywords": [
                {
                  "text": "Farnell Group"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Group"
                }
              ]
            },
            "sentence": " The Farnell Group was founded in 1882 by Albert Farnell as a shop selling pushbikes.",
            "object": {
              "text": "founded in 1882 by Albert Farnell",
              "keywords": [
                {
                  "text": "Albert Farnell"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Albert Farnell"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "by Albert Farnell",
              "keywords": [
                {
                  "text": "Albert Farnell"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Albert Farnell"
                }
              ]
            },
            "sentence": " The Farnell Group was founded in 1882 by Albert Farnell as a shop selling pushbikes.",
            "object": {
              "text": "The Farnell Group",
              "keywords": [
                {
                  "text": "Farnell Group"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Farnell Group"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "found",
                "tense": "past"
              },
              "text": "was founded",
              "normalized": "be found"
            }
          },
          {
            "subject": {
              "text": "He",
              "entities": [
                {
                  "type": "Person",
                  "text": "Albert Farnell"
                }
              ]
            },
            "sentence": " He went on to stock the first motorised Rover pedal cycles and in 1904 built an ancestor of the first Rover car.",
            "object": {
              "text": "the first motorised Rover pedal cycles",
              "keywords": [
                {
                  "text": "Rover pedal cycles"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "stock",
                "tense": "future"
              },
              "text": "to stock",
              "normalized": "to stock"
            }
          },
          {
            "subject": {
              "text": "He",
              "entities": [
                {
                  "type": "Person",
                  "text": "Albert Farnell"
                }
              ]
            },
            "sentence": " He went on to stock the first motorised Rover pedal cycles and in 1904 built an ancestor of the first Rover car.",
            "object": {
              "text": "Rover pedal cycles",
              "keywords": [
                {
                  "text": "Rover pedal cycles"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "motorise",
                "tense": "past"
              },
              "text": "motorised",
              "normalized": "motorise"
            }
          },
          {
            "subject": {
              "text": "The Guiseley site",
              "keywords": [
                {
                  "text": "Guiseley site"
                }
              ]
            },
            "sentence": " The Guiseley site was built in 1984 and the company’s head office relocated from Bradford.",
            "object": {
              "text": "built"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The Guiseley site",
              "keywords": [
                {
                  "text": "Guiseley site"
                }
              ]
            },
            "sentence": " The Guiseley site was built in 1984 and the company’s head office relocated from Bradford.",
            "action": {
              "verb": {
                "text": "build",
                "tense": "past"
              },
              "text": "was built",
              "normalized": "be build"
            }
          },
          {
            "subject": {
              "text": "the company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " The Guiseley site was built in 1984 and the company’s head office relocated from Bradford.",
            "object": {
              "text": "head office relocated from Bradford",
              "keywords": [
                {
                  "text": "Bradford"
                },
                {
                  "text": "head office"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Bradford",
                  "disambiguation": {
                    "subtype": [
                      "AdministrativeDivision",
                      "EnglishMetropolitanBorough",
                      "City"
                    ],
                    "name": "City of Bradford",
                    "dbpedia_resource": "http://dbpedia.org/resource/City_of_Bradford"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "Vertu Motors",
              "keywords": [
                {
                  "text": "Vertu Motors"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Vertu Motors",
                  "disambiguation": {
                    "subtype": [],
                    "name": "Vertu Motors",
                    "dbpedia_resource": "http://dbpedia.org/resource/Vertu_Motors"
                  }
                }
              ]
            },
            "sentence": " Vertu Motors acquired the business in 2013.",
            "object": {
              "text": "the business",
              "keywords": [
                {
                  "text": "business"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "acquire",
                "tense": "past"
              },
              "text": "acquired",
              "normalized": "acquire"
            }
          },
          {
            "subject": {
              "text": "Robert Forrester, Vertu’s chief executive,",
              "keywords": [
                {
                  "text": "Robert Forrester"
                },
                {
                  "text": "Vertu"
                },
                {
                  "text": "chief executive"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Robert Forrester"
                },
                {
                  "type": "Company",
                  "text": "Vertu",
                  "disambiguation": {
                    "subtype": [
                      "Company"
                    ],
                    "name": "Vertu",
                    "dbpedia_resource": "http://dbpedia.org/resource/Vertu"
                  }
                },
                {
                  "type": "JobTitle",
                  "text": "chief executive"
                }
              ]
            },
            "sentence": " At the time Robert Forrester, Vertu’s chief executive, described the deal as the “most significant moment” since the company’s acquisition of Bristol Street Motors kick-started its growth.",
            "object": {
              "text": "the deal",
              "keywords": [
                {
                  "text": "deal"
                }
              ],
              "entities": []
            },
            "action": {
              "verb": {
                "text": "describe",
                "tense": "past"
              },
              "text": "described",
              "normalized": "describe"
            }
          },
          {
            "subject": {
              "text": "the company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " At the time Robert Forrester, Vertu’s chief executive, described the deal as the “most significant moment” since the company’s acquisition of Bristol Street Motors kick-started its growth.",
            "object": {
              "text": "acquisition of Bristol Street Motors kick-started its growth",
              "keywords": [
                {
                  "text": "Bristol Street Motors"
                },
                {
                  "text": "acquisition"
                },
                {
                  "text": "growth"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Bristol Street Motors"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "the company’s acquisition of Bristol Street Motors",
              "keywords": [
                {
                  "text": "Bristol Street Motors"
                },
                {
                  "text": "acquisition"
                },
                {
                  "text": "company"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Bristol Street Motors"
                }
              ]
            },
            "sentence": " At the time Robert Forrester, Vertu’s chief executive, described the deal as the “most significant moment” since the company’s acquisition of Bristol Street Motors kick-started its growth.",
            "object": {
              "text": "its growth",
              "keywords": [
                {
                  "text": "growth"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "kick-started",
                "tense": "past"
              },
              "text": "kick-started",
              "normalized": "kick-started"
            }
          },
          {
            "subject": {
              "text": "Tom",
              "keywords": [
                {
                  "text": "Tom"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Tom Sharpe"
                }
              ]
            },
            "sentence": " A multi-award-winning news journalist, Tom is news and features editor brand.",
            "object": {
              "text": "news and features editor brand",
              "keywords": [
                {
                  "text": "features editor brand"
                },
                {
                  "text": "news"
                }
              ],
              "entities": [
                {
                  "type": "JobTitle",
                  "text": "editor"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "he keep abreast of all industry and business news",
              "keywords": [
                {
                  "text": "business news"
                },
                {
                  "text": "industry"
                }
              ]
            },
            "sentence": " His role demands he keep abreast of all industry and business news to provide coverage of the franchised automotive retail sector and the wider automotive industry, while assisting in the management of the magazine’s production and AM events.",
            "object": {
              "text": "to provide coverage of the franchised automotive retail sector and the wider automotive industry",
              "keywords": [
                {
                  "text": "wider automotive industry"
                },
                {
                  "text": "automotive retail sector"
                },
                {
                  "text": "coverage"
                }
              ],
              "entities": []
            },
            "action": {
              "verb": {
                "text": "demand",
                "tense": "present"
              },
              "text": "demands",
              "normalized": "demand"
            }
          },
          {
            "subject": {
              "text": "production and AM events",
              "keywords": [
                {
                  "text": "production"
                },
                {
                  "text": "events"
                }
              ]
            },
            "sentence": " His role demands he keep abreast of all industry and business news to provide coverage of the franchised automotive retail sector and the wider automotive industry, while assisting in the management of the magazine’s production and AM events.",
            "object": {
              "text": "the magazine",
              "keywords": [
                {
                  "text": "magazine"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          }
        ],
        "concepts": [
          {
            "text": "Tata Motors",
            "relevance": 0.984349,
            "dbpedia_resource": "http://dbpedia.org/resource/Tata_Motors"
          },
          {
            "text": "Land Rover",
            "relevance": 0.918111,
            "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover"
          },
          {
            "text": "Jaguar Cars",
            "relevance": 0.896871,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
          },
          {
            "text": "Jaguar Land Rover",
            "relevance": 0.676345,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Land_Rover"
          },
          {
            "text": "Ford Motor Company",
            "relevance": 0.673405,
            "dbpedia_resource": "http://dbpedia.org/resource/Ford_Motor_Company"
          },
          {
            "text": "British Leyland",
            "relevance": 0.573197,
            "dbpedia_resource": "http://dbpedia.org/resource/British_Leyland"
          },
          {
            "text": "Coventry",
            "relevance": 0.522391,
            "dbpedia_resource": "http://dbpedia.org/resource/Coventry"
          },
          {
            "text": "BMW",
            "relevance": 0.522295,
            "dbpedia_resource": "http://dbpedia.org/resource/BMW"
          },
          {
            "text": "British Motor Holdings",
            "relevance": 0.488596,
            "dbpedia_resource": "http://dbpedia.org/resource/British_Motor_Holdings"
          },
          {
            "text": "Rover Company",
            "relevance": 0.482344,
            "dbpedia_resource": "http://dbpedia.org/resource/Rover_Company"
          },
          {
            "text": "Jaguar AJ-V8 engine",
            "relevance": 0.469868,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_AJ-V8_engine"
          },
          {
            "text": "Jaguar",
            "relevance": 0.454863,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar"
          },
          {
            "text": "Land Rover Series",
            "relevance": 0.416226,
            "dbpedia_resource": "http://dbpedia.org/resource/Land_Rover_Series"
          },
          {
            "text": "Motor vehicle manufacturers of the United Kingdom",
            "relevance": 0.414572,
            "dbpedia_resource": "http://dbpedia.org/resource/Motor_vehicle_manufacturers_of_the_United_Kingdom"
          },
          {
            "text": "Gaydon",
            "relevance": 0.405842,
            "dbpedia_resource": "http://dbpedia.org/resource/Gaydon"
          },
          {
            "text": "Austin Rover Group",
            "relevance": 0.404012,
            "dbpedia_resource": "http://dbpedia.org/resource/Austin_Rover_Group"
          }
        ],
        "categories": [
          {
            "score": 0.999679,
            "label": "/automotive and vehicles/vehicle brands/land rover"
          }
        ],
        "relations": [
          {
            "type": "participantIn",
            "sentence": "Click the thumbs up > Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand following a £4 million refurbishment of its showroom facility.",
            "score": 0.655395,
            "arguments": [
              {
                "text": "Farnell Land Rover Guiseley",
                "location": [
                  163,
                  190
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Farnell Land Rover Guiseley"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  248,
                  254
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar Land Rover"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Farnell JLR operations director, Jatinder Aujla, said: \"This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "score": 0.633564,
            "arguments": [
              {
                "text": "Jatinder Aujla",
                "location": [
                  671,
                  685
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Jatinder Aujla"
                  }
                ]
              },
              {
                "text": "said",
                "location": [
                  687,
                  691
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "said"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "Farnell JLR operations director, Jatinder Aujla, said: \"This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "score": 0.814475,
            "arguments": [
              {
                "text": "Farnell",
                "location": [
                  738,
                  745
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Farnell Land Rover Guiseley"
                  }
                ]
              },
              {
                "text": "division",
                "location": [
                  746,
                  754
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "division"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "Farnell JLR operations director, Jatinder Aujla, said: \"This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "score": 0.509607,
            "arguments": [
              {
                "text": "Land Rover",
                "location": [
                  803,
                  813
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "plug-in Land Rover"
                  }
                ]
              },
              {
                "text": "West Yorkshire",
                "location": [
                  817,
                  831
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "West Yorkshire"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Farnell JLR operations director, Jatinder Aujla, said: \"This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "score": 0.441047,
            "arguments": [
              {
                "text": "1948",
                "location": [
                  838,
                  842
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "1948"
                  }
                ]
              },
              {
                "text": "Jaguar Land Rover",
                "location": [
                  883,
                  900
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar Land Rover"
                  }
                ]
              }
            ]
          },
          {
            "type": "participantIn",
            "sentence": "\"Bringing Jaguar to Guiseley to sit alongside Land Rover is very rewarding and reflects our confidence in both the brand and the local area.",
            "score": 0.800249,
            "arguments": [
              {
                "text": "Land Rover",
                "location": [
                  1254,
                  1264
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "plug-in Land Rover"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1218,
                  1224
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar Land Rover"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "\" In March JLR's UK managing diector told AM that the brands' Arch Concept dealer network CI makeover was only 60% complete, despite plans to have the scheme finished by the end of 2018.",
            "score": 0.804153,
            "arguments": [
              {
                "text": "managing",
                "location": [
                  1368,
                  1376
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Steve Whitaker"
                  }
                ]
              },
              {
                "text": "told",
                "location": [
                  1385,
                  1389
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "said"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "\"It will also enable us to showcase a range of electric vehicles from the plug-in Land Rover hybrid to the multiple award-winning Jaguar I-Pace electric vehicle (EV).",
            "score": 0.554817,
            "arguments": [
              {
                "text": "us",
                "location": [
                  1731,
                  1733
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "our"
                  }
                ]
              },
              {
                "text": "vehicles",
                "location": [
                  1766,
                  1774
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "vehicles"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "\"I am certain that Jaguar customers will enjoy the fantastic facilities, and of course the exemplary customer service they expect from a premium retailer.",
            "score": 0.579286,
            "arguments": [
              {
                "text": "customers",
                "location": [
                  1903,
                  1912
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "customers"
                  }
                ]
              },
              {
                "text": "facilities",
                "location": [
                  1938,
                  1948
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "facilities"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "The Guiseley site was built in 1984 and the company's head office relocated from Bradford.",
            "score": 0.424842,
            "arguments": [
              {
                "text": "head office",
                "location": [
                  2285,
                  2296
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "head office"
                  }
                ]
              },
              {
                "text": "company",
                "location": [
                  2275,
                  2282
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "retailer"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The Guiseley site was built in 1984 and the company's head office relocated from Bradford.",
            "score": 0.387591,
            "arguments": [
              {
                "text": "head office",
                "location": [
                  2285,
                  2296
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "head office"
                  }
                ]
              },
              {
                "text": "Bradford",
                "location": [
                  2312,
                  2320
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Bradford"
                  }
                ]
              }
            ]
          },
          {
            "type": "participantIn",
            "sentence": "Click the thumbs up > Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand following a £4 million refurbishment of its showroom facility.",
            "score": 0.782649,
            "arguments": [
              {
                "text": "its",
                "location": [
                  204,
                  207
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "its",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  248,
                  254
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar Land Rover"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Vertu Motors acquired the business in 2013.",
            "score": 0.909061,
            "arguments": [
              {
                "text": "Vertu Motors",
                "location": [
                  2322,
                  2334
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Vertu Motors"
                  }
                ]
              },
              {
                "text": "acquired",
                "location": [
                  2335,
                  2343
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "Vertu Motors acquired the business in 2013.",
            "score": 0.980871,
            "arguments": [
              {
                "text": "business",
                "location": [
                  2348,
                  2356
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "business",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "acquired",
                "location": [
                  2335,
                  2343
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Vertu Motors acquired the business in 2013.",
            "score": 0.982429,
            "arguments": [
              {
                "text": "2013",
                "location": [
                  2360,
                  2364
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "2013"
                  }
                ]
              },
              {
                "text": "acquired",
                "location": [
                  2335,
                  2343
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.847201,
            "arguments": [
              {
                "text": "Robert Forrester",
                "location": [
                  2378,
                  2394
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Robert Forrester"
                  }
                ]
              },
              {
                "text": "described",
                "location": [
                  2421,
                  2430
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "described"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.630917,
            "arguments": [
              {
                "text": "chief executive",
                "location": [
                  2404,
                  2419
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Robert Forrester"
                  }
                ]
              },
              {
                "text": "Vertu",
                "location": [
                  2396,
                  2401
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Vertu Motors"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.578131,
            "arguments": [
              {
                "text": "company",
                "location": [
                  2483,
                  2490
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "retailer"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2493,
                  2504
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.548967,
            "arguments": [
              {
                "text": "company",
                "location": [
                  2483,
                  2490
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "retailer"
                  }
                ]
              },
              {
                "text": "Bristol Street Motors",
                "location": [
                  2508,
                  2529
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Bristol Street Motors"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "At the time Robert Forrester, Vertu's chief executive, described the deal as the \"most significant moment\" since the company's acquisition of Bristol Street Motors kick-started its growth.",
            "score": 0.842876,
            "arguments": [
              {
                "text": "Bristol Street Motors",
                "location": [
                  2508,
                  2529
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Bristol Street Motors"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2493,
                  2504
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "His role demands he keep abreast of all industry and business news to provide coverage of the franchised automotive retail sector and the wider automotive industry, while assisting in the management of the magazine's production and AM events.",
            "score": 0.928494,
            "arguments": [
              {
                "text": "His",
                "location": [
                  2700,
                  2703
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Tom Sharpe Tom Sharpe"
                  }
                ]
              },
              {
                "text": "demands",
                "location": [
                  2709,
                  2716
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "demands"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "His role demands he keep abreast of all industry and business news to provide coverage of the franchised automotive retail sector and the wider automotive industry, while assisting in the management of the magazine's production and AM events.",
            "score": 0.511854,
            "arguments": [
              {
                "text": "he",
                "location": [
                  2717,
                  2719
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Tom Sharpe Tom Sharpe"
                  }
                ]
              },
              {
                "text": "demands",
                "location": [
                  2709,
                  2716
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "demands"
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "Click the thumbs up > Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand following a £4 million refurbishment of its showroom facility.",
            "score": 0.24864,
            "arguments": [
              {
                "text": "its",
                "location": [
                  301,
                  304
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "its"
                  }
                ]
              },
              {
                "text": "showroom",
                "location": [
                  305,
                  313
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "facility"
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "Click the thumbs up > Farnell Land Rover Guiseley is expanding its offering to incorporate the prestigious Jaguar brand following a £4 million refurbishment of its showroom facility.",
            "score": 0.49533,
            "arguments": [
              {
                "text": "its",
                "location": [
                  301,
                  304
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "its"
                  }
                ]
              },
              {
                "text": "facility",
                "location": [
                  314,
                  322
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "facility"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The Vertu Motors-owned group's Bradford Road site now features a 10-car showroom designed under JLR's Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology.",
            "score": 0.434063,
            "arguments": [
              {
                "text": "Vertu Motors",
                "location": [
                  328,
                  340
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Vertu Motors"
                  }
                ]
              },
              {
                "text": "Bradford Road",
                "location": [
                  355,
                  368
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "Bradford Road"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The Vertu Motors-owned group's Bradford Road site now features a 10-car showroom designed under JLR's Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology.",
            "score": 0.311946,
            "arguments": [
              {
                "text": "group",
                "location": [
                  347,
                  352
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Vertu Motors"
                  }
                ]
              },
              {
                "text": "Bradford Road",
                "location": [
                  355,
                  368
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "Bradford Road"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The Vertu Motors-owned group's Bradford Road site now features a 10-car showroom designed under JLR's Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology.",
            "score": 0.57341,
            "arguments": [
              {
                "text": "car",
                "location": [
                  392,
                  395
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "vehicles"
                  }
                ]
              },
              {
                "text": "showroom",
                "location": [
                  396,
                  404
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "facility"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The new site's head of business, Steve Whitaker , said: \"This is a fantastic endorsement of Farnell Guiseley and the new Jaguar cars look amazing in the redeveloped showroom.",
            "score": 0.708695,
            "arguments": [
              {
                "text": "cars",
                "location": [
                  1663,
                  1667
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "vehicles"
                  }
                ]
              },
              {
                "text": "showroom",
                "location": [
                  1700,
                  1708
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "facility"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The Vertu Motors-owned group's Bradford Road site now features a 10-car showroom designed under JLR's Arch Concept corporate identity to showcase new products, in addition to state-of-the-art servicing technology.",
            "score": 0.584464,
            "arguments": [
              {
                "text": "Arch Concept",
                "location": [
                  426,
                  438
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Arch Concept",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "JLR",
                "location": [
                  420,
                  423
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "JLR",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Officially unveiled last month, the new facility now features a Jaguar showroom for the first time.",
            "score": 0.589361,
            "arguments": [
              {
                "text": "last month",
                "location": [
                  558,
                  568
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "last month"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  602,
                  608
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar Land Rover"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "Officially unveiled last month, the new facility now features a Jaguar showroom for the first time.",
            "score": 0.329306,
            "arguments": [
              {
                "text": "Jaguar",
                "location": [
                  602,
                  608
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar Land Rover"
                  }
                ]
              },
              {
                "text": "showroom",
                "location": [
                  609,
                  617
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "facility"
                  }
                ]
              }
            ]
          },
          {
            "type": "colleague",
            "sentence": "Farnell JLR operations director, Jatinder Aujla, said: \"This is an incredibly exciting time for the Farnell division, a name which has been inextricably linked with Land Rover in West Yorkshire since 1948 and is now becoming synonymous with the Jaguar Land Rover brand.",
            "score": 0.549816,
            "arguments": [
              {
                "text": "operations director",
                "location": [
                  650,
                  669
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Jatinder Aujla"
                  }
                ]
              },
              {
                "text": "Farnell JLR",
                "location": [
                  638,
                  649
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Farnell JLR"
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "Farnell Land Rover Guiseley",
            "sentiment": {
              "score": 0.754887,
              "label": "positive"
            },
            "relevance": 0.828944,
            "count": 2
          },
          {
            "text": "upgrade Farnell Land Rover Guiseley",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.671544,
            "count": 1
          },
          {
            "text": "first time",
            "sentiment": {
              "score": 0.871275,
              "label": "positive"
            },
            "relevance": 0.643549,
            "count": 1
          },
          {
            "text": "JLR’s Arch Concept",
            "sentiment": {
              "score": 0.85753,
              "label": "positive"
            },
            "relevance": 0.614848,
            "count": 1
          },
          {
            "text": "features editor",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.590692,
            "count": 1
          },
          {
            "text": "Farnell JLR operations director",
            "sentiment": {
              "score": 0.871275,
              "label": "positive"
            },
            "relevance": 0.584649,
            "count": 1
          },
          {
            "text": "Vertu Motors",
            "sentiment": {
              "score": 0.754887,
              "label": "positive"
            },
            "relevance": 0.583189,
            "count": 2
          },
          {
            "text": "group’s Bradford Road site",
            "sentiment": {
              "score": 0.809239,
              "label": "positive"
            },
            "relevance": 0.578197,
            "count": 1
          },
          {
            "text": "time Robert Forrester",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.573233,
            "count": 1
          },
          {
            "text": "Land Rover",
            "sentiment": {
              "score": 0.839653,
              "label": "positive"
            },
            "relevance": 0.571758,
            "count": 2
          },
          {
            "text": "prestigious Jaguar brand",
            "sentiment": {
              "score": 0.754887,
              "label": "positive"
            },
            "relevance": 0.5646,
            "count": 1
          },
          {
            "text": "Tom Sharpe Tom Sharpe News",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.558329,
            "count": 1
          },
          {
            "text": "new products",
            "sentiment": {
              "score": 0.85753,
              "label": "positive"
            },
            "relevance": 0.552943,
            "count": 1
          },
          {
            "text": "fantastic endorsement of Farnell Guiseley",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.551069,
            "count": 1
          },
          {
            "text": "West Yorkshire",
            "sentiment": {
              "score": 0.867006,
              "label": "positive"
            },
            "relevance": 0.549615,
            "count": 1
          },
          {
            "text": "significant moment",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.549423,
            "count": 1
          },
          {
            "text": "corporate identity",
            "sentiment": {
              "score": 0.85753,
              "label": "positive"
            },
            "relevance": 0.548926,
            "count": 1
          },
          {
            "text": "Jatinder Aujla",
            "sentiment": {
              "score": 0.871275,
              "label": "positive"
            },
            "relevance": 0.545249,
            "count": 1
          },
          {
            "text": "Jaguar",
            "sentiment": {
              "score": 0.810479,
              "label": "positive"
            },
            "relevance": 0.544538,
            "count": 4
          },
          {
            "text": "showroom facility",
            "sentiment": {
              "score": 0.754887,
              "label": "positive"
            },
            "relevance": 0.542791,
            "count": 1
          },
          {
            "text": "Jaguar Land Rover brand",
            "sentiment": {
              "score": 0.867006,
              "label": "positive"
            },
            "relevance": 0.5358,
            "count": 1
          },
          {
            "text": "10-car showroom",
            "sentiment": {
              "score": 0.85753,
              "label": "positive"
            },
            "relevance": 0.534738,
            "count": 1
          },
          {
            "text": "March JLR's UK",
            "sentiment": {
              "score": 0.967059,
              "label": "positive"
            },
            "relevance": 0.529938,
            "count": 1
          },
          {
            "text": "business news",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529046,
            "count": 1
          },
          {
            "text": "electric vehicle",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.526787,
            "count": 1
          },
          {
            "text": "role demands",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.525428,
            "count": 1
          },
          {
            "text": "new site’s head",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.523572,
            "count": 1
          },
          {
            "text": "Steve Whitaker",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.521757,
            "count": 1
          },
          {
            "text": "last month",
            "sentiment": {
              "score": 0.85753,
              "label": "positive"
            },
            "relevance": 0.521012,
            "count": 1
          },
          {
            "text": "Farnell division",
            "sentiment": {
              "score": 0.867006,
              "label": "positive"
            },
            "relevance": 0.520266,
            "count": 1
          },
          {
            "text": "considerable growth",
            "sentiment": {
              "score": 0.867006,
              "label": "positive"
            },
            "relevance": 0.519102,
            "count": 1
          },
          {
            "text": "Jaguar Land Rover brands",
            "sentiment": {
              "score": 0.867006,
              "label": "positive"
            },
            "relevance": 0.518948,
            "count": 1
          },
          {
            "text": "talented people",
            "sentiment": {
              "score": 0.810479,
              "label": "positive"
            },
            "relevance": 0.518816,
            "count": 1
          },
          {
            "text": "plug-in Land Rover hybrid",
            "sentiment": {
              "score": 0.998291,
              "label": "positive"
            },
            "relevance": 0.515231,
            "count": 1
          },
          {
            "text": "company’s head office",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.51519,
            "count": 1
          },
          {
            "text": "range of electric vehicles",
            "sentiment": {
              "score": 0.998291,
              "label": "positive"
            },
            "relevance": 0.514574,
            "count": 1
          },
          {
            "text": "retail sites",
            "sentiment": {
              "score": 0.745242,
              "label": "positive"
            },
            "relevance": 0.514383,
            "count": 1
          },
          {
            "text": "Jaguar showroom",
            "sentiment": {
              "score": 0.871275,
              "label": "positive"
            },
            "relevance": 0.514197,
            "count": 1
          },
          {
            "text": "business",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.513974,
            "count": 2
          },
          {
            "text": "local area",
            "sentiment": {
              "score": 0.967059,
              "label": "positive"
            },
            "relevance": 0.512801,
            "count": 1
          },
          {
            "text": "automotive retail sector",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.511667,
            "count": 1
          },
          {
            "text": "showcase",
            "sentiment": {
              "score": 0.938888,
              "label": "positive"
            },
            "relevance": 0.511206,
            "count": 2
          },
          {
            "text": "award",
            "sentiment": {
              "score": 0.998291,
              "label": "positive"
            },
            "relevance": 0.510321,
            "count": 1
          },
          {
            "text": "industry",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.50917,
            "count": 1
          },
          {
            "text": "Guiseley",
            "sentiment": {
              "score": 0.810479,
              "label": "positive"
            },
            "relevance": 0.508488,
            "count": 1
          },
          {
            "text": "deal",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.50738,
            "count": 1
          },
          {
            "text": "Farnell Group",
            "sentiment": {
              "score": 0.962509,
              "label": "positive"
            },
            "relevance": 0.507313,
            "count": 1
          },
          {
            "text": "name",
            "sentiment": {
              "score": 0.867006,
              "label": "positive"
            },
            "relevance": 0.507146,
            "count": 1
          },
          {
            "text": "Author",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.50645,
            "count": 1
          },
          {
            "text": "new facility",
            "sentiment": {
              "score": 0.85753,
              "label": "positive"
            },
            "relevance": 0.506366,
            "count": 1
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "044715d26b803f3b975a5467ca9d8c4e4986f15b",
        "filename": "1563445857300.zip-6c633c4adc7cd5a2df2655af8bc5cc86.xml",
        "file_type": "json"
      },
      "title": "Farnell Land Rover Guiseley adds Jaguar after £4m upgrade",
      "forum_title": "Latest News news"
    },
    {
      "id": "CrNztgQrxvQl7JJJzdDnw-6nSLyYZGtrXKN-MOYgyDC2jMzSBfHbw_5wsqtaOSUt",
      "result_metadata": {
        "score": 20.51584
      },
      "author": "Accesswire",
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Health Strengthens Company",
            "relevance": 0.33,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 Million",
            "relevance": 0.33,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 Million",
            "relevance": 0.33,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0,
            "label": "neutral"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Jaguar Health Strengthens Company",
              "keywords": [
                {
                  "text": "Health Strengthens Company"
                },
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health Strengthens Company"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company’s Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
            "object": {
              "text": "Balance Sheet",
              "keywords": [
                {
                  "text": "Balance Sheet"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger",
              "keywords": [
                {
                  "text": "Debt Incurred"
                },
                {
                  "text": "Merger"
                },
                {
                  "text": "Effect"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$10.5 Million"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company’s Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
            "object": {
              "text": "to Approximately $4.4 Million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$4.4 Million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Reducing",
                "tense": "present"
              },
              "text": "Reducing",
              "normalized": "Reducing"
            }
          }
        ],
        "concepts": [],
        "categories": [
          {
            "score": 0.983317,
            "label": "/business and industrial/company/merger and acquisition"
          }
        ],
        "relations": [],
        "keywords": [
          {
            "text": "Jaguar Health Strengthens Company’s Balance Sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.744408,
            "count": 1
          },
          {
            "text": "Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.585918,
            "count": 1
          },
          {
            "text": "Effect",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.558755,
            "count": 1
          },
          {
            "text": "Merger",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.548529,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-15T16:34:29Z",
      "url": "http://sproutnews.com/jaguar-health-strengthens-companys-balance-sheet-by-reducing-approximately-10-5-million-of-debt-incurred-to-effect-2017-merger-to-approximately-4-4-million/",
      "host": "sproutnews.com",
      "text": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
      "country": "US",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-15T12:01:00Z",
      "enriched_text": {
        "entities": [
          {
            "count": 7,
            "sentiment": {
              "score": 0.460269,
              "label": "positive"
            },
            "text": "Jaguar",
            "relevance": 0.956317,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AwardWinner"
              ],
              "name": "Jaguar Cars",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
            }
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0.418751,
              "label": "positive"
            },
            "text": "Jaguar Health, Inc.",
            "relevance": 0.686876,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Health Strengthens Company",
            "relevance": 0.603587,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.534748,
              "label": "positive"
            },
            "text": "Jaguar Health",
            "relevance": 0.571676,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo Pharmaceuticals, Inc.",
            "relevance": 0.523984,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Animal Health, Inc.",
            "relevance": 0.462268,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.351542,
              "label": "positive"
            },
            "text": "Jaguar Animal Health",
            "relevance": 0.459785,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo",
            "relevance": 0.318129,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "StateOrCounty"
              ]
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Mytesi",
            "relevance": 0.315253,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Napo",
            "relevance": 0.28826,
            "type": "Organization"
          },
          {
            "count": 2,
            "sentiment": {
              "score": -0.679083,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.281442,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "U.S. Securities and Exchange Commission",
            "relevance": 0.281193,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency",
                "GovernmentalBody"
              ],
              "name": "U.S. Securities and Exchange Commission",
              "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Crofelemer",
            "relevance": 0.266643,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "upper respiratory tract infection",
            "relevance": 0.266291,
            "type": "HealthCondition",
            "disambiguation": {
              "subtype": [
                "DiseaseOrMedicalCondition",
                "RiskFactor",
                "Symptom"
              ],
              "name": "Upper respiratory tract infection",
              "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Chicago Venture Partners L.P.",
            "relevance": 0.265151,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "SAN FRANCISCO",
            "relevance": 0.260424,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.353209,
              "label": "negative"
            },
            "text": "FDA",
            "relevance": 0.257525,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency"
              ],
              "name": "Food and Drug Administration",
              "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.553674,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.255538,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "president and chief executive officer",
            "relevance": 0.248776,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Lisa Conte",
            "relevance": 0.234876,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Amazon",
            "relevance": 0.20913,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.1%",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 Million",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 million",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$2.3 million",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 Million",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 million",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$6.4 million",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "one-year",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$5.58",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.5%",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.9%",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "5.7%",
            "relevance": 0.20913,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "8-K",
            "relevance": 0.20913,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": -0.327931,
            "label": "negative"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Jaguar Health Strengthens Company",
              "keywords": [
                {
                  "text": "Health Strengthens Company"
                },
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health Strengthens Company"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company’s Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
            "object": {
              "text": "Balance Sheet",
              "keywords": [
                {
                  "text": "Balance Sheet"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger",
              "keywords": [
                {
                  "text": "Debt Incurred"
                },
                {
                  "text": "Merger"
                },
                {
                  "text": "Effect"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$10.5 Million"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company’s Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
            "object": {
              "text": "to Approximately $4.4 Million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$4.4 Million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Reducing",
                "tense": "present"
              },
              "text": "Reducing",
              "normalized": "Reducing"
            }
          },
          {
            "subject": {
              "text": "Maturity Date of Remaining Merger-related Debt",
              "keywords": [
                {
                  "text": "Maturity Date"
                },
                {
                  "text": "Merger-related Debt"
                }
              ]
            },
            "sentence": " Maturity Date of Remaining Merger-related Debt is December 31, 2020",
            "object": {
              "text": "December 31"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " The Company accomplished this reduction in indebtedness through the issuance of approximately 1,119,440 shares of common stock, at a weighted average price of approximately $5.58 per share, to Chicago Venture Partners L.P. (“CVP”) pursuant to exchange agreements entered into between the Company and CVP from May 29, 2019 through July 12, 2019.",
            "object": {
              "text": "this reduction",
              "keywords": [
                {
                  "text": "reduction"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "accomplish",
                "tense": "past"
              },
              "text": "accomplished",
              "normalized": "accomplish"
            }
          },
          {
            "subject": {
              "text": "the Merger",
              "keywords": [
                {
                  "text": "Merger"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "effective July 31"
            },
            "action": {
              "verb": {
                "text": "become",
                "tense": "past"
              },
              "text": "became",
              "normalized": "become"
            }
          },
          {
            "subject": {
              "text": "Jaguar Animal Health’s name",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "action": {
              "verb": {
                "text": "change",
                "tense": "past"
              },
              "text": "changed",
              "normalized": "change"
            }
          },
          {
            "subject": {
              "text": "Inc. and Napo Pharmaceuticals, Inc.",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "Inc."
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "operating as a wholly-owned subsidiary of Jaguar focused on human health",
              "keywords": [
                {
                  "text": "wholly-owned subsidiary"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "operating"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "begin",
                "tense": "past"
              },
              "text": "began",
              "normalized": "begin"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer)",
              "keywords": [
                {
                  "text": "follow-on indications"
                },
                {
                  "text": "ongoing commercialization"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "development"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "focus",
                "tense": "past"
              },
              "text": "focused",
              "normalized": "focus"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "FDA-approved drug product",
              "keywords": [
                {
                  "text": "FDA-approved drug product"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "We"
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "Lisa Conte"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                },
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "Lisa Conte"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                },
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "pipeline opportunities",
              "keywords": [
                {
                  "text": "pipeline opportunities"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "pipeline opportunities, which include our commercial product, Mytesi,",
              "keywords": [
                {
                  "text": "pipeline opportunities"
                },
                {
                  "text": "commercial product"
                },
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "into the specialty market",
              "keywords": [
                {
                  "text": "specialty market"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "launch",
                "tense": "past"
              },
              "text": "launched",
              "normalized": "launch"
            }
          },
          {
            "subject": {
              "text": "Lisa Conte, president and chief executive officer of Jaguar,",
              "keywords": [
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "Lisa Conte"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "president"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "deep pipeline"
                },
                {
                  "text": "pipeline opportunities"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "state",
                "tense": "past"
              },
              "text": "stated",
              "normalized": "state"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31",
              "keywords": [
                {
                  "text": "one-year extension"
                },
                {
                  "text": "Original Debt"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "a one-year extension",
              "keywords": [
                {
                  "text": "one-year extension"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "past"
              },
              "text": "has received",
              "normalized": "have receive"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "previously scheduled to mature on December 31, 2019"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "action": {
              "verb": {
                "text": "schedule",
                "tense": "past"
              },
              "text": "scheduled",
              "normalized": "schedule"
            }
          },
          {
            "subject": {
              "text": "The extension of the maturity date",
              "keywords": [
                {
                  "text": "maturity date"
                },
                {
                  "text": "extension"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "part of a larger restructuring of the Original Debt",
              "keywords": [
                {
                  "text": "larger restructuring"
                },
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "the acquisition of the Original Debt by CVP",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "Original Debt"
                },
                {
                  "text": "acquisition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "follow",
                "tense": "present"
              },
              "text": "following",
              "normalized": "follow"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " As consideration for such restructuring, which included among other things the extension of the maturity date by means of an exchange of the Original Debt for new secured debt with a maturity date of December 31, 2020, Jaguar paid CVP a fee of approximately $2.3 million in the form of additional debt (the “Additional Debt”).",
            "object": {
              "text": "CVP a fee of approximately $2.3 million",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "fee"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$2.3 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "pay",
                "tense": "past"
              },
              "text": "paid",
              "normalized": "pay"
            }
          },
          {
            "subject": {
              "text": "The Additional Debt",
              "keywords": [
                {
                  "text": "Additional Debt"
                }
              ]
            },
            "sentence": " The Additional Debt is not included in the Original Debt.",
            "object": {
              "text": "in the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "past",
                "negated": true
              },
              "text": "included",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "The details of this transaction",
              "keywords": [
                {
                  "text": "transaction"
                },
                {
                  "text": "details"
                }
              ]
            },
            "sentence": " The details of this transaction are further described in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "object": {
              "text": "further described in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019",
              "keywords": [
                {
                  "text": "U.S. Securities"
                },
                {
                  "text": "Current Report"
                },
                {
                  "text": "Form 8-K"
                },
                {
                  "text": "Exchange Commission"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "U.S. Securities and Exchange Commission",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency",
                      "GovernmentalBody"
                    ],
                    "name": "U.S. Securities and Exchange Commission",
                    "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
                  }
                },
                {
                  "type": "Quantity",
                  "text": "8-K"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The details of this transaction",
              "keywords": [
                {
                  "text": "transaction"
                },
                {
                  "text": "details"
                }
              ]
            },
            "sentence": " The details of this transaction are further described in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "object": {
              "text": "in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019",
              "keywords": [
                {
                  "text": "U.S. Securities"
                },
                {
                  "text": "Current Report"
                },
                {
                  "text": "Form 8-K"
                },
                {
                  "text": "Exchange Commission"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "U.S. Securities and Exchange Commission",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency",
                      "GovernmentalBody"
                    ],
                    "name": "U.S. Securities and Exchange Commission",
                    "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
                  }
                },
                {
                  "type": "Quantity",
                  "text": "8-K"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "describe",
                "tense": "past"
              },
              "text": "are further described",
              "normalized": "be further describe"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " The details of this transaction are further described in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "object": {
              "text": "Current Report",
              "keywords": [
                {
                  "text": "Current Report"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "object": {
              "text": "all of the approximately $6.4 million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$6.4 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "extinguish",
                "tense": "past"
              },
              "text": "extinguished",
              "normalized": "extinguish"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "action": {
              "verb": {
                "text": "issue",
                "tense": "past"
              },
              "text": "issued",
              "normalized": "issue"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "a commercial stage pharmaceuticals company focused on developing novel",
              "keywords": [
                {
                  "text": "commercial stage pharmaceuticals"
                },
                {
                  "text": "company"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "novel, sustainably derived gastrointestinal products on a global basis",
              "keywords": [
                {
                  "text": "gastrointestinal products"
                },
                {
                  "text": "global basis"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "develop",
                "tense": "future"
              },
              "text": "developing",
              "normalized": "develop"
            }
          },
          {
            "subject": {
              "text": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc.,",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "wholly-owned subsidiary"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "object": {
              "text": "proprietary human gastrointestinal pharmaceuticals",
              "keywords": [
                {
                  "text": "gastrointestinal pharmaceuticals"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "commercialize",
                "tense": "present"
              },
              "text": "commercializing",
              "normalized": "commercialize"
            }
          },
          {
            "subject": {
              "text": "plants",
              "keywords": [
                {
                  "text": "plants"
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "action": {
              "verb": {
                "text": "use",
                "tense": "past"
              },
              "text": "used",
              "normalized": "use"
            }
          },
          {
            "subject": {
              "text": "Our Mytesi® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi®"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ]
            },
            "sentence": " Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "approved by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "sentence": " Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "Our Mytesi® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi®"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "approve",
                "tense": "past"
              },
              "text": "is approved",
              "normalized": "be approve"
            }
          },
          {
            "subject": {
              "text": "Mytesi (crofelemer)",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "object": {
              "text": "an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea",
              "keywords": [
                {
                  "text": "noninfectious diarrhea"
                },
                {
                  "text": "symptomatic relief"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "not indicated for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "indicate",
                "tense": "past",
                "negated": true
              },
              "text": "indicated",
              "normalized": "indicate"
            }
          },
          {
            "subject": {
              "text": "infectious etiologies of diarrhea",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "diarrhea"
                }
              ]
            },
            "sentence": " Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "action": {
              "verb": {
                "text": "Rule",
                "tense": "present"
              },
              "text": "Rule",
              "normalized": "Rule"
            }
          },
          {
            "subject": {
              "text": "patients with infectious etiologies",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "patients"
                }
              ]
            },
            "sentence": " If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen.",
            "object": {
              "text": "the appropriate therapy and their disease",
              "keywords": [
                {
                  "text": "appropriate therapy"
                },
                {
                  "text": "disease"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "future",
                "negated": true
              },
              "text": "receive",
              "normalized": "receive"
            }
          },
          {
            "subject": {
              "text": "a rate greater than placebo",
              "keywords": [
                {
                  "text": "placebo"
                },
                {
                  "text": "rate"
                }
              ]
            },
            "sentence": " In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).",
            "object": {
              "text": "upper respiratory tract infection",
              "keywords": [
                {
                  "text": "respiratory tract infection"
                }
              ],
              "entities": [
                {
                  "type": "HealthCondition",
                  "text": "upper respiratory tract infection",
                  "disambiguation": {
                    "subtype": [
                      "DiseaseOrMedicalCondition",
                      "RiskFactor",
                      "Symptom"
                    ],
                    "name": "Upper respiratory tract infection",
                    "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "were",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Crofelemer, the active ingredient in Mytesi,",
              "keywords": [
                {
                  "text": "active ingredient"
                },
                {
                  "text": "Crofelemer"
                },
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Crofelemer"
                },
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest.",
            "object": {
              "text": "a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest",
              "keywords": [
                {
                  "text": "red bark sap"
                },
                {
                  "text": "medicinal Croton"
                },
                {
                  "text": "Amazon rainforest"
                },
                {
                  "text": "drug"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Amazon"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "established a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "establish",
                "tense": "past"
              },
              "text": "has established",
              "normalized": "have establish"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a high degree of quality and ecological integrity",
              "keywords": [
                {
                  "text": "ecological integrity"
                },
                {
                  "text": "high degree"
                },
                {
                  "text": "quality"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "ensure",
                "tense": "future"
              },
              "text": "to ensure",
              "normalized": "to ensure"
            }
          },
          {
            "subject": {
              "text": "Certain statements in this press release",
              "keywords": [
                {
                  "text": "Certain statements"
                },
                {
                  "text": "press release"
                }
              ],
              "entities": []
            },
            "sentence": " Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s planned clinical and commercial milestones.",
            "object": {
              "text": "“forward-looking statements.” These include statements regarding the Company’s planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "forward-looking statements."
                },
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "action": {
              "verb": {
                "text": "constitute",
                "tense": "present"
              },
              "text": "constitute",
              "normalized": "constitute"
            }
          },
          {
            "subject": {
              "text": "statements regarding the Company’s planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "statements"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s planned clinical and commercial milestones.",
            "object": {
              "text": "Certain statements in this press release constitute “forward-looking statements.” These",
              "keywords": [
                {
                  "text": "forward-looking statements."
                },
                {
                  "text": "Certain statements"
                },
                {
                  "text": "press release"
                }
              ],
              "entities": []
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s planned clinical and commercial milestones.",
            "object": {
              "text": "planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "has",
              "normalized": "has"
            }
          },
          {
            "subject": {
              "text": "you"
            },
            "sentence": " In some cases, you can identify forward-looking statements by terms such as “may,”“will,”“should,”“expect,”“plan,”“aim,”“anticipate,”“could,”“intend,”“target,”“project,”“contemplate,”“believe,”“estimate,”“predict,”“potential” or “continue” or the negative of these terms or other similar expressions.",
            "object": {
              "text": "forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "identify",
                "tense": "future"
              },
              "text": "can identify",
              "normalized": "can identify"
            }
          },
          {
            "subject": {
              "text": "The forward-looking statements in this release",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "release"
                }
              ],
              "entities": []
            },
            "sentence": " The forward-looking statements in this release are only predictions.",
            "object": {
              "text": "only predictions",
              "keywords": [
                {
                  "text": "predictions"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Jaguar has based these forward-looking statements largely on its current expectations and projections about future events.",
            "object": {
              "text": "based these forward-looking statements largely on its current expectations and projections about future events",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "current expectations"
                },
                {
                  "text": "future events"
                },
                {
                  "text": "projections"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "These forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "sentence": " These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control.",
            "action": {
              "verb": {
                "text": "speak",
                "tense": "present"
              },
              "text": "speak",
              "normalized": "speak"
            }
          }
        ],
        "concepts": [
          {
            "text": "Medicine",
            "relevance": 0.96323,
            "dbpedia_resource": "http://dbpedia.org/resource/Medicine"
          },
          {
            "text": "AIDS",
            "relevance": 0.786813,
            "dbpedia_resource": "http://dbpedia.org/resource/AIDS"
          },
          {
            "text": "Subsidiary",
            "relevance": 0.70876,
            "dbpedia_resource": "http://dbpedia.org/resource/Subsidiary"
          },
          {
            "text": "Antiretroviral drug",
            "relevance": 0.663636,
            "dbpedia_resource": "http://dbpedia.org/resource/Antiretroviral_drug"
          },
          {
            "text": "Respiratory system",
            "relevance": 0.641876,
            "dbpedia_resource": "http://dbpedia.org/resource/Respiratory_system"
          },
          {
            "text": "HIV",
            "relevance": 0.627196,
            "dbpedia_resource": "http://dbpedia.org/resource/HIV"
          },
          {
            "text": "Clinical trial",
            "relevance": 0.605137,
            "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"
          },
          {
            "text": "Health",
            "relevance": 0.593548,
            "dbpedia_resource": "http://dbpedia.org/resource/Health"
          },
          {
            "text": "Loan",
            "relevance": 0.588197,
            "dbpedia_resource": "http://dbpedia.org/resource/Loan"
          },
          {
            "text": "Upper respiratory tract infection",
            "relevance": 0.583569,
            "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
          },
          {
            "text": "Debt",
            "relevance": 0.570839,
            "dbpedia_resource": "http://dbpedia.org/resource/Debt"
          },
          {
            "text": "Maturity",
            "relevance": 0.559318,
            "dbpedia_resource": "http://dbpedia.org/resource/Maturity_(finance)"
          },
          {
            "text": "Pharmacology",
            "relevance": 0.554892,
            "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"
          },
          {
            "text": "Jaguar",
            "relevance": 0.54558,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar"
          },
          {
            "text": "Etiology",
            "relevance": 0.544262,
            "dbpedia_resource": "http://dbpedia.org/resource/Etiology"
          },
          {
            "text": "Gastroenteritis",
            "relevance": 0.509459,
            "dbpedia_resource": "http://dbpedia.org/resource/Gastroenteritis"
          },
          {
            "text": "Security",
            "relevance": 0.508989,
            "dbpedia_resource": "http://dbpedia.org/resource/Security_(finance)"
          },
          {
            "text": "Rolling",
            "relevance": 0.508918,
            "dbpedia_resource": "http://dbpedia.org/resource/Rolling_(finance)"
          }
        ],
        "categories": [
          {
            "score": 0.972444,
            "label": "/health and fitness/disease/aids and hiv"
          },
          {
            "score": 0.722733,
            "label": "/health and fitness/disease/epidemic"
          },
          {
            "score": 0.682741,
            "label": "/finance/financial news"
          }
        ],
        "relations": [
          {
            "type": "locatedAt",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.947054,
            "arguments": [
              {
                "text": "SAN FRANCISCO",
                "location": [
                  227,
                  240
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "SAN FRANCISCO"
                  }
                ]
              },
              {
                "text": "CA",
                "location": [
                  242,
                  244
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "CA"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.390573,
            "arguments": [
              {
                "text": "Mytesi®",
                "location": [
                  1432,
                  1439
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi®\nMytesi"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1317,
                  1323
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.717601,
            "arguments": [
              {
                "text": "Mytesi®",
                "location": [
                  1432,
                  1439
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  1548,
                  1556
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.581568,
            "arguments": [
              {
                "text": "Mytesi®",
                "location": [
                  3682,
                  3689
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3783,
                  3791
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.895097,
            "arguments": [
              {
                "text": "Mytesi®\nMytesi",
                "location": [
                  3969,
                  3983
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4071,
                  4079
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Mytesi is not indicated for the treatment of infectious diarrhea.",
            "score": 0.643525,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  4145,
                  4151
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4201,
                  4209
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "score": 0.930052,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  4270,
                  4276
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4245,
                  4253
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.852454,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  1560,
                  1566
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  1548,
                  1556
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.824225,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  3795,
                  3801
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3783,
                  3791
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.504364,
            "arguments": [
              {
                "text": "people",
                "location": [
                  1925,
                  1931
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "people"
                  }
                ]
              },
              {
                "text": "HIV/AIDS",
                "location": [
                  1944,
                  1952
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "HIV/AIDS"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.636627,
            "arguments": [
              {
                "text": "chief executive officer",
                "location": [
                  2098,
                  2121
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Lisa Conte"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  2125,
                  2131
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "score": 0.969167,
            "arguments": [
              {
                "text": "June 3, 2019",
                "location": [
                  2154,
                  2166
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "June 3, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  2144,
                  2153
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.558802,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  2376,
                  2389
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2404,
                  2415
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.435512,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  2440,
                  2443
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2404,
                  2415
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.811688,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  2423,
                  2436
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "CVP",
                "location": [
                  2440,
                  2443
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The details of this transaction are further described in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "score": 0.986494,
            "arguments": [
              {
                "text": "Securities and Exchange Commission",
                "location": [
                  2948,
                  2982
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Securities and Exchange Commission",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  2943,
                  2947
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Original Debt"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.941607,
            "arguments": [
              {
                "text": "Jaguar Health, Inc.",
                "location": [
                  276,
                  295
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "JAGX",
                "location": [
                  305,
                  309
                ],
                "entities": [
                  {
                    "type": "Ticker",
                    "text": "JAGX"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.979174,
            "arguments": [
              {
                "text": "Jaguar",
                "location": [
                  3003,
                  3009
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  3010,
                  3019
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.985113,
            "arguments": [
              {
                "text": "May 29, 2019",
                "location": [
                  3020,
                  3032
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "May 29, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  3010,
                  3019
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.898709,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  3038,
                  3045
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              },
              {
                "text": "$6.4 million",
                "location": [
                  3093,
                  3105
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$6.4 million",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.979945,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  3197,
                  3204
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3216,
                  3222
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.88192,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  3226,
                  3229
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3216,
                  3222
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.842766,
            "arguments": [
              {
                "text": "July 2017",
                "location": [
                  3233,
                  3242
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "July 2017"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3216,
                  3222
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.526381,
            "arguments": [
              {
                "text": "March 2018",
                "location": [
                  3251,
                  3261
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "March 2018"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3216,
                  3222
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "score": 0.532118,
            "arguments": [
              {
                "text": "subsidiary",
                "location": [
                  3466,
                  3476
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  3478,
                  3504
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.613956,
            "arguments": [
              {
                "text": "Mytesi®",
                "location": [
                  3682,
                  3689
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi®\nMytesi"
                  }
                ]
              },
              {
                "text": "Our",
                "location": [
                  3678,
                  3681
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Our"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.996698,
            "arguments": [
              {
                "text": "FDA",
                "location": [
                  3735,
                  3738
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "FDA",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  3730,
                  3734
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Original Debt"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.986869,
            "arguments": [
              {
                "text": "today",
                "location": [
                  486,
                  491
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "today"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  476,
                  485
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "For more information about Napo, visit napopharma.com .",
            "score": 0.572924,
            "arguments": [
              {
                "text": "Napo",
                "location": [
                  3934,
                  3938
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "napopharma.com",
                "location": [
                  3946,
                  3960
                ],
                "entities": [
                  {
                    "type": "Web",
                    "text": "napopharma.com"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.927523,
            "arguments": [
              {
                "text": "patients",
                "location": [
                  4089,
                  4097
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "patients"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4071,
                  4079
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.424034,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  501,
                  508
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  554,
                  560
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.767511,
            "arguments": [
              {
                "text": "2017",
                "location": [
                  549,
                  553
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "2017"
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  554,
                  560
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.641285,
            "arguments": [
              {
                "text": "Jaguar Animal Health, Inc.",
                "location": [
                  564,
                  590
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Animal Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  554,
                  560
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "participantIn",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.336378,
            "arguments": [
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  595,
                  621
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  554,
                  560
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.741167,
            "arguments": [
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  595,
                  621
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "$10.5 million",
                "location": [
                  656,
                  669
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$10.5 million",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.544866,
            "arguments": [
              {
                "text": "subsidiary",
                "location": [
                  1303,
                  1313
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1317,
                  1323
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "Jaguar Health",
            "sentiment": {
              "score": 0.859669,
              "label": "positive"
            },
            "relevance": 0.609394,
            "count": 4
          },
          {
            "text": "Napo Pharmaceuticals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.600265,
            "count": 3
          },
          {
            "text": "clinical studies",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.571777,
            "count": 1
          },
          {
            "text": "pharmaceutical company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.571054,
            "count": 1
          },
          {
            "text": "merger of Jaguar Animal Health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.561863,
            "count": 1
          },
          {
            "text": "development of follow",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.557484,
            "count": 1
          },
          {
            "text": "commercial stage",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.555046,
            "count": 1
          },
          {
            "text": "SAN FRANCISCO",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.552986,
            "count": 1
          },
          {
            "text": "gastrointestinal products",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.547456,
            "count": 2
          },
          {
            "text": "human health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.54351,
            "count": 1
          },
          {
            "text": "press release",
            "sentiment": {
              "score": -0.607008,
              "label": "negative"
            },
            "relevance": 0.541017,
            "count": 1
          },
          {
            "text": "Jaguar Animal Health’s name",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.540573,
            "count": 1
          },
          {
            "text": "shares of common stock",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.539102,
            "count": 1
          },
          {
            "text": "pipeline opportunities",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.538829,
            "count": 1
          },
          {
            "text": "active ingredient",
            "sentiment": {
              "score": -0.804786,
              "label": "negative"
            },
            "relevance": 0.538133,
            "count": 1
          },
          {
            "text": "treatment of infectious diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.535527,
            "count": 1
          },
          {
            "text": "Jaguar Health Strengthens Company’s Balance Sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.533459,
            "count": 1
          },
          {
            "text": "commercial product",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.531083,
            "count": 1
          },
          {
            "text": "promissory notes",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529881,
            "count": 1
          },
          {
            "text": "infectious etiologies of diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.529209,
            "count": 1
          },
          {
            "text": "average price",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529165,
            "count": 1
          },
          {
            "text": "upper respiratory tract infection",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529,
            "count": 1
          },
          {
            "text": "Original Debt",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.528944,
            "count": 3
          },
          {
            "text": "subsidiary of Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.528224,
            "count": 1
          },
          {
            "text": "symptomatic relief of noninfectious diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.527998,
            "count": 3
          },
          {
            "text": "class anti-secretory agent",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.527941,
            "count": 1
          },
          {
            "text": "extension of the maturity date",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.527563,
            "count": 2
          },
          {
            "text": "adult patients",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.525749,
            "count": 1
          },
          {
            "text": "part of a larger restructuring of the Original Debt",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.525347,
            "count": 1
          },
          {
            "text": "effective July",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.524888,
            "count": 1
          },
          {
            "text": "one-year extension",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.524195,
            "count": 1
          },
          {
            "text": "such restructuring",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.523644,
            "count": 1
          },
          {
            "text": "Statements",
            "sentiment": {
              "score": -0.607008,
              "label": "negative"
            },
            "relevance": 0.522158,
            "count": 9
          },
          {
            "text": "commercial milestones",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.521231,
            "count": 2
          },
          {
            "text": "Company",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.520767,
            "count": 8
          },
          {
            "text": "details of this transaction",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.520304,
            "count": 1
          },
          {
            "text": "Company’s balance sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519614,
            "count": 1
          },
          {
            "text": "Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519587,
            "count": 3
          },
          {
            "text": "further reduction of the Company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.518168,
            "count": 1
          },
          {
            "text": "drug product",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.518108,
            "count": 1
          },
          {
            "text": "Exchange Commission",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517901,
            "count": 1
          },
          {
            "text": "applicable law",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517757,
            "count": 1
          },
          {
            "text": "plan",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.516515,
            "count": 1
          },
          {
            "text": "Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.515706,
            "count": 6
          },
          {
            "text": "ongoing commercialization",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.515356,
            "count": 1
          },
          {
            "text": "global marketplace",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.515291,
            "count": 1
          },
          {
            "text": "global basis",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.51507,
            "count": 2
          },
          {
            "text": "commercial stage pharmaceuticals company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514816,
            "count": 1
          },
          {
            "text": "chief executive officer of Jaguar",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.514555,
            "count": 1
          },
          {
            "text": "means of an exchange of the Original Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514344,
            "count": 1
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "ef1563d8686ed7b4966ddc69661f8a52a250a802",
        "filename": "1563208469530.zip-0a18af1b1011f5737fa8ba55659c0e38.xml",
        "file_type": "json"
      },
      "external_links": [
        "http://pr.report/4KhQR-nx",
        "http://pr.report/gT3iZsMS",
        "http://pr.report/6kwvcahl"
      ],
      "title": "Jaguar Health Strengthens Company’s Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
      "forum_title": "SproutNews"
    },
    {
      "id": "6T6t2nemh9FC3H2NXWpOB8dKNG5DjMyGZ520cOtVBSY4_DHO1Krne76WLipScQVZ",
      "result_metadata": {
        "score": 20.48465
      },
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Health Strengthens Company",
            "relevance": 0.33,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 Million",
            "relevance": 0.33,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 Million",
            "relevance": 0.33,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0,
            "label": "neutral"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger",
              "keywords": [
                {
                  "text": "Debt Incurred"
                },
                {
                  "text": "Merger"
                },
                {
                  "text": "Effect"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$10.5 Million"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
            "object": {
              "text": "to Approximately $4.4 Million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$4.4 Million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Reducing",
                "tense": "present"
              },
              "text": "Reducing",
              "normalized": "Reducing"
            }
          }
        ],
        "concepts": [],
        "categories": [
          {
            "score": 0.987001,
            "label": "/business and industrial/company/merger and acquisition"
          }
        ],
        "relations": [],
        "keywords": [
          {
            "text": "Jaguar Health Strengthens Company's Balance Sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.744408,
            "count": 1
          },
          {
            "text": "Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.585918,
            "count": 1
          },
          {
            "text": "Effect",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.558755,
            "count": 1
          },
          {
            "text": "Merger",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.548529,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-15T13:11:00Z",
      "url": "https://www.bioportfolio.com/news/article/4037065/Jaguar-Health-Strengthens-Companys-Balance-Sheet-by-Reducing-Approximately-10-5-Million.html",
      "host": "bioportfolio.com",
      "text": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
      "country": "GB",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-15T08:00:00Z",
      "enriched_text": {
        "entities": [
          {
            "count": 8,
            "sentiment": {
              "score": 0.460269,
              "label": "positive"
            },
            "text": "Jaguar",
            "relevance": 0.954663,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AwardWinner"
              ],
              "name": "Jaguar Cars",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
            }
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0.534748,
              "label": "positive"
            },
            "text": "Jaguar Health",
            "relevance": 0.685152,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.425457,
              "label": "positive"
            },
            "text": "Jaguar Health, Inc.",
            "relevance": 0.553732,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.353787,
              "label": "positive"
            },
            "text": "Jaguar Animal Health",
            "relevance": 0.483236,
            "type": "Company"
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Mytesi",
            "relevance": 0.444858,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo Pharmaceuticals, Inc.",
            "relevance": 0.427733,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo",
            "relevance": 0.312871,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "StateOrCounty"
              ]
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": -0.679083,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.297678,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Napo",
            "relevance": 0.282275,
            "type": "Organization"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "U.S. Securities and Exchange Commission",
            "relevance": 0.280208,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency",
                "GovernmentalBody"
              ],
              "name": "U.S. Securities and Exchange Commission",
              "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "president and chief executive officer",
            "relevance": 0.276821,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Mytesi ®",
            "relevance": 0.276516,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.553674,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.27301,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "upper respiratory tract infection",
            "relevance": 0.271365,
            "type": "HealthCondition",
            "disambiguation": {
              "subtype": [
                "DiseaseOrMedicalCondition",
                "RiskFactor",
                "Symptom"
              ],
              "name": "Upper respiratory tract infection",
              "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Crofelemer",
            "relevance": 0.266986,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Lisa Conte",
            "relevance": 0.261286,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.353209,
              "label": "negative"
            },
            "text": "FDA",
            "relevance": 0.244736,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency"
              ],
              "name": "Food and Drug Administration",
              "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Amazon",
            "relevance": 0.209489,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.1%",
            "relevance": 0.209489,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$2.3 million",
            "relevance": 0.209489,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$6.4 million",
            "relevance": 0.209489,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "one-year",
            "relevance": 0.209489,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.5%",
            "relevance": 0.209489,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.9%",
            "relevance": 0.209489,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "5.7%",
            "relevance": 0.209489,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "8-K",
            "relevance": 0.209489,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": -0.320429,
            "label": "negative"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "an Extension of the Maturity of Such Debt",
              "keywords": [
                {
                  "text": "Maturity"
                },
                {
                  "text": "Debt"
                },
                {
                  "text": "Extension"
                }
              ]
            },
            "sentence": "Jaguar Health Refinances .5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020",
            "object": {
              "text": "Jaguar Health Refinances .5 Million of Secured Debt",
              "keywords": [
                {
                  "text": "Jaguar Health Refinances"
                },
                {
                  "text": "Secured Debt"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Including",
                "tense": "present"
              },
              "text": "Including",
              "normalized": "Including"
            }
          },
          {
            "subject": {
              "text": "the Merger",
              "keywords": [
                {
                  "text": "Merger"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "effective July 31"
            },
            "action": {
              "verb": {
                "text": "become",
                "tense": "past"
              },
              "text": "became",
              "normalized": "become"
            }
          },
          {
            "subject": {
              "text": "Jaguar Animal Health's name",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "action": {
              "verb": {
                "text": "change",
                "tense": "past"
              },
              "text": "changed",
              "normalized": "change"
            }
          },
          {
            "subject": {
              "text": "Inc. and Napo Pharmaceuticals, Inc.",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "Inc."
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "operating as a wholly-owned subsidiary of Jaguar focused on human health",
              "keywords": [
                {
                  "text": "wholly-owned subsidiary"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "operating"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "begin",
                "tense": "past"
              },
              "text": "began",
              "normalized": "begin"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer)",
              "keywords": [
                {
                  "text": "follow-on indications"
                },
                {
                  "text": "ongoing commercialization"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "development"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "focus",
                "tense": "past"
              },
              "text": "focused",
              "normalized": "focus"
            }
          },
          {
            "subject": {
              "text": "We"
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "we"
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "important assets"
                },
                {
                  "text": "pipeline opportunities"
                },
                {
                  "text": "value recognition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "continue",
                "tense": "present"
              },
              "text": "continue",
              "normalized": "continue"
            }
          },
          {
            "subject": {
              "text": "our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "Lisa Conte"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                },
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "pipeline opportunities",
              "keywords": [
                {
                  "text": "pipeline opportunities"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "Lisa Conte, president and chief executive officer of Jaguar,",
              "keywords": [
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "Lisa Conte"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "president"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "deep pipeline"
                },
                {
                  "text": "pipeline opportunities"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "state",
                "tense": "past"
              },
              "text": "stated",
              "normalized": "state"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31",
              "keywords": [
                {
                  "text": "one-year extension"
                },
                {
                  "text": "Original Debt"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "a one-year extension",
              "keywords": [
                {
                  "text": "one-year extension"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "past"
              },
              "text": "has received",
              "normalized": "have receive"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "previously scheduled to mature on December 31, 2019"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "action": {
              "verb": {
                "text": "schedule",
                "tense": "past"
              },
              "text": "scheduled",
              "normalized": "schedule"
            }
          },
          {
            "subject": {
              "text": "The extension of the maturity date",
              "keywords": [
                {
                  "text": "maturity date"
                },
                {
                  "text": "extension"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "part of a larger restructuring of the Original Debt",
              "keywords": [
                {
                  "text": "larger restructuring"
                },
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "the acquisition of the Original Debt by CVP",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "Original Debt"
                },
                {
                  "text": "acquisition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "follow",
                "tense": "present"
              },
              "text": "following",
              "normalized": "follow"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " As consideration for such restructuring, which included among other things the extension of the maturity date by means of an exchange of the Original Debt for new secured debt with a maturity date of December 31, 2020, Jaguar paid CVP a fee of approximately $2.3 million in the form of additional debt (the \"Additional Debt\").",
            "object": {
              "text": "CVP a fee of approximately $2.3 million",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "fee"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$2.3 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "pay",
                "tense": "past"
              },
              "text": "paid",
              "normalized": "pay"
            }
          },
          {
            "subject": {
              "text": "The Additional Debt",
              "keywords": [
                {
                  "text": "Additional Debt"
                }
              ]
            },
            "sentence": " The Additional Debt is not included in the Original Debt.",
            "object": {
              "text": "in the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "past",
                "negated": true
              },
              "text": "included",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "The details of this transaction",
              "keywords": [
                {
                  "text": "transaction"
                },
                {
                  "text": "details"
                }
              ]
            },
            "sentence": " The details of this transaction are further described in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "object": {
              "text": "on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019",
              "keywords": [
                {
                  "text": "U.S. Securities"
                },
                {
                  "text": "Form 8-K"
                },
                {
                  "text": "Exchange Commission"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "U.S. Securities and Exchange Commission",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency",
                      "GovernmentalBody"
                    ],
                    "name": "U.S. Securities and Exchange Commission",
                    "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
                  }
                },
                {
                  "type": "Quantity",
                  "text": "8-K"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "describe",
                "tense": "past"
              },
              "text": "are further described",
              "normalized": "be further describe"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ]
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "object": {
              "text": "all of the approximately $6.4 million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$6.4 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "extinguish",
                "tense": "past"
              },
              "text": "extinguished",
              "normalized": "extinguish"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ]
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "action": {
              "verb": {
                "text": "issue",
                "tense": "past"
              },
              "text": "issued",
              "normalized": "issue"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "a commercial stage pharmaceuticals company focused on developing novel",
              "keywords": [
                {
                  "text": "commercial stage pharmaceuticals"
                },
                {
                  "text": "company"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "novel, sustainably derived gastrointestinal products on a global basis",
              "keywords": [
                {
                  "text": "gastrointestinal products"
                },
                {
                  "text": "global basis"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "develop",
                "tense": "future"
              },
              "text": "developing",
              "normalized": "develop"
            }
          },
          {
            "subject": {
              "text": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc.,",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "wholly-owned subsidiary"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "object": {
              "text": "proprietary human gastrointestinal pharmaceuticals",
              "keywords": [
                {
                  "text": "gastrointestinal pharmaceuticals"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "commercialize",
                "tense": "present"
              },
              "text": "commercializing",
              "normalized": "commercialize"
            }
          },
          {
            "subject": {
              "text": "plants",
              "keywords": [
                {
                  "text": "plants"
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "action": {
              "verb": {
                "text": "use",
                "tense": "past"
              },
              "text": "used",
              "normalized": "use"
            }
          },
          {
            "subject": {
              "text": "Our Mytesi ® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "approved by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "sentence": " Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "Our Mytesi ® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "approve",
                "tense": "past"
              },
              "text": "is approved",
              "normalized": "be approve"
            }
          },
          {
            "subject": {
              "text": "Mytesi (crofelemer)",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "object": {
              "text": "an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea",
              "keywords": [
                {
                  "text": "noninfectious diarrhea"
                },
                {
                  "text": "symptomatic relief"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "not indicated for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "indicate",
                "tense": "past",
                "negated": true
              },
              "text": "indicated",
              "normalized": "indicate"
            }
          },
          {
            "subject": {
              "text": "infectious etiologies of diarrhea",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "diarrhea"
                }
              ]
            },
            "sentence": " Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "action": {
              "verb": {
                "text": "Rule",
                "tense": "present"
              },
              "text": "Rule",
              "normalized": "Rule"
            }
          },
          {
            "subject": {
              "text": "patients with infectious etiologies",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "patients"
                }
              ]
            },
            "sentence": " If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen.",
            "object": {
              "text": "the appropriate therapy and their disease",
              "keywords": [
                {
                  "text": "appropriate therapy"
                },
                {
                  "text": "disease"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "future",
                "negated": true
              },
              "text": "receive",
              "normalized": "receive"
            }
          },
          {
            "subject": {
              "text": "a rate greater than placebo",
              "keywords": [
                {
                  "text": "placebo"
                },
                {
                  "text": "rate"
                }
              ]
            },
            "sentence": " In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).",
            "object": {
              "text": "upper respiratory tract infection",
              "keywords": [
                {
                  "text": "respiratory tract infection"
                }
              ],
              "entities": [
                {
                  "type": "HealthCondition",
                  "text": "upper respiratory tract infection",
                  "disambiguation": {
                    "subtype": [
                      "DiseaseOrMedicalCondition",
                      "RiskFactor",
                      "Symptom"
                    ],
                    "name": "Upper respiratory tract infection",
                    "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "were",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Crofelemer, the active ingredient in Mytesi,",
              "keywords": [
                {
                  "text": "active ingredient"
                },
                {
                  "text": "Crofelemer"
                },
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Crofelemer"
                },
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest.",
            "object": {
              "text": "a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest",
              "keywords": [
                {
                  "text": "red bark sap"
                },
                {
                  "text": "medicinal Croton"
                },
                {
                  "text": "Amazon rainforest"
                },
                {
                  "text": "drug"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Amazon"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "established a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "establish",
                "tense": "past"
              },
              "text": "has established",
              "normalized": "have establish"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a high degree of quality and ecological integrity",
              "keywords": [
                {
                  "text": "ecological integrity"
                },
                {
                  "text": "high degree"
                },
                {
                  "text": "quality"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "ensure",
                "tense": "future"
              },
              "text": "to ensure",
              "normalized": "to ensure"
            }
          },
          {
            "subject": {
              "text": "Certain statements in this press release",
              "keywords": [
                {
                  "text": "Certain statements"
                },
                {
                  "text": "press release"
                }
              ],
              "entities": []
            },
            "sentence": " Certain statements in this press release constitute \"forward-looking statements.\"",
            "object": {
              "text": "\"forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "constitute",
                "tense": "present"
              },
              "text": "constitute",
              "normalized": "constitute"
            }
          },
          {
            "subject": {
              "text": "statements regarding the Company's planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "statements"
                },
                {
                  "text": "Company"
                }
              ]
            },
            "sentence": " These include statements regarding the Company's planned clinical and commercial milestones.",
            "object": {
              "text": "These"
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "statements",
              "keywords": [
                {
                  "text": "statements"
                }
              ]
            },
            "sentence": " These include statements regarding the Company's planned clinical and commercial milestones.",
            "object": {
              "text": "the Company's planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "Company"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "regard",
                "tense": "present"
              },
              "text": "regarding",
              "normalized": "regard"
            }
          },
          {
            "subject": {
              "text": "you"
            },
            "sentence": " In some cases, you can identify forward-looking statements by terms such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"aim,\" \"anticipate,\" \"could,\" \"intend,\" \"target,\" \"project,\" \"contemplate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential\" or \"continue\" or the negative of these terms or other similar expressions.",
            "object": {
              "text": "forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "identify",
                "tense": "future"
              },
              "text": "can identify",
              "normalized": "can identify"
            }
          },
          {
            "subject": {
              "text": "The forward-looking statements in this release",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "release"
                }
              ],
              "entities": []
            },
            "sentence": " The forward-looking statements in this release are only predictions.",
            "object": {
              "text": "only predictions",
              "keywords": [
                {
                  "text": "predictions"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Jaguar has based these forward-looking statements largely on its current expectations and projections about future events.",
            "object": {
              "text": "based these forward-looking statements largely on its current expectations and projections about future events",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "current expectations"
                },
                {
                  "text": "future events"
                },
                {
                  "text": "projections"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "These forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "sentence": " These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control.",
            "action": {
              "verb": {
                "text": "speak",
                "tense": "present"
              },
              "text": "speak",
              "normalized": "speak"
            }
          },
          {
            "subject": {
              "text": "These forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "sentence": " These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control.",
            "object": {
              "text": "subject to a number of risks, uncertainties and assumptions",
              "keywords": [
                {
                  "text": "uncertainties"
                },
                {
                  "text": "assumptions"
                },
                {
                  "text": "risks"
                },
                {
                  "text": "number"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.",
            "object": {
              "text": "not plan",
              "keywords": [
                {
                  "text": "plan"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "do",
                "tense": "present"
              },
              "text": "does",
              "normalized": "do"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.",
            "object": {
              "text": "to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "new information"
                },
                {
                  "text": "future events"
                },
                {
                  "text": "circumstances"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "plan",
                "tense": "present",
                "negated": true
              },
              "text": "plan",
              "normalized": "plan"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.",
            "object": {
              "text": "any forward-looking statements contained herein",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "update",
                "tense": "present"
              },
              "text": "update",
              "normalized": "update"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.",
            "object": {
              "text": "any forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "revise",
                "tense": "present"
              },
              "text": "does not plan to publicly update or revise",
              "normalized": "do not plan to publicly update or revise"
            }
          }
        ],
        "concepts": [
          {
            "text": "Medicine",
            "relevance": 0.947877,
            "dbpedia_resource": "http://dbpedia.org/resource/Medicine"
          },
          {
            "text": "AIDS",
            "relevance": 0.750389,
            "dbpedia_resource": "http://dbpedia.org/resource/AIDS"
          },
          {
            "text": "Subsidiary",
            "relevance": 0.70826,
            "dbpedia_resource": "http://dbpedia.org/resource/Subsidiary"
          },
          {
            "text": "Respiratory system",
            "relevance": 0.708157,
            "dbpedia_resource": "http://dbpedia.org/resource/Respiratory_system"
          },
          {
            "text": "Upper respiratory tract infection",
            "relevance": 0.673755,
            "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
          },
          {
            "text": "Antiretroviral drug",
            "relevance": 0.654776,
            "dbpedia_resource": "http://dbpedia.org/resource/Antiretroviral_drug"
          },
          {
            "text": "HIV",
            "relevance": 0.622993,
            "dbpedia_resource": "http://dbpedia.org/resource/HIV"
          },
          {
            "text": "Amazon Rainforest",
            "relevance": 0.587348,
            "dbpedia_resource": "http://dbpedia.org/resource/Amazon_Rainforest"
          },
          {
            "text": "Health",
            "relevance": 0.572632,
            "dbpedia_resource": "http://dbpedia.org/resource/Health"
          },
          {
            "text": "Upper respiratory tract",
            "relevance": 0.565507,
            "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract"
          },
          {
            "text": "Brazil",
            "relevance": 0.540633,
            "dbpedia_resource": "http://dbpedia.org/resource/Brazil"
          },
          {
            "text": "Maturity",
            "relevance": 0.533038,
            "dbpedia_resource": "http://dbpedia.org/resource/Maturity_(finance)"
          },
          {
            "text": "South America",
            "relevance": 0.529279,
            "dbpedia_resource": "http://dbpedia.org/resource/South_America"
          },
          {
            "text": "Jaguar",
            "relevance": 0.5196,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar"
          },
          {
            "text": "Etiology",
            "relevance": 0.518698,
            "dbpedia_resource": "http://dbpedia.org/resource/Etiology"
          },
          {
            "text": "Secured loan",
            "relevance": 0.518001,
            "dbpedia_resource": "http://dbpedia.org/resource/Secured_loan"
          },
          {
            "text": "Parent company",
            "relevance": 0.508808,
            "dbpedia_resource": "http://dbpedia.org/resource/Parent_company"
          },
          {
            "text": "Loan",
            "relevance": 0.486,
            "dbpedia_resource": "http://dbpedia.org/resource/Loan"
          },
          {
            "text": "Gastroenteritis",
            "relevance": 0.485658,
            "dbpedia_resource": "http://dbpedia.org/resource/Gastroenteritis"
          },
          {
            "text": "Rolling",
            "relevance": 0.485038,
            "dbpedia_resource": "http://dbpedia.org/resource/Rolling_(finance)"
          }
        ],
        "categories": [
          {
            "score": 0.986652,
            "label": "/health and fitness/disease/aids and hiv"
          },
          {
            "score": 0.771733,
            "label": "/health and fitness/disease/epidemic"
          },
          {
            "score": 0.706885,
            "label": "/health and fitness/therapy"
          }
        ],
        "relations": [
          {
            "type": "partOf",
            "sentence": "Jaguar Health Refinances .5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020 Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.530751,
            "arguments": [
              {
                "text": "subsidiary",
                "location": [
                  333,
                  343
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc. and Napo Pharmaceuticals, Inc."
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  347,
                  353
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc."
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.811688,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  1454,
                  1467
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "CVP",
                "location": [
                  1471,
                  1474
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The details of this transaction are further described in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "score": 0.984349,
            "arguments": [
              {
                "text": "Securities and Exchange Commission",
                "location": [
                  1979,
                  2013
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Securities and Exchange Commission",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  1974,
                  1978
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc."
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.979174,
            "arguments": [
              {
                "text": "Jaguar",
                "location": [
                  2034,
                  2040
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc."
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  2041,
                  2050
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.985113,
            "arguments": [
              {
                "text": "May 29, 2019",
                "location": [
                  2051,
                  2063
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "May 29, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  2041,
                  2050
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.977561,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  2228,
                  2235
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc."
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  2247,
                  2253
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.866544,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  2257,
                  2260
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  2247,
                  2253
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.781224,
            "arguments": [
              {
                "text": "July 2017",
                "location": [
                  2264,
                  2273
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "July 2017"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  2247,
                  2253
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "score": 0.361761,
            "arguments": [
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  2509,
                  2535
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc. and Napo Pharmaceuticals, Inc."
                  }
                ]
              },
              {
                "text": "plants",
                "location": [
                  2662,
                  2668
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "plants"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.613956,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  2713,
                  2721
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "Our",
                "location": [
                  2709,
                  2712
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Our"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.996698,
            "arguments": [
              {
                "text": "FDA",
                "location": [
                  2767,
                  2770
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "FDA",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  2762,
                  2766
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc."
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Jaguar Health Refinances .5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020 Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.390573,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  462,
                  470
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  347,
                  353
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc."
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "For more information about Napo, visit napopharma.com .",
            "score": 0.56475,
            "arguments": [
              {
                "text": "Napo",
                "location": [
                  2966,
                  2970
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc. and Napo Pharmaceuticals, Inc."
                  }
                ]
              },
              {
                "text": "napopharma.com",
                "location": [
                  2978,
                  2992
                ],
                "entities": [
                  {
                    "type": "Web",
                    "text": "napopharma.com"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi ® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.927523,
            "arguments": [
              {
                "text": "patients",
                "location": [
                  3122,
                  3130
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "patients"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3104,
                  3112
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Jaguar Health Refinances .5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020 Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.717601,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  462,
                  470
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  579,
                  587
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.581568,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  2713,
                  2721
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  2815,
                  2823
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi ® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.895097,
            "arguments": [
              {
                "text": "Mytesi ®\nMytesi",
                "location": [
                  3001,
                  3016
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3104,
                  3112
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Mytesi is not indicated for the treatment of infectious diarrhea.",
            "score": 0.643525,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  3178,
                  3184
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3234,
                  3242
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "score": 0.930052,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  3303,
                  3309
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3278,
                  3286
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Jaguar Health Refinances .5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020 Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.852454,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  591,
                  597
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  579,
                  587
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.824225,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  2827,
                  2833
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  2815,
                  2823
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.504364,
            "arguments": [
              {
                "text": "people",
                "location": [
                  956,
                  962
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "people"
                  }
                ]
              },
              {
                "text": "HIV/AIDS",
                "location": [
                  975,
                  983
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "HIV/AIDS"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.636627,
            "arguments": [
              {
                "text": "chief executive officer",
                "location": [
                  1129,
                  1152
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Lisa Conte"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1156,
                  1162
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc."
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "score": 0.969167,
            "arguments": [
              {
                "text": "June 3, 2019",
                "location": [
                  1185,
                  1197
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "June 3, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  1175,
                  1184
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.558802,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  1407,
                  1420
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  1435,
                  1446
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.435512,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  1471,
                  1474
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  1435,
                  1446
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "Jaguar Health",
            "sentiment": {
              "score": -0.821627,
              "label": "negative"
            },
            "relevance": 0.752866,
            "count": 4
          },
          {
            "text": "Jaguar Animal Health's name",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.627455,
            "count": 1
          },
          {
            "text": "Napo Pharmaceuticals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.60548,
            "count": 2
          },
          {
            "text": "development of follow",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.59745,
            "count": 1
          },
          {
            "text": "Company's FDA",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.594161,
            "count": 1
          },
          {
            "text": "clinical studies",
            "sentiment": {
              "score": -0.604306,
              "label": "negative"
            },
            "relevance": 0.590632,
            "count": 1
          },
          {
            "text": "Extension of the Maturity of Such Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.580254,
            "count": 1
          },
          {
            "text": "Secured Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.565051,
            "count": 1
          },
          {
            "text": "subsidiary of Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.558496,
            "count": 1
          },
          {
            "text": "human health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.557909,
            "count": 1
          },
          {
            "text": "press release",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.547566,
            "count": 1
          },
          {
            "text": "effective July",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.546361,
            "count": 1
          },
          {
            "text": "extension of the maturity date",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.545842,
            "count": 2
          },
          {
            "text": "commercial milestones",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.543046,
            "count": 2
          },
          {
            "text": "active ingredient",
            "sentiment": {
              "score": -0.938438,
              "label": "negative"
            },
            "relevance": 0.542962,
            "count": 1
          },
          {
            "text": "further reduction of the Company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.542724,
            "count": 1
          },
          {
            "text": "pipeline opportunities",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.541574,
            "count": 1
          },
          {
            "text": "commercial product",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.54122,
            "count": 1
          },
          {
            "text": "treatment of infectious diarrhea",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.537459,
            "count": 1
          },
          {
            "text": "promissory notes",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.534548,
            "count": 1
          },
          {
            "text": "chief executive officer of Jaguar",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.533898,
            "count": 1
          },
          {
            "text": "upper respiratory tract infection",
            "sentiment": {
              "score": -0.627843,
              "label": "negative"
            },
            "relevance": 0.532644,
            "count": 1
          },
          {
            "text": "class anti-secretory agent",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.5317,
            "count": 1
          },
          {
            "text": "infectious etiologies of diarrhea",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.53023,
            "count": 1
          },
          {
            "text": "symptomatic relief of noninfectious diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.530138,
            "count": 3
          },
          {
            "text": "adult patients",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.529305,
            "count": 1
          },
          {
            "text": "drug product",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.528903,
            "count": 1
          },
          {
            "text": "part of a larger restructuring of the Original Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.528541,
            "count": 1
          },
          {
            "text": "commercial stage pharmaceuticals company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.526209,
            "count": 1
          },
          {
            "text": "Statements",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.524831,
            "count": 9
          },
          {
            "text": "Original Debt",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.523389,
            "count": 2
          },
          {
            "text": "applicable law",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.520911,
            "count": 1
          },
          {
            "text": "ongoing commercialization",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519259,
            "count": 1
          },
          {
            "text": "details of this transaction",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519067,
            "count": 1
          },
          {
            "text": "plan",
            "sentiment": {
              "score": 0.803701,
              "label": "positive"
            },
            "relevance": 0.519021,
            "count": 1
          },
          {
            "text": "future events",
            "sentiment": {
              "score": -0.821627,
              "label": "negative"
            },
            "relevance": 0.517508,
            "count": 2
          },
          {
            "text": "global marketplace",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.51469,
            "count": 1
          },
          {
            "text": "common adverse reactions",
            "sentiment": {
              "score": -0.604306,
              "label": "negative"
            },
            "relevance": 0.51469,
            "count": 1
          },
          {
            "text": "Company's Current Report",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514579,
            "count": 1
          },
          {
            "text": "Exchange Commission",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.51407,
            "count": 1
          },
          {
            "text": "antiretroviral therapy",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.513082,
            "count": 3
          },
          {
            "text": "sustainable harvesting program",
            "sentiment": {
              "score": -0.607008,
              "label": "negative"
            },
            "relevance": 0.512783,
            "count": 1
          },
          {
            "text": "value recognition",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.51018,
            "count": 1
          },
          {
            "text": "form of additional debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.509722,
            "count": 1
          },
          {
            "text": "deep pipeline",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.509549,
            "count": 1
          },
          {
            "text": "proprietary human gastrointestinal pharmaceuticals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.509444,
            "count": 1
          },
          {
            "text": "Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.509147,
            "count": 5
          },
          {
            "text": "risk",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.508228,
            "count": 1
          },
          {
            "text": "important assets",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.508148,
            "count": 1
          },
          {
            "text": "Company",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.50813,
            "count": 4
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "97712ecb5d5cb8ca79bc8e59513d1639fede30ae",
        "filename": "1563196260546.zip-4ccb87cd77b119e4fd51d21075abed11.xml",
        "file_type": "json"
      },
      "external_links": [
        "http://pr.report/4KhQR-nx",
        "http://pr.report/gT3iZsMS",
        "http://pr.report/6kwvcahl"
      ],
      "title": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
      "forum_title": "BioPortfolio Rising Global Prevalence Migraine Headaches Drive Migraine Drugs News"
    },
    {
      "id": "JAMXhZd5NDUwk6WzxXNdPnCCG2tn_uP0TMejHH5MQaUtJ7PkUkAdMXJ6V5Y_Eq1h",
      "result_metadata": {
        "score": 20.479635
      },
      "author": "ACCESSWIRE",
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Health Strengthens Company",
            "relevance": 0.33,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 Million",
            "relevance": 0.33,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 Million",
            "relevance": 0.33,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0,
            "label": "neutral"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger",
              "keywords": [
                {
                  "text": "Debt Incurred"
                },
                {
                  "text": "Merger"
                },
                {
                  "text": "Effect"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$10.5 Million"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
            "object": {
              "text": "to Approximately $4.4 Million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$4.4 Million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Reducing",
                "tense": "present"
              },
              "text": "Reducing",
              "normalized": "Reducing"
            }
          }
        ],
        "concepts": [],
        "categories": [
          {
            "score": 0.987001,
            "label": "/business and industrial/company/merger and acquisition"
          }
        ],
        "relations": [],
        "keywords": [
          {
            "text": "Jaguar Health Strengthens Company's Balance Sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.744408,
            "count": 1
          },
          {
            "text": "Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.585918,
            "count": 1
          },
          {
            "text": "Effect",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.558755,
            "count": 1
          },
          {
            "text": "Merger",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.548529,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-15T13:15:58Z",
      "url": "http://money.ca/canadian_money/2019/07/15/jaguar-health-strengthens-companys-balance-sheet-by-reducing-approximately-10-5-million-of-debt-incurred-to-effect-2017-merger-to-approximately-4-4-million/",
      "host": "money.ca",
      "text": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
      "country": "CA",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-15T00:00:00-05:00",
      "enriched_text": {
        "entities": [
          {
            "count": 7,
            "sentiment": {
              "score": 0.460269,
              "label": "positive"
            },
            "text": "Jaguar",
            "relevance": 0.833956,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AwardWinner"
              ],
              "name": "Jaguar Cars",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
            }
          },
          {
            "count": 5,
            "sentiment": {
              "score": 0.550897,
              "label": "positive"
            },
            "text": "Jaguar Health",
            "relevance": 0.774512,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0.418751,
              "label": "positive"
            },
            "text": "Jaguar Health, Inc.",
            "relevance": 0.617163,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Health Strengthens Company",
            "relevance": 0.533144,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo Pharmaceuticals, Inc.",
            "relevance": 0.426741,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Animal Health, Inc.",
            "relevance": 0.414385,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.351542,
              "label": "positive"
            },
            "text": "Jaguar Animal Health",
            "relevance": 0.409118,
            "type": "Company"
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Mytesi",
            "relevance": 0.3595,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo",
            "relevance": 0.262842,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "StateOrCounty"
              ]
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": -0.679083,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.246338,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Napo",
            "relevance": 0.239511,
            "type": "Organization"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "U.S. Securities and Exchange Commission",
            "relevance": 0.233499,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency",
                "GovernmentalBody"
              ],
              "name": "U.S. Securities and Exchange Commission",
              "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Mytesi ®",
            "relevance": 0.226245,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.553674,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.224018,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Crofelemer",
            "relevance": 0.223472,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "upper respiratory tract infection",
            "relevance": 0.222542,
            "type": "HealthCondition",
            "disambiguation": {
              "subtype": [
                "DiseaseOrMedicalCondition",
                "RiskFactor",
                "Symptom"
              ],
              "name": "Upper respiratory tract infection",
              "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Peter Hodge",
            "relevance": 0.221744,
            "type": "Person",
            "disambiguation": {
              "subtype": [],
              "name": "Peter Hodge",
              "dbpedia_resource": "http://dbpedia.org/resource/Peter_Hodge"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Chicago Venture Partners L.P.",
            "relevance": 0.220005,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "SAN FRANCISCO",
            "relevance": 0.21635,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "president and chief executive officer",
            "relevance": 0.206292,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.353209,
              "label": "negative"
            },
            "text": "FDA",
            "relevance": 0.203449,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency"
              ],
              "name": "Food and Drug Administration",
              "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Lisa Conte",
            "relevance": 0.195026,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Amazon",
            "relevance": 0.176165,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.1%",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 Million",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 million",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$2.3 million",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 Million",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 million",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$6.4 million",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "one-year",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$5.58",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.5%",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.9%",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "5.7%",
            "relevance": 0.176165,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "8-K",
            "relevance": 0.176165,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": -0.327931,
            "label": "negative"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Jaguar Health Strengthens Company",
              "keywords": [
                {
                  "text": "Health Strengthens Company"
                },
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health Strengthens Company"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company’s Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE",
            "object": {
              "text": "Balance Sheet",
              "keywords": [
                {
                  "text": "Balance Sheet"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger",
              "keywords": [
                {
                  "text": "Debt Incurred"
                },
                {
                  "text": "Merger"
                },
                {
                  "text": "Effect"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$10.5 Million"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company’s Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE",
            "object": {
              "text": "to Approximately $4.4 Million ACCESSWIRE",
              "keywords": [
                {
                  "text": "ACCESSWIRE"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$4.4 Million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Reducing",
                "tense": "present"
              },
              "text": "Reducing",
              "normalized": "Reducing"
            }
          },
          {
            "subject": {
              "text": "Maturity Date of Remaining Merger-related Debt",
              "keywords": [
                {
                  "text": "Maturity Date"
                },
                {
                  "text": "Merger-related Debt"
                }
              ]
            },
            "sentence": " Maturity Date of Remaining Merger-related Debt is December 31, 2020",
            "object": {
              "text": "December 31"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " The Company accomplished this reduction in indebtedness through the issuance of approximately 1,119,440 shares of common stock, at a weighted average price of approximately $5.58 per share, to Chicago Venture Partners L.P. (“CVP”) pursuant to exchange agreements entered into between the Company and CVP from May 29, 2019 through July 12, 2019.",
            "object": {
              "text": "this reduction",
              "keywords": [
                {
                  "text": "reduction"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "accomplish",
                "tense": "past"
              },
              "text": "accomplished",
              "normalized": "accomplish"
            }
          },
          {
            "subject": {
              "text": "the Merger",
              "keywords": [
                {
                  "text": "Merger"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "effective July 31"
            },
            "action": {
              "verb": {
                "text": "become",
                "tense": "past"
              },
              "text": "became",
              "normalized": "become"
            }
          },
          {
            "subject": {
              "text": "Jaguar Animal Health’s name",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "action": {
              "verb": {
                "text": "change",
                "tense": "past"
              },
              "text": "changed",
              "normalized": "change"
            }
          },
          {
            "subject": {
              "text": "Inc. and Napo Pharmaceuticals, Inc.",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "Inc."
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "operating as a wholly-owned subsidiary of Jaguar focused on human health",
              "keywords": [
                {
                  "text": "wholly-owned subsidiary"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "operating"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "begin",
                "tense": "past"
              },
              "text": "began",
              "normalized": "begin"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer)",
              "keywords": [
                {
                  "text": "follow-on indications"
                },
                {
                  "text": "ongoing commercialization"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "development"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "focus",
                "tense": "past"
              },
              "text": "focused",
              "normalized": "focus"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health’s name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company’s FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "FDA-approved drug product",
              "keywords": [
                {
                  "text": "FDA-approved drug product"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "We"
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "Lisa Conte"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                },
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "Lisa Conte"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                },
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "pipeline opportunities",
              "keywords": [
                {
                  "text": "pipeline opportunities"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "pipeline opportunities, which include our commercial product, Mytesi,",
              "keywords": [
                {
                  "text": "pipeline opportunities"
                },
                {
                  "text": "commercial product"
                },
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "into the specialty market",
              "keywords": [
                {
                  "text": "specialty market"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "launch",
                "tense": "past"
              },
              "text": "launched",
              "normalized": "launch"
            }
          },
          {
            "subject": {
              "text": "Lisa Conte, president and chief executive officer of Jaguar,",
              "keywords": [
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "Lisa Conte"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "president"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " “We are pleased about this further reduction of the Company’s liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,” Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "deep pipeline"
                },
                {
                  "text": "pipeline opportunities"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "state",
                "tense": "past"
              },
              "text": "stated",
              "normalized": "state"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31",
              "keywords": [
                {
                  "text": "one-year extension"
                },
                {
                  "text": "Original Debt"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "a one-year extension",
              "keywords": [
                {
                  "text": "one-year extension"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "past"
              },
              "text": "has received",
              "normalized": "have receive"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "previously scheduled to mature on December 31, 2019"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "action": {
              "verb": {
                "text": "schedule",
                "tense": "past"
              },
              "text": "scheduled",
              "normalized": "schedule"
            }
          },
          {
            "subject": {
              "text": "The extension of the maturity date",
              "keywords": [
                {
                  "text": "maturity date"
                },
                {
                  "text": "extension"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "part of a larger restructuring of the Original Debt",
              "keywords": [
                {
                  "text": "larger restructuring"
                },
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "the acquisition of the Original Debt by CVP",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "Original Debt"
                },
                {
                  "text": "acquisition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "follow",
                "tense": "present"
              },
              "text": "following",
              "normalized": "follow"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " As consideration for such restructuring, which included among other things the extension of the maturity date by means of an exchange of the Original Debt for new secured debt with a maturity date of December 31, 2020, Jaguar paid CVP a fee of approximately $2.3 million in the form of additional debt (the “Additional Debt”).",
            "object": {
              "text": "CVP a fee of approximately $2.3 million",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "fee"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$2.3 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "pay",
                "tense": "past"
              },
              "text": "paid",
              "normalized": "pay"
            }
          },
          {
            "subject": {
              "text": "The Additional Debt",
              "keywords": [
                {
                  "text": "Additional Debt"
                }
              ]
            },
            "sentence": " The Additional Debt is not included in the Original Debt.",
            "object": {
              "text": "in the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "past",
                "negated": true
              },
              "text": "included",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "The details of this transaction",
              "keywords": [
                {
                  "text": "transaction"
                },
                {
                  "text": "details"
                }
              ]
            },
            "sentence": " The details of this transaction are further described in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "object": {
              "text": "further described in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019",
              "keywords": [
                {
                  "text": "U.S. Securities"
                },
                {
                  "text": "Current Report"
                },
                {
                  "text": "Form 8-K"
                },
                {
                  "text": "Exchange Commission"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "U.S. Securities and Exchange Commission",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency",
                      "GovernmentalBody"
                    ],
                    "name": "U.S. Securities and Exchange Commission",
                    "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
                  }
                },
                {
                  "type": "Quantity",
                  "text": "8-K"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The details of this transaction",
              "keywords": [
                {
                  "text": "transaction"
                },
                {
                  "text": "details"
                }
              ]
            },
            "sentence": " The details of this transaction are further described in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "object": {
              "text": "in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019",
              "keywords": [
                {
                  "text": "U.S. Securities"
                },
                {
                  "text": "Current Report"
                },
                {
                  "text": "Form 8-K"
                },
                {
                  "text": "Exchange Commission"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "U.S. Securities and Exchange Commission",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency",
                      "GovernmentalBody"
                    ],
                    "name": "U.S. Securities and Exchange Commission",
                    "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
                  }
                },
                {
                  "type": "Quantity",
                  "text": "8-K"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "describe",
                "tense": "past"
              },
              "text": "are further described",
              "normalized": "be further describe"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " The details of this transaction are further described in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "object": {
              "text": "Current Report",
              "keywords": [
                {
                  "text": "Current Report"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "object": {
              "text": "all of the approximately $6.4 million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$6.4 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "extinguish",
                "tense": "past"
              },
              "text": "extinguished",
              "normalized": "extinguish"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "action": {
              "verb": {
                "text": "issue",
                "tense": "past"
              },
              "text": "issued",
              "normalized": "issue"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "a commercial stage pharmaceuticals company focused on developing novel",
              "keywords": [
                {
                  "text": "commercial stage pharmaceuticals"
                },
                {
                  "text": "company"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "novel, sustainably derived gastrointestinal products on a global basis",
              "keywords": [
                {
                  "text": "gastrointestinal products"
                },
                {
                  "text": "global basis"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "develop",
                "tense": "future"
              },
              "text": "developing",
              "normalized": "develop"
            }
          },
          {
            "subject": {
              "text": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc.,",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "wholly-owned subsidiary"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "object": {
              "text": "proprietary human gastrointestinal pharmaceuticals",
              "keywords": [
                {
                  "text": "gastrointestinal pharmaceuticals"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "commercialize",
                "tense": "present"
              },
              "text": "commercializing",
              "normalized": "commercialize"
            }
          },
          {
            "subject": {
              "text": "plants",
              "keywords": [
                {
                  "text": "plants"
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "action": {
              "verb": {
                "text": "use",
                "tense": "past"
              },
              "text": "used",
              "normalized": "use"
            }
          },
          {
            "subject": {
              "text": "Our Mytesi ® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "approved by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "sentence": " Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "Our Mytesi ® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "approve",
                "tense": "past"
              },
              "text": "is approved",
              "normalized": "be approve"
            }
          },
          {
            "subject": {
              "text": "Mytesi (crofelemer)",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "object": {
              "text": "an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea",
              "keywords": [
                {
                  "text": "noninfectious diarrhea"
                },
                {
                  "text": "symptomatic relief"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "not indicated for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "indicate",
                "tense": "past",
                "negated": true
              },
              "text": "indicated",
              "normalized": "indicate"
            }
          },
          {
            "subject": {
              "text": "infectious etiologies of diarrhea",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "diarrhea"
                }
              ]
            },
            "sentence": " Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "action": {
              "verb": {
                "text": "Rule",
                "tense": "present"
              },
              "text": "Rule",
              "normalized": "Rule"
            }
          },
          {
            "subject": {
              "text": "patients with infectious etiologies",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "patients"
                }
              ]
            },
            "sentence": " If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen.",
            "object": {
              "text": "the appropriate therapy and their disease",
              "keywords": [
                {
                  "text": "appropriate therapy"
                },
                {
                  "text": "disease"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "future",
                "negated": true
              },
              "text": "receive",
              "normalized": "receive"
            }
          },
          {
            "subject": {
              "text": "a rate greater than placebo",
              "keywords": [
                {
                  "text": "placebo"
                },
                {
                  "text": "rate"
                }
              ]
            },
            "sentence": " In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).",
            "object": {
              "text": "upper respiratory tract infection",
              "keywords": [
                {
                  "text": "respiratory tract infection"
                }
              ],
              "entities": [
                {
                  "type": "HealthCondition",
                  "text": "upper respiratory tract infection",
                  "disambiguation": {
                    "subtype": [
                      "DiseaseOrMedicalCondition",
                      "RiskFactor",
                      "Symptom"
                    ],
                    "name": "Upper respiratory tract infection",
                    "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "were",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Crofelemer, the active ingredient in Mytesi,",
              "keywords": [
                {
                  "text": "active ingredient"
                },
                {
                  "text": "Crofelemer"
                },
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Crofelemer"
                },
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest.",
            "object": {
              "text": "a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest",
              "keywords": [
                {
                  "text": "red bark sap"
                },
                {
                  "text": "medicinal Croton"
                },
                {
                  "text": "Amazon rainforest"
                },
                {
                  "text": "drug"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Amazon"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "established a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "establish",
                "tense": "past"
              },
              "text": "has established",
              "normalized": "have establish"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a high degree of quality and ecological integrity",
              "keywords": [
                {
                  "text": "ecological integrity"
                },
                {
                  "text": "high degree"
                },
                {
                  "text": "quality"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "ensure",
                "tense": "future"
              },
              "text": "to ensure",
              "normalized": "to ensure"
            }
          },
          {
            "subject": {
              "text": "Certain statements in this press release",
              "keywords": [
                {
                  "text": "Certain statements"
                },
                {
                  "text": "press release"
                }
              ],
              "entities": []
            },
            "sentence": " Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s planned clinical and commercial milestones.",
            "object": {
              "text": "“forward-looking statements.” These include statements regarding the Company’s planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "forward-looking statements."
                },
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "action": {
              "verb": {
                "text": "constitute",
                "tense": "present"
              },
              "text": "constitute",
              "normalized": "constitute"
            }
          },
          {
            "subject": {
              "text": "statements regarding the Company’s planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "statements"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s planned clinical and commercial milestones.",
            "object": {
              "text": "Certain statements in this press release constitute “forward-looking statements.” These",
              "keywords": [
                {
                  "text": "forward-looking statements."
                },
                {
                  "text": "Certain statements"
                },
                {
                  "text": "press release"
                }
              ],
              "entities": []
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the Company’s planned clinical and commercial milestones.",
            "object": {
              "text": "planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "has",
              "normalized": "has"
            }
          },
          {
            "subject": {
              "text": "you"
            },
            "sentence": " In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions.",
            "object": {
              "text": "forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "identify",
                "tense": "future"
              },
              "text": "can identify",
              "normalized": "can identify"
            }
          },
          {
            "subject": {
              "text": "The forward-looking statements in this release",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "release"
                }
              ],
              "entities": []
            },
            "sentence": " The forward-looking statements in this release are only predictions.",
            "object": {
              "text": "only predictions",
              "keywords": [
                {
                  "text": "predictions"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Jaguar has based these forward-looking statements largely on its current expectations and projections about future events.",
            "object": {
              "text": "based these forward-looking statements largely on its current expectations and projections about future events",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "current expectations"
                },
                {
                  "text": "future events"
                },
                {
                  "text": "projections"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "These forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "sentence": " These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control.",
            "action": {
              "verb": {
                "text": "speak",
                "tense": "present"
              },
              "text": "speak",
              "normalized": "speak"
            }
          }
        ],
        "concepts": [
          {
            "text": "Medicine",
            "relevance": 0.960319,
            "dbpedia_resource": "http://dbpedia.org/resource/Medicine"
          },
          {
            "text": "AIDS",
            "relevance": 0.694728,
            "dbpedia_resource": "http://dbpedia.org/resource/AIDS"
          },
          {
            "text": "Subsidiary",
            "relevance": 0.603472,
            "dbpedia_resource": "http://dbpedia.org/resource/Subsidiary"
          },
          {
            "text": "Antiretroviral drug",
            "relevance": 0.581799,
            "dbpedia_resource": "http://dbpedia.org/resource/Antiretroviral_drug"
          },
          {
            "text": "HIV",
            "relevance": 0.548639,
            "dbpedia_resource": "http://dbpedia.org/resource/HIV"
          },
          {
            "text": "Respiratory system",
            "relevance": 0.531692,
            "dbpedia_resource": "http://dbpedia.org/resource/Respiratory_system"
          },
          {
            "text": "Health",
            "relevance": 0.52501,
            "dbpedia_resource": "http://dbpedia.org/resource/Health"
          },
          {
            "text": "Clinical trial",
            "relevance": 0.522767,
            "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"
          },
          {
            "text": "Loan",
            "relevance": 0.51706,
            "dbpedia_resource": "http://dbpedia.org/resource/Loan"
          },
          {
            "text": "Debt",
            "relevance": 0.500077,
            "dbpedia_resource": "http://dbpedia.org/resource/Debt"
          },
          {
            "text": "Maturity",
            "relevance": 0.495793,
            "dbpedia_resource": "http://dbpedia.org/resource/Maturity_(finance)"
          },
          {
            "text": "Upper respiratory tract infection",
            "relevance": 0.483913,
            "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
          },
          {
            "text": "Jaguar",
            "relevance": 0.483748,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar"
          },
          {
            "text": "Etiology",
            "relevance": 0.482475,
            "dbpedia_resource": "http://dbpedia.org/resource/Etiology"
          },
          {
            "text": "Pharmacology",
            "relevance": 0.468931,
            "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"
          },
          {
            "text": "Pharmacy",
            "relevance": 0.468384,
            "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"
          },
          {
            "text": "Gastroenteritis",
            "relevance": 0.451586,
            "dbpedia_resource": "http://dbpedia.org/resource/Gastroenteritis"
          },
          {
            "text": "Rolling",
            "relevance": 0.451105,
            "dbpedia_resource": "http://dbpedia.org/resource/Rolling_(finance)"
          }
        ],
        "categories": [
          {
            "score": 0.971978,
            "label": "/health and fitness/disease/aids and hiv"
          },
          {
            "score": 0.728295,
            "label": "/health and fitness/disease/epidemic"
          },
          {
            "score": 0.683466,
            "label": "/finance/financial news"
          }
        ],
        "relations": [
          {
            "type": "locatedAt",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE By Jaguar Health, Inc. Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million,",
            "score": 0.933983,
            "arguments": [
              {
                "text": "SAN FRANCISCO",
                "location": [
                  261,
                  274
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "SAN FRANCISCO"
                  }
                ]
              },
              {
                "text": "CA",
                "location": [
                  276,
                  278
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "CA"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.544866,
            "arguments": [
              {
                "text": "subsidiary",
                "location": [
                  1337,
                  1347
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1351,
                  1357
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.390573,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  1466,
                  1474
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1351,
                  1357
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.717601,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  1466,
                  1474
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  1583,
                  1591
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.581568,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  3717,
                  3725
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3819,
                  3827
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi ® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.895097,
            "arguments": [
              {
                "text": "Mytesi ®\nMytesi",
                "location": [
                  4005,
                  4020
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4108,
                  4116
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Mytesi is not indicated for the treatment of infectious diarrhea.",
            "score": 0.643525,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  4182,
                  4188
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4238,
                  4246
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "score": 0.930052,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  4307,
                  4313
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4282,
                  4290
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.852454,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  1595,
                  1601
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  1583,
                  1591
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.824225,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  3831,
                  3837
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3819,
                  3827
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.504364,
            "arguments": [
              {
                "text": "people",
                "location": [
                  1960,
                  1966
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "people"
                  }
                ]
              },
              {
                "text": "HIV/AIDS",
                "location": [
                  1979,
                  1987
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "HIV/AIDS"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.636627,
            "arguments": [
              {
                "text": "chief executive officer",
                "location": [
                  2133,
                  2156
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Lisa Conte"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  2160,
                  2166
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "score": 0.969167,
            "arguments": [
              {
                "text": "June 3, 2019",
                "location": [
                  2189,
                  2201
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "June 3, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  2179,
                  2188
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.558802,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  2411,
                  2424
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2439,
                  2450
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.435512,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  2475,
                  2478
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2439,
                  2450
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.811688,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  2458,
                  2471
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "CVP",
                "location": [
                  2475,
                  2478
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE By Jaguar Health, Inc. Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million,",
            "score": 0.956883,
            "arguments": [
              {
                "text": "Jaguar Health, Inc.",
                "location": [
                  310,
                  329
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nMaturity Date",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "JAGX",
                "location": [
                  339,
                  343
                ],
                "entities": [
                  {
                    "type": "Ticker",
                    "text": "JAGX"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The details of this transaction are further described in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "score": 0.986494,
            "arguments": [
              {
                "text": "Securities and Exchange Commission",
                "location": [
                  2983,
                  3017
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Securities and Exchange Commission",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  2978,
                  2982
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Original Debt"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.979174,
            "arguments": [
              {
                "text": "Jaguar",
                "location": [
                  3038,
                  3044
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  3045,
                  3054
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.985113,
            "arguments": [
              {
                "text": "May 29, 2019",
                "location": [
                  3055,
                  3067
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "May 29, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  3045,
                  3054
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.898709,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  3073,
                  3080
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              },
              {
                "text": "$6.4 million",
                "location": [
                  3128,
                  3140
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$6.4 million",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.979945,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  3232,
                  3239
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3251,
                  3257
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.88192,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  3261,
                  3264
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3251,
                  3257
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.842766,
            "arguments": [
              {
                "text": "July 2017",
                "location": [
                  3268,
                  3277
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "July 2017"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3251,
                  3257
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.526381,
            "arguments": [
              {
                "text": "March 2018",
                "location": [
                  3286,
                  3296
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "March 2018"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3251,
                  3257
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "score": 0.532118,
            "arguments": [
              {
                "text": "subsidiary",
                "location": [
                  3501,
                  3511
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  3513,
                  3539
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.613956,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  3717,
                  3725
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "Our",
                "location": [
                  3713,
                  3716
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Our"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE By Jaguar Health, Inc. Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million,",
            "score": 0.461917,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  363,
                  370
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              },
              {
                "text": "Jaguar Health, Inc.",
                "location": [
                  310,
                  329
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nMaturity Date",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.996698,
            "arguments": [
              {
                "text": "FDA",
                "location": [
                  3771,
                  3774
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "FDA",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  3766,
                  3770
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Original Debt"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "For more information about Napo, visit napopharma.com .",
            "score": 0.572924,
            "arguments": [
              {
                "text": "Napo",
                "location": [
                  3970,
                  3974
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "napopharma.com",
                "location": [
                  3982,
                  3996
                ],
                "entities": [
                  {
                    "type": "Web",
                    "text": "napopharma.com"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi ® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.927523,
            "arguments": [
              {
                "text": "patients",
                "location": [
                  4126,
                  4134
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "patients"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4108,
                  4116
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Source: Jaguar Health, Inc. Contact: Peter Hodge Jaguar Health, Inc. phodge@jaguar.health Jaguar-JAGX SOURCE: Jaguar Health, Inc. ReleaseID: 551917",
            "score": 0.765541,
            "arguments": [
              {
                "text": "Peter Hodge\nJaguar",
                "location": [
                  6300,
                  6318
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Peter Hodge\nJaguar"
                  }
                ]
              },
              {
                "text": "Health, Inc.\nphodge@jaguar.health\nJaguar-JAGX\nSOURCE",
                "location": [
                  6319,
                  6371
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Health, Inc.\nphodge@jaguar.health\nJaguar-JAGX\nSOURCE",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE By Jaguar Health, Inc. Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million,",
            "score": 0.982054,
            "arguments": [
              {
                "text": "today",
                "location": [
                  520,
                  525
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "today"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  510,
                  519
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE By Jaguar Health, Inc. Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million,",
            "score": 0.395322,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  535,
                  542
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health Strengthens Company"
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  588,
                  594
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE By Jaguar Health, Inc. Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million,",
            "score": 0.767646,
            "arguments": [
              {
                "text": "2017",
                "location": [
                  583,
                  587
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "2017"
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  588,
                  594
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE By Jaguar Health, Inc. Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million,",
            "score": 0.66856,
            "arguments": [
              {
                "text": "Jaguar Animal Health, Inc.",
                "location": [
                  598,
                  624
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Animal Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  588,
                  594
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "participantIn",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE By Jaguar Health, Inc. Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million,",
            "score": 0.325759,
            "arguments": [
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  629,
                  655
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  588,
                  594
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million ACCESSWIRE By Jaguar Health, Inc. Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million,",
            "score": 0.746217,
            "arguments": [
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  629,
                  655
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "$10.5 million",
                "location": [
                  690,
                  703
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$10.5 million",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "Jaguar Health",
            "sentiment": {
              "score": 0.297014,
              "mixed": "1",
              "label": "positive"
            },
            "relevance": 0.613236,
            "count": 6
          },
          {
            "text": "Napo Pharmaceuticals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.595888,
            "count": 3
          },
          {
            "text": "clinical studies",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.571587,
            "count": 1
          },
          {
            "text": "pharmaceutical company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.571097,
            "count": 1
          },
          {
            "text": "extension of the maturity date",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.570432,
            "count": 2
          },
          {
            "text": "development of follow",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.55656,
            "count": 1
          },
          {
            "text": "commercial stage",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.554282,
            "count": 1
          },
          {
            "text": "merger of Jaguar Animal Health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.548491,
            "count": 1
          },
          {
            "text": "gastrointestinal products",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.547199,
            "count": 2
          },
          {
            "text": "SAN FRANCISCO",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.542056,
            "count": 1
          },
          {
            "text": "human health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.541315,
            "count": 1
          },
          {
            "text": "press release",
            "sentiment": {
              "score": -0.607008,
              "label": "negative"
            },
            "relevance": 0.540999,
            "count": 1
          },
          {
            "text": "shares of common stock",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.538588,
            "count": 1
          },
          {
            "text": "pipeline opportunities",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.538427,
            "count": 1
          },
          {
            "text": "active ingredient",
            "sentiment": {
              "score": -0.804786,
              "label": "negative"
            },
            "relevance": 0.538043,
            "count": 1
          },
          {
            "text": "Remaining Merger-related Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.537235,
            "count": 1
          },
          {
            "text": "treatment of infectious diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.535128,
            "count": 1
          },
          {
            "text": "Jaguar Health Strengthens Company’s Balance Sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.534308,
            "count": 1
          },
          {
            "text": "Jaguar Animal Health’s name",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.531607,
            "count": 1
          },
          {
            "text": "commercial product",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.531013,
            "count": 1
          },
          {
            "text": "promissory notes",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529651,
            "count": 1
          },
          {
            "text": "Original Debt",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.529496,
            "count": 3
          },
          {
            "text": "average price",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529075,
            "count": 1
          },
          {
            "text": "upper respiratory tract infection",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.528922,
            "count": 1
          },
          {
            "text": "infectious etiologies of diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.528819,
            "count": 1
          },
          {
            "text": "class anti-secretory agent",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.527634,
            "count": 1
          },
          {
            "text": "symptomatic relief of noninfectious diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.527534,
            "count": 3
          },
          {
            "text": "adult patients",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.525714,
            "count": 1
          },
          {
            "text": "part of a larger restructuring of the Original Debt",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.525396,
            "count": 1
          },
          {
            "text": "subsidiary of Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.524627,
            "count": 1
          },
          {
            "text": "one-year extension",
            "sentiment": {
              "score": 0.982186,
              "label": "positive"
            },
            "relevance": 0.524097,
            "count": 1
          },
          {
            "text": "effective July",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.523608,
            "count": 1
          },
          {
            "text": "such restructuring",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.523316,
            "count": 1
          },
          {
            "text": "Statements",
            "sentiment": {
              "score": -0.607008,
              "label": "negative"
            },
            "relevance": 0.52211,
            "count": 9
          },
          {
            "text": "Company",
            "sentiment": {
              "score": 0.491335,
              "mixed": "1",
              "label": "positive"
            },
            "relevance": 0.520786,
            "count": 8
          },
          {
            "text": "commercial milestones",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.520726,
            "count": 2
          },
          {
            "text": "Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.520346,
            "count": 3
          },
          {
            "text": "details of this transaction",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.51993,
            "count": 1
          },
          {
            "text": "Company’s balance sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519416,
            "count": 1
          },
          {
            "text": "Exchange Commission",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.5179,
            "count": 1
          },
          {
            "text": "drug product",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.51777,
            "count": 1
          },
          {
            "text": "further reduction of the Company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517758,
            "count": 1
          },
          {
            "text": "applicable law",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517498,
            "count": 1
          },
          {
            "text": "plan",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.516475,
            "count": 1
          },
          {
            "text": "global marketplace",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.515303,
            "count": 1
          },
          {
            "text": "global basis",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514987,
            "count": 2
          },
          {
            "text": "ongoing commercialization",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514886,
            "count": 1
          },
          {
            "text": "means of an exchange of the Original Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514218,
            "count": 1
          },
          {
            "text": "future events",
            "sentiment": {
              "score": 0.859669,
              "label": "positive"
            },
            "relevance": 0.51393,
            "count": 2
          },
          {
            "text": "commercial stage pharmaceuticals company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.513733,
            "count": 1
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "5c7889644bbb11a397e4ae70f74b0f32dd873edc",
        "filename": "1563196558823.zip-55972396af0116f893788ddf20edb4e5.xml",
        "file_type": "json"
      },
      "external_links": [
        "http://www.accesswire.com/viewarticle.aspx?id=551917",
        "http://pr.report/4KhQR-nx",
        "http://pr.report/gT3iZsMS",
        "http://pr.report/6kwvcahl"
      ],
      "title": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
      "forum_title": "Canadian Money | brought to you by MONEY®"
    },
    {
      "id": "vOEx-TOL3qjvLX2c74GZSE8OWumjRYRHI0JdmA2JUEH3SA6JgiBUdiYtmfrG0zKn",
      "result_metadata": {
        "score": 20.411911
      },
      "author": "pbaghmar",
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": -0.512111,
              "label": "negative"
            },
            "text": "Canada",
            "relevance": 0.33,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "Country"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "27.5%",
            "relevance": 0.33,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0,
            "label": "neutral"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Canada",
              "keywords": [
                {
                  "text": "Canada"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Canada",
                  "disambiguation": {
                    "subtype": [
                      "Country"
                    ]
                  }
                }
              ]
            },
            "sentence": "Canada’s metals & mining industry sees a drop of 27.5% in deal activity in June 2019",
            "object": {
              "text": "metals & mining industry",
              "keywords": [
                {
                  "text": "metals"
                },
                {
                  "text": "mining industry"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "Canada’s metals & mining industry",
              "keywords": [
                {
                  "text": "metals"
                },
                {
                  "text": "mining industry"
                },
                {
                  "text": "Canada"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Canada",
                  "disambiguation": {
                    "subtype": [
                      "Country"
                    ]
                  }
                }
              ]
            },
            "sentence": "Canada’s metals & mining industry sees a drop of 27.5% in deal activity in June 2019",
            "object": {
              "text": "a drop of 27.5% in deal activity in June 2019",
              "keywords": [
                {
                  "text": "deal activity"
                },
                {
                  "text": "drop"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "27.5"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "see",
                "tense": "present"
              },
              "text": "sees",
              "normalized": "see"
            }
          }
        ],
        "concepts": [
          {
            "text": "Iron",
            "relevance": 0.91036,
            "dbpedia_resource": "http://dbpedia.org/resource/Iron"
          },
          {
            "text": "Uranium",
            "relevance": 0.819886,
            "dbpedia_resource": "http://dbpedia.org/resource/Uranium"
          },
          {
            "text": "Mining",
            "relevance": 0.7832,
            "dbpedia_resource": "http://dbpedia.org/resource/Mining"
          },
          {
            "text": "Fire-setting",
            "relevance": 0.7128,
            "dbpedia_resource": "http://dbpedia.org/resource/Fire-setting"
          }
        ],
        "categories": [
          {
            "score": 0.999998,
            "label": "/business and industrial/mining industry"
          }
        ],
        "relations": [],
        "keywords": [
          {
            "text": "Canada’s metals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.997949,
            "count": 1
          },
          {
            "text": "mining industry",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.992061,
            "count": 1
          },
          {
            "text": "June",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.564564,
            "count": 1
          },
          {
            "text": "deal activity",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.253774,
            "count": 1
          },
          {
            "text": "drop",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.043514,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-16T20:56:17Z",
      "url": "https://www.mining-technology.com/deals-analysis/canada-metals-mining-industry-deals-in-june-2019/",
      "host": "mining-technology.com",
      "text": "In second place was the $150m venture financing of DeepGreen Resources by Allseas Group and in third place was Eric Steven Sprott and Tocqueville Asset Management’s $25m private equity deal with Jaguar Mining. The $22m acquisition of ECU Silver Mining by Compania Minera Autlan SAB de CV and Sailfish Royalty’s",
      "main_image_url": "https://www.mining-technology.com/wp-content/uploads/sites/8/2019/03/deals_4.jpg",
      "country": "US",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-16T04:30:00Z",
      "enriched_text": {
        "entities": [
          {
            "count": 3,
            "sentiment": {
              "score": -0.50025,
              "label": "negative"
            },
            "text": "Canada",
            "relevance": 0.875982,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "Country"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Canada metals",
            "relevance": 0.755483,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Mining",
            "relevance": 0.688768,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Tocqueville Asset Management",
            "relevance": 0.495307,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Eric Steven Sprott",
            "relevance": 0.487368,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Pala Investments",
            "relevance": 0.47028,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "ECU",
            "relevance": 0.448504,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Sailfish Royalty",
            "relevance": 0.432352,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Allseas Group",
            "relevance": 0.430809,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Terraco Gold",
            "relevance": 0.392148,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "12-month",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "696.95m",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "27.5%",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "17 hours",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "137.78m",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "150.08m",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "373.59m",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "409.08m",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "21.02m",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "591.6m",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "20.7%",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "72.4%",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "84.9%",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "100%",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "150m",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "6.9%",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "22m",
            "relevance": 0.392148,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "25m",
            "relevance": 0.392148,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0.920269,
            "label": "positive"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "16 July 2019 Deals Analysis Canada",
              "keywords": [
                {
                  "text": "Deals Analysis"
                },
                {
                  "text": "Canada"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Canada",
                  "disambiguation": {
                    "subtype": [
                      "Country"
                    ]
                  }
                }
              ]
            },
            "sentence": "16 July 2019 Deals Analysis Canada’s metals & mining industry sees a drop of 27.5% in deal activity in June 2019 Share pbaghmar 17 hours ago",
            "object": {
              "text": "metals & mining industry",
              "keywords": [
                {
                  "text": "metals"
                },
                {
                  "text": "mining industry"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "16 July 2019 Deals Analysis Canada’s metals & mining industry",
              "keywords": [
                {
                  "text": "Deals Analysis"
                },
                {
                  "text": "mining industry"
                },
                {
                  "text": "metals"
                },
                {
                  "text": "Canada"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Canada",
                  "disambiguation": {
                    "subtype": [
                      "Country"
                    ]
                  }
                }
              ]
            },
            "sentence": "16 July 2019 Deals Analysis Canada’s metals & mining industry sees a drop of 27.5% in deal activity in June 2019 Share pbaghmar 17 hours ago",
            "object": {
              "text": "a drop of 27.5% in deal activity in June 2019 Share pbaghmar 17 hours ago",
              "keywords": [
                {
                  "text": "deal activity"
                },
                {
                  "text": "Share pbaghmar"
                },
                {
                  "text": "drop"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "17 hours"
                },
                {
                  "type": "Quantity",
                  "text": "27.5"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "see",
                "tense": "present"
              },
              "text": "sees",
              "normalized": "see"
            }
          },
          {
            "subject": {
              "text": "Canada",
              "keywords": [
                {
                  "text": "Canada"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Canada",
                  "disambiguation": {
                    "subtype": [
                      "Country"
                    ]
                  }
                }
              ]
            },
            "sentence": " Canada’s metals & mining industry saw a drop of 27.5% in overall deal activity during June 2019, when compared with the last 12-month average, according to GlobalData’s deals database.",
            "object": {
              "text": "metals & mining industry",
              "keywords": [
                {
                  "text": "metals"
                },
                {
                  "text": "mining industry"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "Canada’s metals & mining industry",
              "keywords": [
                {
                  "text": "metals"
                },
                {
                  "text": "mining industry"
                },
                {
                  "text": "Canada"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Canada",
                  "disambiguation": {
                    "subtype": [
                      "Country"
                    ]
                  }
                }
              ]
            },
            "sentence": " Canada’s metals & mining industry saw a drop of 27.5% in overall deal activity during June 2019, when compared with the last 12-month average, according to GlobalData’s deals database.",
            "object": {
              "text": "a drop of 27.5% in overall deal activity during June 2019",
              "keywords": [
                {
                  "text": "overall deal activity"
                },
                {
                  "text": "drop"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "27.5"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "see",
                "tense": "past"
              },
              "text": "saw",
              "normalized": "see"
            }
          },
          {
            "subject": {
              "text": "this chart",
              "keywords": [
                {
                  "text": "chart"
                }
              ]
            },
            "sentence": " Embed this chart into your website",
            "object": {
              "text": "into your website",
              "keywords": [
                {
                  "text": "website"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Embed",
                "tense": "past"
              },
              "text": "Embed",
              "normalized": "Embed"
            }
          },
          {
            "subject": {
              "text": "the code below",
              "keywords": [
                {
                  "text": "code"
                }
              ]
            },
            "sentence": " Copy and paste the code below into your website to display the chart.",
            "object": {
              "text": "into your website",
              "keywords": [
                {
                  "text": "website"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "paste",
                "tense": "present"
              },
              "text": "paste",
              "normalized": "paste"
            }
          },
          {
            "subject": {
              "text": "A total of 29 deals worth $696.95m",
              "keywords": [
                {
                  "text": "deals"
                },
                {
                  "text": "total"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "696.95m"
                }
              ]
            },
            "sentence": " A total of 29 deals worth $696.95m were announced in June 2019, compared to the 12-month average of 40 deals.",
            "object": {
              "text": "announced in June 2019"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "were",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "A total of 29 deals worth $696.95m",
              "keywords": [
                {
                  "text": "deals"
                },
                {
                  "text": "total"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "696.95m"
                }
              ]
            },
            "sentence": " A total of 29 deals worth $696.95m were announced in June 2019, compared to the 12-month average of 40 deals.",
            "action": {
              "verb": {
                "text": "announce",
                "tense": "past"
              },
              "text": "were announced",
              "normalized": "be announce"
            }
          },
          {
            "subject": {
              "text": "A total of 29 deals worth $696.95m",
              "keywords": [
                {
                  "text": "deals"
                },
                {
                  "text": "total"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "696.95m"
                }
              ]
            },
            "sentence": " A total of 29 deals worth $696.95m were announced in June 2019, compared to the 12-month average of 40 deals.",
            "object": {
              "text": "to the 12-month average of 40 deals",
              "keywords": [
                {
                  "text": "12-month average"
                },
                {
                  "text": "deals"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "12-month"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "compare",
                "tense": "past"
              },
              "text": "compared",
              "normalized": "compare"
            }
          },
          {
            "subject": {
              "text": "M&A",
              "keywords": [
                {
                  "text": "M&A"
                }
              ]
            },
            "sentence": " M&A was the leading category in the month in terms of volume with 21 deals which accounted for 72.4% of all deals.",
            "object": {
              "text": "the leading category",
              "keywords": [
                {
                  "text": "category"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "21 deals",
              "keywords": [
                {
                  "text": "deals"
                }
              ]
            },
            "sentence": " M&A was the leading category in the month in terms of volume with 21 deals which accounted for 72.4% of all deals.",
            "object": {
              "text": "for 72.4% of all deals",
              "keywords": [
                {
                  "text": "deals"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "72.4"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "account",
                "tense": "past"
              },
              "text": "accounted",
              "normalized": "account"
            }
          },
          {
            "subject": {
              "text": "private equity with six deals",
              "keywords": [
                {
                  "text": "private equity"
                },
                {
                  "text": "deals"
                }
              ]
            },
            "sentence": " In second place was private equity with six deals, followed by venture financing with two transactions, respectively accounting for 20.7% and 6.9% of overall deal activity in the country’s metals & mining industry during the month.",
            "object": {
              "text": "by venture financing with two transactions",
              "keywords": [
                {
                  "text": "venture"
                },
                {
                  "text": "transactions"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "follow",
                "tense": "past"
              },
              "text": "followed",
              "normalized": "follow"
            }
          },
          {
            "subject": {
              "text": "metals & mining industry",
              "keywords": [
                {
                  "text": "metals"
                },
                {
                  "text": "mining industry"
                }
              ]
            },
            "sentence": " In second place was private equity with six deals, followed by venture financing with two transactions, respectively accounting for 20.7% and 6.9% of overall deal activity in the country’s metals & mining industry during the month.",
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "private equity and venture financing deals",
              "keywords": [
                {
                  "text": "venture financing deals"
                },
                {
                  "text": "private equity"
                }
              ]
            },
            "sentence": " In terms of value of deals, M&A was the leading deal category in Canada’s metals & mining industry with total deals worth $409.08m, while private equity and venture financing deals totalled $150.08m and $137.78m, respectively.",
            "object": {
              "text": "$150.08m",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "150.08m"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "total",
                "tense": "past"
              },
              "text": "totalled",
              "normalized": "total"
            }
          },
          {
            "subject": {
              "text": "The top five metals & mining industry deals",
              "keywords": [
                {
                  "text": "mining industry deals"
                },
                {
                  "text": "metals"
                }
              ]
            },
            "sentence": " The top five metals & mining industry deals accounted for 84.9% of the overall value during June 2019.",
            "object": {
              "text": "for 84.9% of the overall value",
              "keywords": [
                {
                  "text": "overall value"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "84.9"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "account",
                "tense": "past"
              },
              "text": "accounted",
              "normalized": "account"
            }
          },
          {
            "subject": {
              "text": "The combined value of the top five metals & mining industry deals",
              "keywords": [
                {
                  "text": "mining industry deals"
                },
                {
                  "text": "combined value"
                },
                {
                  "text": "metals"
                }
              ]
            },
            "sentence": " The combined value of the top five metals & mining industry deals stood at $591.6m, against the overall value of $696.95m recorded for the month.",
            "object": {
              "text": "at $591.6m",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "591.6m"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "stand",
                "tense": "past"
              },
              "text": "stood",
              "normalized": "stand"
            }
          },
          {
            "subject": {
              "text": "the overall value of $696.95m",
              "keywords": [
                {
                  "text": "overall value"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "696.95m"
                }
              ]
            },
            "sentence": " The combined value of the top five metals & mining industry deals stood at $591.6m, against the overall value of $696.95m recorded for the month.",
            "action": {
              "verb": {
                "text": "record",
                "tense": "past"
              },
              "text": "recorded",
              "normalized": "record"
            }
          },
          {
            "subject": {
              "text": "The top"
            },
            "sentence": " The top announced Canada metals & mining industry deal tracked by GlobalData in June 2019 was Pala Investments’ $373.59m private equity deal with Cobalt 27 Capital.",
            "object": {
              "text": "Canada metals & mining industry deal tracked by GlobalData in June 2019 was Pala Investments’ $373.59m private equity deal with Cobalt 27 Capital",
              "keywords": [
                {
                  "text": "private equity deal"
                },
                {
                  "text": "mining industry deal"
                },
                {
                  "text": "Pala Investments"
                },
                {
                  "text": "Canada metals"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Canada metals"
                },
                {
                  "type": "Company",
                  "text": "Pala Investments"
                },
                {
                  "type": "Quantity",
                  "text": "373.59m"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "announce",
                "tense": "past"
              },
              "text": "announced",
              "normalized": "announce"
            }
          },
          {
            "subject": {
              "text": "by GlobalData",
              "keywords": [
                {
                  "text": "GlobalData"
                }
              ]
            },
            "sentence": " The top announced Canada metals & mining industry deal tracked by GlobalData in June 2019 was Pala Investments’ $373.59m private equity deal with Cobalt 27 Capital.",
            "object": {
              "text": "Canada metals & mining industry deal",
              "keywords": [
                {
                  "text": "mining industry deal"
                },
                {
                  "text": "Canada metals"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Canada metals"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "track",
                "tense": "past"
              },
              "text": "tracked",
              "normalized": "track"
            }
          },
          {
            "subject": {
              "text": "the $150m venture financing of DeepGreen Resources by Allseas Group and in third place",
              "keywords": [
                {
                  "text": "150m venture financing"
                },
                {
                  "text": "DeepGreen Resources"
                },
                {
                  "text": "Allseas Group"
                },
                {
                  "text": "place"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Allseas Group"
                },
                {
                  "type": "Quantity",
                  "text": "150m"
                }
              ]
            },
            "sentence": " In second place was the $150m venture financing of DeepGreen Resources by Allseas Group and in third place was Eric Steven Sprott and Tocqueville Asset Management’s $25m private equity deal with Jaguar Mining.",
            "object": {
              "text": "Eric Steven Sprott and Tocqueville Asset Management’s $25m private equity deal with Jaguar Mining",
              "keywords": [
                {
                  "text": "Eric Steven Sprott"
                },
                {
                  "text": "Tocqueville Asset Management"
                },
                {
                  "text": "private equity deal"
                },
                {
                  "text": "Jaguar Mining"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Eric Steven Sprott"
                },
                {
                  "type": "JobTitle",
                  "text": "Tocqueville Asset Management"
                },
                {
                  "type": "Company",
                  "text": "Jaguar Mining"
                },
                {
                  "type": "Quantity",
                  "text": "25m"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Eric Steven Sprott and Tocqueville Asset Management",
              "keywords": [
                {
                  "text": "Eric Steven Sprott"
                },
                {
                  "text": "Tocqueville Asset Management"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Eric Steven Sprott"
                },
                {
                  "type": "JobTitle",
                  "text": "Tocqueville Asset Management"
                }
              ]
            },
            "sentence": " In second place was the $150m venture financing of DeepGreen Resources by Allseas Group and in third place was Eric Steven Sprott and Tocqueville Asset Management’s $25m private equity deal with Jaguar Mining.",
            "object": {
              "text": "$25m private equity deal with Jaguar Mining",
              "keywords": [
                {
                  "text": "private equity deal"
                },
                {
                  "text": "Jaguar Mining"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Mining"
                },
                {
                  "type": "Quantity",
                  "text": "25m"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "Sailfish Royalty",
              "keywords": [
                {
                  "text": "Sailfish Royalty"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Sailfish Royalty"
                }
              ]
            },
            "sentence": " The $22m acquisition of ECU Silver Mining by Compania Minera Autlan SAB de CV and Sailfish Royalty’s acquisition of Terraco Gold for $21.02m held fourth and fifth positions, respectively.",
            "object": {
              "text": "acquisition of Terraco Gold",
              "keywords": [
                {
                  "text": "acquisition"
                },
                {
                  "text": "Terraco Gold"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Terraco Gold"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "has",
                "tense": "present"
              },
              "text": "s",
              "normalized": "s"
            }
          },
          {
            "subject": {
              "text": "This analysis",
              "keywords": [
                {
                  "text": "analysis"
                }
              ]
            },
            "sentence": " This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals.",
            "object": {
              "text": "deals from the GlobalData financial deals database",
              "keywords": [
                {
                  "text": "GlobalData financial deals"
                },
                {
                  "text": "database"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "complete",
                "tense": "past"
              },
              "text": "completed",
              "normalized": "complete"
            }
          },
          {
            "subject": {
              "text": "This analysis",
              "keywords": [
                {
                  "text": "analysis"
                }
              ]
            },
            "sentence": " This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals.",
            "object": {
              "text": "all terminated and rumoured deals",
              "keywords": [
                {
                  "text": "deals"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "exclude",
                "tense": "present"
              },
              "text": "excludes",
              "normalized": "exclude"
            }
          },
          {
            "subject": {
              "text": "Country and industry",
              "keywords": [
                {
                  "text": "Country"
                },
                {
                  "text": "industry"
                }
              ]
            },
            "sentence": " Country and industry are defined according to the headquarters and dominant industry of the target firm.",
            "object": {
              "text": "according to the headquarters and dominant industry of the target firm",
              "keywords": [
                {
                  "text": "dominant industry"
                },
                {
                  "text": "target firm"
                },
                {
                  "text": "headquarters"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "define",
                "tense": "past"
              },
              "text": "are defined",
              "normalized": "be define"
            }
          },
          {
            "subject": {
              "text": "Country and industry",
              "keywords": [
                {
                  "text": "Country"
                },
                {
                  "text": "industry"
                }
              ]
            },
            "sentence": " Country and industry are defined according to the headquarters and dominant industry of the target firm.",
            "object": {
              "text": "to the headquarters and dominant industry of the target firm",
              "keywords": [
                {
                  "text": "dominant industry"
                },
                {
                  "text": "target firm"
                },
                {
                  "text": "headquarters"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "accord",
                "tense": "present"
              },
              "text": "according",
              "normalized": "accord"
            }
          },
          {
            "subject": {
              "text": "both"
            },
            "sentence": " The term ‘acquisition’ refers to both completed deals and those in the bidding stage.",
            "object": {
              "text": "deals",
              "keywords": [
                {
                  "text": "deals"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "complete",
                "tense": "past"
              },
              "text": "completed",
              "normalized": "complete"
            }
          },
          {
            "subject": {
              "text": "data",
              "keywords": [
                {
                  "text": "data"
                }
              ]
            },
            "sentence": " GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.",
            "object": {
              "text": "all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources",
              "keywords": [
                {
                  "text": "private equity/venture capital"
                },
                {
                  "text": "asset transaction activity"
                },
                {
                  "text": "reliable sources"
                },
                {
                  "text": "company websites"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "concern",
                "tense": "present"
              },
              "text": "concerning",
              "normalized": "concern"
            }
          },
          {
            "subject": {
              "text": "More in-depth reports and analysis on all",
              "keywords": [
                {
                  "text": "in-depth reports"
                },
                {
                  "text": "analysis"
                }
              ]
            },
            "sentence": " More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database .",
            "object": {
              "text": "deals",
              "keywords": [
                {
                  "text": "deals"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "report",
                "tense": "past"
              },
              "text": "reported",
              "normalized": "report"
            }
          },
          {
            "subject": {
              "text": "More in-depth reports and analysis on all reported deals",
              "keywords": [
                {
                  "text": "in-depth reports"
                },
                {
                  "text": "deals"
                },
                {
                  "text": "analysis"
                }
              ]
            },
            "sentence": " More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database .",
            "object": {
              "text": "available for subscribers to GlobalData’s deals database",
              "keywords": [
                {
                  "text": "GlobalData’s deals"
                },
                {
                  "text": "subscribers"
                },
                {
                  "text": "database"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          }
        ],
        "concepts": [
          {
            "text": "Venture capital",
            "relevance": 0.953723,
            "dbpedia_resource": "http://dbpedia.org/resource/Venture_capital"
          },
          {
            "text": "Mergers and acquisitions",
            "relevance": 0.783724,
            "dbpedia_resource": "http://dbpedia.org/resource/Mergers_and_acquisitions"
          },
          {
            "text": "Investment",
            "relevance": 0.761751,
            "dbpedia_resource": "http://dbpedia.org/resource/Investment"
          },
          {
            "text": "Private equity",
            "relevance": 0.65551,
            "dbpedia_resource": "http://dbpedia.org/resource/Private_equity"
          },
          {
            "text": "Iron",
            "relevance": 0.6207,
            "dbpedia_resource": "http://dbpedia.org/resource/Iron"
          },
          {
            "text": "Corporate finance",
            "relevance": 0.593591,
            "dbpedia_resource": "http://dbpedia.org/resource/Corporate_finance"
          },
          {
            "text": "Laurium",
            "relevance": 0.580867,
            "dbpedia_resource": "http://dbpedia.org/resource/Laurium"
          },
          {
            "text": "Capitalism",
            "relevance": 0.574127,
            "dbpedia_resource": "http://dbpedia.org/resource/Capitalism"
          }
        ],
        "categories": [
          {
            "score": 0.891863,
            "label": "/finance/investing"
          },
          {
            "score": 0.891863,
            "label": "/finance/investing/beginning investing"
          },
          {
            "score": 0.884965,
            "label": "/business and industrial/mining industry"
          }
        ],
        "relations": [
          {
            "type": "timeOf",
            "sentence": "<iframe src=\"http://image.digitalinsightresearch.in/Uploads/ImageLibrary/DealArticles/Template5_Monthly_6_2019_metals_mining_Canada____Embed.html\" style=\"width: 100%;height: 500px;border: none;\"></iframe> A total of 29 deals worth $696.95m were announced in June 2019, compared to the 12-month average of 40 deals.",
            "score": 0.940664,
            "arguments": [
              {
                "text": "June 2019",
                "location": [
                  689,
                  698
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "June 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  676,
                  685
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.",
            "score": 0.671477,
            "arguments": [
              {
                "text": "GlobalData",
                "location": [
                  2572,
                  2582
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "GlobalData financial"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2631,
                  2642
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "basedIn",
            "sentence": "GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.",
            "score": 0.719342,
            "arguments": [
              {
                "text": "company websites",
                "location": [
                  2741,
                  2757
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "company websites",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "world",
                "location": [
                  2717,
                  2722
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "world",
                    "disambiguation": {
                      "subtype": [
                        "Area"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "In terms of value of deals, M&A was the leading deal category in Canada's metals & mining industry with total deals worth $409.08m, while private equity and venture financing deals totalled $150.08m and $137.78m, respectively.",
            "score": 0.431356,
            "arguments": [
              {
                "text": "M&A",
                "location": [
                  1121,
                  1124
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "M&A"
                  }
                ]
              },
              {
                "text": "Canada",
                "location": [
                  1158,
                  1164
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Canada",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "In second place was the $150m venture financing of DeepGreen Resources by Allseas Group and in third place was Eric Steven Sprott and Tocqueville Asset Management's $25m private equity deal with Jaguar Mining.",
            "score": 0.711276,
            "arguments": [
              {
                "text": "DeepGreen Resources",
                "location": [
                  1847,
                  1866
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "DeepGreen Resources"
                  }
                ]
              },
              {
                "text": "Allseas Group",
                "location": [
                  1870,
                  1883
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Allseas Group",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "In second place was the $150m venture financing of DeepGreen Resources by Allseas Group and in third place was Eric Steven Sprott and Tocqueville Asset Management's $25m private equity deal with Jaguar Mining.",
            "score": 0.620091,
            "arguments": [
              {
                "text": "Tocqueville Asset Management",
                "location": [
                  1930,
                  1958
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Tocqueville Asset Management"
                  }
                ]
              },
              {
                "text": "Jaguar Mining",
                "location": [
                  1991,
                  2004
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Mining",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "The $22m acquisition of ECU Silver Mining by Compania Minera Autlan SAB de CV and Sailfish Royalty's acquisition of Terraco Gold for $21.02m held fourth and fifth positions, respectively.",
            "score": 0.829435,
            "arguments": [
              {
                "text": "ECU Silver Mining",
                "location": [
                  2030,
                  2047
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "ECU Silver Mining"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2015,
                  2026
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The $22m acquisition of ECU Silver Mining by Compania Minera Autlan SAB de CV and Sailfish Royalty's acquisition of Terraco Gold for $21.02m held fourth and fifth positions, respectively.",
            "score": 0.600854,
            "arguments": [
              {
                "text": "Compania Minera Autlan SAB",
                "location": [
                  2051,
                  2077
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Compania Minera Autlan SAB"
                  }
                ]
              },
              {
                "text": "ECU Silver Mining",
                "location": [
                  2030,
                  2047
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "ECU Silver Mining"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The $22m acquisition of ECU Silver Mining by Compania Minera Autlan SAB de CV and Sailfish Royalty's acquisition of Terraco Gold for $21.02m held fourth and fifth positions, respectively.",
            "score": 0.66214,
            "arguments": [
              {
                "text": "Sailfish Royalty",
                "location": [
                  2088,
                  2104
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Sailfish Royalty"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2107,
                  2118
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "The $22m acquisition of ECU Silver Mining by Compania Minera Autlan SAB de CV and Sailfish Royalty's acquisition of Terraco Gold for $21.02m held fourth and fifth positions, respectively.",
            "score": 0.652881,
            "arguments": [
              {
                "text": "Terraco Gold for",
                "location": [
                  2122,
                  2138
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Terraco Gold for"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2107,
                  2118
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "The $22m acquisition of ECU Silver Mining by Compania Minera Autlan SAB de CV and Sailfish Royalty's acquisition of Terraco Gold for $21.02m held fourth and fifth positions, respectively.",
            "score": 0.426445,
            "arguments": [
              {
                "text": "Terraco Gold for",
                "location": [
                  2122,
                  2138
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Terraco Gold for"
                  }
                ]
              },
              {
                "text": "$21.02m",
                "location": [
                  2139,
                  2146
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$21.02m"
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "Deals Analysis Canada’s metals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.890902,
            "count": 1
          },
          {
            "text": "mining industry",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.784018,
            "count": 4
          },
          {
            "text": "deal activity",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.703459,
            "count": 1
          },
          {
            "text": "private equity",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.659209,
            "count": 3
          },
          {
            "text": "overall deal activity",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.635866,
            "count": 2
          },
          {
            "text": "second place",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.634196,
            "count": 2
          },
          {
            "text": "acquisition of ECU Silver Mining",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.625112,
            "count": 1
          },
          {
            "text": "GlobalData’s deals database",
            "sentiment": {
              "score": 0.920269,
              "label": "positive"
            },
            "relevance": 0.623818,
            "count": 2
          },
          {
            "text": "iframe src",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.60997,
            "count": 1
          },
          {
            "text": "terms of value of deals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.576241,
            "count": 1
          },
          {
            "text": "terms of volume",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.569468,
            "count": 1
          },
          {
            "text": "overall value",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.563173,
            "count": 2
          },
          {
            "text": "Canada’s metals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.554239,
            "count": 2
          },
          {
            "text": "M&A",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.553958,
            "count": 2
          },
          {
            "text": "Top deals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.544351,
            "count": 1
          },
          {
            "text": "Sailfish Royalty’s acquisition",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.541967,
            "count": 1
          },
          {
            "text": "venture financing deals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.53975,
            "count": 1
          },
          {
            "text": "venture financing of DeepGreen Resources",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.538873,
            "count": 1
          },
          {
            "text": "real-time data",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.536097,
            "count": 1
          },
          {
            "text": "venture capital",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.534916,
            "count": 1
          },
          {
            "text": "last 12-month average",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.530726,
            "count": 1
          },
          {
            "text": "country’s metals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.528255,
            "count": 1
          },
          {
            "text": "depth reports",
            "sentiment": {
              "score": 0.920269,
              "label": "positive"
            },
            "relevance": 0.525564,
            "count": 1
          },
          {
            "text": "venture",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.524578,
            "count": 1
          },
          {
            "text": "deals",
            "sentiment": {
              "score": 0.920269,
              "label": "positive"
            },
            "relevance": 0.520916,
            "count": 9
          },
          {
            "text": "June",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519336,
            "count": 6
          },
          {
            "text": "reliable sources",
            "sentiment": {
              "score": 0.920269,
              "label": "positive"
            },
            "relevance": 0.517562,
            "count": 1
          },
          {
            "text": "Allseas Group",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517146,
            "count": 1
          },
          {
            "text": "category",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.516707,
            "count": 1
          },
          {
            "text": "500px",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514713,
            "count": 1
          },
          {
            "text": "style",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514372,
            "count": 1
          },
          {
            "text": "width",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.512915,
            "count": 1
          },
          {
            "text": "border",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.512558,
            "count": 1
          },
          {
            "text": "height",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.51215,
            "count": 1
          },
          {
            "text": "mining industry deals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.511869,
            "count": 3
          },
          {
            "text": "acquisition",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.511228,
            "count": 2
          },
          {
            "text": "transactions",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.510804,
            "count": 1
          },
          {
            "text": "none",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.510359,
            "count": 1
          },
          {
            "text": "Tocqueville Asset Management",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.509334,
            "count": 1
          },
          {
            "text": "merger",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.509056,
            "count": 1
          },
          {
            "text": "term",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.508614,
            "count": 1
          },
          {
            "text": "analysis",
            "sentiment": {
              "score": 0.920269,
              "label": "positive"
            },
            "relevance": 0.508546,
            "count": 2
          },
          {
            "text": "Verdict",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.506863,
            "count": 1
          },
          {
            "text": "Capital",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.506666,
            "count": 1
          },
          {
            "text": "Country",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.506408,
            "count": 1
          },
          {
            "text": "metals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.506277,
            "count": 2
          },
          {
            "text": "world",
            "sentiment": {
              "score": 0.920269,
              "label": "positive"
            },
            "relevance": 0.505404,
            "count": 1
          },
          {
            "text": "headquarters",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.505323,
            "count": 1
          },
          {
            "text": "website",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.505019,
            "count": 1
          },
          {
            "text": "subscribers",
            "sentiment": {
              "score": 0.920269,
              "label": "positive"
            },
            "relevance": 0.504912,
            "count": 1
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "0c9914f65293f9248aa949357f84e3ee1601f022",
        "filename": "1563310577113.zip-bb2b89e79b49de046141e391c7363b5e.xml",
        "file_type": "json"
      },
      "external_links": [
        "https://mining.globaldata.com/",
        "http://image.digitalinsightresearch.in/Uploads/ImageLibrary/DealArticles/Template5_Monthly_6_2019_metals_mining_Canada____Embed.html”"
      ],
      "title": "Canada’s metals & mining industry sees a drop of 27.5% in deal activity in June 2019",
      "forum_title": "Mining Technology | Mining News and Views Updated Daily"
    },
    {
      "id": "0W4GZdFSXYa8byZDLm004sc-uAEiJv466KGq5Z9IHCUd20gkF7gKDW-whY21dMzA",
      "result_metadata": {
        "score": 20.392029
      },
      "author": "Charles Blunt",
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": 0.361146,
              "label": "positive"
            },
            "text": "Jaguar Mining",
            "relevance": 0.994447,
            "type": "Company"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0,
            "label": "neutral"
          }
        },
        "semantic_roles": [],
        "concepts": [],
        "categories": [
          {
            "score": 0.812593,
            "label": "/automotive and vehicles/cars/performance vehicles"
          },
          {
            "score": 0.644012,
            "label": "/automotive and vehicles/cars/car culture"
          },
          {
            "score": 0.570445,
            "label": "/automotive and vehicles/motor shows"
          }
        ],
        "relations": [],
        "keywords": [
          {
            "text": "Jaguar Mining",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.99885,
            "count": 1
          },
          {
            "text": "Critical Survey",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.457046,
            "count": 1
          },
          {
            "text": "OTCMKTS",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.216952,
            "count": 2
          },
          {
            "text": "JAGGF",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.162834,
            "count": 1
          },
          {
            "text": "Centamin",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.152334,
            "count": 1
          },
          {
            "text": "CELTF",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.123752,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-19T22:58:40Z",
      "url": "https://mayfieldrecorder.com/2019/07/19/contrasting-jaguar-mining-otcmktsjaggf-and-centamin-otcmktsceltf.html",
      "host": "mayfieldrecorder.com",
      "text": "Centamin has higher revenue and earnings than Jaguar Mining. Summary Centamin beats Jaguar Mining on 8 of the 10 factors compared between the two stocks. About Jaguar Mining Jaguar Mining Inc. engages in the acquisition, exploration, development, and operation of gold producing properties in Brazil.",
      "main_image_url": "https://www.marketbeat.com/logos/centamin-plc-logo.png",
      "country": "US",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-19T22:58:40Z",
      "enriched_text": {
        "entities": [
          {
            "count": 3,
            "sentiment": {
              "score": 0.722877,
              "label": "positive"
            },
            "text": "Jaguar Mining Inc.",
            "relevance": 0.899002,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Mining",
            "relevance": 0.692883,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Turmalina Gold Mine Complex",
            "relevance": 0.289933,
            "type": "Facility"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Gold Mine Complex",
            "relevance": 0.250104,
            "type": "Facility"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.359447,
              "label": "positive"
            },
            "text": "Centamin Plc",
            "relevance": 0.21026,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Centamin",
              "dbpedia_resource": "http://dbpedia.org/resource/Centamin"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Burkina Faso",
            "relevance": 0.196971,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "Organization",
                "GovernmentalJurisdiction",
                "Country"
              ],
              "name": "Burkina Faso",
              "dbpedia_resource": "http://dbpedia.org/resource/Burkina_Faso"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Saint Helier",
            "relevance": 0.194987,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ],
              "name": "Saint Helier",
              "dbpedia_resource": "http://dbpedia.org/resource/Saint_Helier"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Minas Gerais",
            "relevance": 0.194358,
            "type": "GeographicFeature"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.325859,
              "label": "positive"
            },
            "text": "Cote d’Ivoire",
            "relevance": 0.175493,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Iron Quadrangle",
            "relevance": 0.166065,
            "type": "Facility"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "United Kingdom",
            "relevance": 0.164089,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "Location",
                "AdministrativeDivision",
                "Country",
                "GovernmentalJurisdiction",
                "Kingdom",
                "MeteorologicalService"
              ],
              "name": "United Kingdom",
              "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Brazil",
            "relevance": 0.158762,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "GovernmentalJurisdiction",
                "CompanyShareholder",
                "Country"
              ],
              "name": "Brazil",
              "dbpedia_resource": "http://dbpedia.org/resource/Brazil"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Toronto",
            "relevance": 0.154335,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "AdministrativeDivision",
                "GovernmentalJurisdiction",
                "OlympicBiddingCity",
                "SchoolDistrict",
                "City"
              ],
              "name": "Toronto",
              "dbpedia_resource": "http://dbpedia.org/resource/Toronto"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "principal",
            "relevance": 0.152793,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Egypt",
            "relevance": 0.147024,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "Country"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Canada",
            "relevance": 0.142354,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "GovernmentalJurisdiction",
                "Kingdom",
                "AwardDiscipline",
                "FilmScreeningVenue",
                "Country"
              ],
              "name": "Canada",
              "dbpedia_resource": "http://dbpedia.org/resource/Canada"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "MarketBeat.com",
            "relevance": 0.139703,
            "type": "Company"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0.697754,
            "label": "positive"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Centamin",
              "keywords": [
                {
                  "text": "Centamin"
                }
              ]
            },
            "sentence": "Centamin has higher revenue and earnings than Jaguar Mining.",
            "object": {
              "text": "higher revenue and earnings than Jaguar Mining",
              "keywords": [
                {
                  "text": "higher revenue"
                },
                {
                  "text": "Jaguar Mining"
                },
                {
                  "text": "earnings"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Mining Inc."
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "Centamin",
              "keywords": [
                {
                  "text": "Centamin"
                }
              ]
            },
            "sentence": " Centamin beats Jaguar Mining on 8 of the 10 factors compared between the two stocks.",
            "object": {
              "text": "Jaguar Mining",
              "keywords": [
                {
                  "text": "Jaguar Mining"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Mining Inc."
                }
              ]
            },
            "action": {
              "verb": {
                "text": "beat",
                "tense": "present"
              },
              "text": "beats",
              "normalized": "beat"
            }
          },
          {
            "subject": {
              "text": "the 10 factors",
              "keywords": [
                {
                  "text": "factors"
                }
              ]
            },
            "sentence": " Centamin beats Jaguar Mining on 8 of the 10 factors compared between the two stocks.",
            "object": {
              "text": "between the two stocks",
              "keywords": [
                {
                  "text": "stocks"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "compare",
                "tense": "past"
              },
              "text": "compared",
              "normalized": "compare"
            }
          },
          {
            "subject": {
              "text": "exploration, development, and operation of gold",
              "keywords": [
                {
                  "text": "exploration"
                },
                {
                  "text": "development"
                },
                {
                  "text": "operation"
                },
                {
                  "text": "gold"
                }
              ]
            },
            "sentence": " Jaguar Mining Inc. engages in the acquisition, exploration, development, and operation of gold producing properties in Brazil.",
            "object": {
              "text": "properties",
              "keywords": [
                {
                  "text": "properties"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "produce",
                "tense": "present"
              },
              "text": "producing",
              "normalized": "produce"
            }
          },
          {
            "subject": {
              "text": "the Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex located in the Iron Quadrangle in the state of Minas Gerais",
              "keywords": [
                {
                  "text": "Minas Gerais"
                },
                {
                  "text": "Iron Quadrangle"
                },
                {
                  "text": "Gold Mine Complex"
                },
                {
                  "text": "Turmalina Gold"
                }
              ],
              "entities": [
                {
                  "type": "Facility",
                  "text": "Turmalina Gold Mine Complex"
                },
                {
                  "type": "Facility",
                  "text": "Gold Mine Complex"
                },
                {
                  "type": "Facility",
                  "text": "Iron Quadrangle"
                },
                {
                  "type": "GeographicFeature",
                  "text": "Minas Gerais"
                }
              ]
            },
            "sentence": " Its principal assets include the Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex located in the Iron Quadrangle in the state of Minas Gerais.",
            "object": {
              "text": "Its principal assets",
              "keywords": [
                {
                  "text": "principal assets"
                }
              ],
              "entities": [
                {
                  "type": "JobTitle",
                  "text": "principal"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "the Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex",
              "keywords": [
                {
                  "text": "Gold Mine Complex"
                },
                {
                  "text": "Turmalina Gold"
                },
                {
                  "text": "CaetÃ© Gold"
                }
              ],
              "entities": [
                {
                  "type": "Facility",
                  "text": "Turmalina Gold Mine Complex"
                },
                {
                  "type": "Facility",
                  "text": "Gold Mine Complex"
                }
              ]
            },
            "sentence": " Its principal assets include the Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex located in the Iron Quadrangle in the state of Minas Gerais.",
            "action": {
              "verb": {
                "text": "locate",
                "tense": "past"
              },
              "text": "located",
              "normalized": "locate"
            }
          },
          {
            "subject": {
              "text": "The company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " The company was founded in 1984 and is headquartered in Toronto, Canada.",
            "object": {
              "text": "founded in 1984"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " The company was founded in 1984 and is headquartered in Toronto, Canada.",
            "action": {
              "verb": {
                "text": "found",
                "tense": "past"
              },
              "text": "was founded",
              "normalized": "be found"
            }
          },
          {
            "subject": {
              "text": "The company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " The company was founded in 1984 and is headquartered in Toronto, Canada.",
            "object": {
              "text": "headquartered in Toronto, Canada",
              "keywords": [
                {
                  "text": "Toronto"
                },
                {
                  "text": "Canada"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Toronto",
                  "disambiguation": {
                    "subtype": [
                      "AdministrativeDivision",
                      "GovernmentalJurisdiction",
                      "OlympicBiddingCity",
                      "SchoolDistrict",
                      "CityTown",
                      "City"
                    ],
                    "name": "Toronto",
                    "dbpedia_resource": "http://dbpedia.org/resource/Toronto"
                  }
                },
                {
                  "type": "Location",
                  "text": "Canada",
                  "disambiguation": {
                    "subtype": [
                      "Country",
                      "GovernmentalJurisdiction",
                      "Kingdom",
                      "AwardDiscipline",
                      "FilmScreeningVenue",
                      "Country"
                    ],
                    "name": "Canada",
                    "dbpedia_resource": "http://dbpedia.org/resource/Canada"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " The company was founded in 1984 and is headquartered in Toronto, Canada.",
            "action": {
              "verb": {
                "text": "headquarter",
                "tense": "past"
              },
              "text": "is headquartered",
              "normalized": "be headquarter"
            }
          },
          {
            "subject": {
              "text": "The company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " The company was founded on March 24, 1970 and is headquartered in Saint Helier, the United Kingdom.",
            "action": {
              "verb": {
                "text": "found",
                "tense": "past"
              },
              "text": "was founded",
              "normalized": "be found"
            }
          },
          {
            "subject": {
              "text": "The company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " The company was founded on March 24, 1970 and is headquartered in Saint Helier, the United Kingdom.",
            "object": {
              "text": "headquartered in Saint Helier, the United Kingdom",
              "keywords": [
                {
                  "text": "Saint Helier"
                },
                {
                  "text": "United Kingdom"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Saint Helier",
                  "disambiguation": {
                    "subtype": [
                      "City"
                    ],
                    "name": "Saint Helier",
                    "dbpedia_resource": "http://dbpedia.org/resource/Saint_Helier"
                  }
                },
                {
                  "type": "Organization",
                  "text": "United Kingdom",
                  "disambiguation": {
                    "subtype": [
                      "Location",
                      "AdministrativeDivision",
                      "Country",
                      "GovernmentalJurisdiction",
                      "Kingdom",
                      "MeteorologicalService"
                    ],
                    "name": "United Kingdom",
                    "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "The company",
              "keywords": [
                {
                  "text": "company"
                }
              ]
            },
            "sentence": " The company was founded on March 24, 1970 and is headquartered in Saint Helier, the United Kingdom.",
            "action": {
              "verb": {
                "text": "headquarter",
                "tense": "past"
              },
              "text": "is headquartered",
              "normalized": "be headquarter"
            }
          },
          {
            "subject": {
              "text": "News & Ratings for Jaguar Mining Daily",
              "keywords": [
                {
                  "text": "Jaguar Mining Daily"
                },
                {
                  "text": "Ratings"
                },
                {
                  "text": "News"
                }
              ]
            },
            "sentence": " Receive News & Ratings for Jaguar Mining Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Mining and related companies with MarketBeat.com's FREE daily email newsletter .",
            "object": {
              "text": "your email address",
              "keywords": [
                {
                  "text": "email address"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Enter",
                "tense": "present"
              },
              "text": "Enter",
              "normalized": "Enter"
            }
          }
        ],
        "concepts": [
          {
            "text": "Brazil",
            "relevance": 0.977555,
            "dbpedia_resource": "http://dbpedia.org/resource/Brazil"
          },
          {
            "text": "Minas Gerais",
            "relevance": 0.80438,
            "dbpedia_resource": "http://dbpedia.org/resource/Minas_Gerais"
          },
          {
            "text": "Burkina Faso",
            "relevance": 0.744834,
            "dbpedia_resource": "http://dbpedia.org/resource/Burkina_Faso"
          },
          {
            "text": "Côte d'Ivoire",
            "relevance": 0.722,
            "dbpedia_resource": "http://dbpedia.org/resource/Côte_d'Ivoire"
          },
          {
            "text": "Gold",
            "relevance": 0.701043,
            "dbpedia_resource": "http://dbpedia.org/resource/Gold"
          },
          {
            "text": "United Kingdom",
            "relevance": 0.64546,
            "dbpedia_resource": "http://dbpedia.org/resource/United_Kingdom"
          },
          {
            "text": "Jersey",
            "relevance": 0.634326,
            "dbpedia_resource": "http://dbpedia.org/resource/Jersey"
          }
        ],
        "categories": [
          {
            "score": 0.822473,
            "label": "/business and industrial/mining industry"
          },
          {
            "score": 0.812134,
            "label": "/finance/financial news"
          },
          {
            "score": 0.774943,
            "label": "/business and industrial/business news"
          }
        ],
        "relations": [
          {
            "type": "employedBy",
            "sentence": "Summary Centamin beats Jaguar Mining on 8 of the 10 factors compared between the two stocks.",
            "score": 0.614864,
            "arguments": [
              {
                "text": "Summary\nCentamin",
                "location": [
                  61,
                  77
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Summary\nCentamin"
                  }
                ]
              },
              {
                "text": "Jaguar Mining",
                "location": [
                  84,
                  97
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Mining\nJaguar Mining Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Receive News & Ratings for Jaguar Mining Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Mining and related companies with MarketBeat.com's FREE daily email newsletter .",
            "score": 0.574761,
            "arguments": [
              {
                "text": "companies",
                "location": [
                  1014,
                  1023
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "companies",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "Jaguar Mining",
                "location": [
                  988,
                  1001
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Mining\nJaguar Mining Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "About Jaguar Mining Jaguar Mining Inc. engages in the acquisition, exploration, development, and operation of gold producing properties in Brazil.",
            "score": 0.569862,
            "arguments": [
              {
                "text": "Jaguar Mining\nJaguar Mining Inc.",
                "location": [
                  160,
                  192
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Mining\nJaguar Mining Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  208,
                  219
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Its principal assets include the Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex located in the Iron Quadrangle in the state of Minas Gerais.",
            "score": 0.844289,
            "arguments": [
              {
                "text": "principal",
                "location": [
                  305,
                  314
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "principal"
                  }
                ]
              },
              {
                "text": "Its",
                "location": [
                  301,
                  304
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Its"
                  }
                ]
              }
            ]
          },
          {
            "type": "basedIn",
            "sentence": "Its principal assets include the Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex located in the Iron Quadrangle in the state of Minas Gerais.",
            "score": 0.778169,
            "arguments": [
              {
                "text": "Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex",
                "location": [
                  334,
                  390
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex"
                  }
                ]
              },
              {
                "text": "Iron Quadrangle",
                "location": [
                  406,
                  421
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Iron Quadrangle"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "Its principal assets include the Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex located in the Iron Quadrangle in the state of Minas Gerais.",
            "score": 0.493349,
            "arguments": [
              {
                "text": "Iron Quadrangle",
                "location": [
                  406,
                  421
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Iron Quadrangle"
                  }
                ]
              },
              {
                "text": "state of Minas Gerais",
                "location": [
                  429,
                  450
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "state of Minas Gerais"
                  }
                ]
              }
            ]
          },
          {
            "type": "foundedOn",
            "sentence": "The company was founded in 1984 and is headquartered in Toronto, Canada.",
            "score": 0.503992,
            "arguments": [
              {
                "text": "company",
                "location": [
                  456,
                  463
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex"
                  }
                ]
              },
              {
                "text": "1984",
                "location": [
                  479,
                  483
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "1984",
                    "disambiguation": {
                      "subtype": [
                        "Starting"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "basedIn",
            "sentence": "The company was founded in 1984 and is headquartered in Toronto, Canada.",
            "score": 0.513969,
            "arguments": [
              {
                "text": "company",
                "location": [
                  456,
                  463
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Turmalina Gold Mine Complex and CaetÃ© Gold Mine Complex"
                  }
                ]
              },
              {
                "text": "Toronto",
                "location": [
                  508,
                  515
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Toronto"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The company was founded in 1984 and is headquartered in Toronto, Canada.",
            "score": 0.989945,
            "arguments": [
              {
                "text": "Toronto",
                "location": [
                  508,
                  515
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Toronto"
                  }
                ]
              },
              {
                "text": "Canada",
                "location": [
                  517,
                  523
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Canada",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The company was founded on March 24, 1970 and is headquartered in Saint Helier, the United Kingdom.",
            "score": 0.814715,
            "arguments": [
              {
                "text": "Saint Helier",
                "location": [
                  794,
                  806
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Saint Helier"
                  }
                ]
              },
              {
                "text": "United Kingdom",
                "location": [
                  812,
                  826
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "United Kingdom",
                    "disambiguation": {
                      "subtype": [
                        "Area"
                      ]
                    }
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "Jaguar Mining",
            "sentiment": {
              "score": 0.697754,
              "label": "positive"
            },
            "relevance": 0.843945,
            "count": 3
          },
          {
            "text": "Jaguar Mining Daily",
            "sentiment": {
              "score": 0.704432,
              "label": "positive"
            },
            "relevance": 0.735494,
            "count": 1
          },
          {
            "text": "email address",
            "sentiment": {
              "score": 0.704432,
              "label": "positive"
            },
            "relevance": 0.722036,
            "count": 1
          },
          {
            "text": "concise daily summary of the latest news",
            "sentiment": {
              "score": 0.704432,
              "label": "positive"
            },
            "relevance": 0.712063,
            "count": 1
          },
          {
            "text": "related companies",
            "sentiment": {
              "score": 0.704432,
              "label": "positive"
            },
            "relevance": 0.653656,
            "count": 1
          },
          {
            "text": "principal assets",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.611099,
            "count": 1
          },
          {
            "text": "Turmalina Gold Mine Complex",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.605833,
            "count": 1
          },
          {
            "text": "MarketBeat.com's FREE daily email newsletter",
            "sentiment": {
              "score": 0.704432,
              "label": "positive"
            },
            "relevance": 0.579099,
            "count": 1
          },
          {
            "text": "Burkina Faso",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.578041,
            "count": 1
          },
          {
            "text": "analysts' ratings",
            "sentiment": {
              "score": 0.704432,
              "label": "positive"
            },
            "relevance": 0.576677,
            "count": 1
          },
          {
            "text": "operation of gold",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.562663,
            "count": 1
          },
          {
            "text": "Saint Helier",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.55595,
            "count": 1
          },
          {
            "text": "company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.550837,
            "count": 2
          },
          {
            "text": "Ratings",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.548312,
            "count": 1
          },
          {
            "text": "News",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.543974,
            "count": 1
          },
          {
            "text": "United Kingdom",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.538143,
            "count": 1
          },
          {
            "text": "mining of precious metals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.528348,
            "count": 1
          },
          {
            "text": "higher revenue",
            "sentiment": {
              "score": 0.691957,
              "label": "positive"
            },
            "relevance": 0.52734,
            "count": 1
          },
          {
            "text": "exploration",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519689,
            "count": 2
          },
          {
            "text": "development",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517273,
            "count": 2
          },
          {
            "text": "acquisition",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.513529,
            "count": 1
          },
          {
            "text": "Egypt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.512944,
            "count": 1
          },
          {
            "text": "earnings",
            "sentiment": {
              "score": 0.691957,
              "label": "positive"
            },
            "relevance": 0.512673,
            "count": 1
          },
          {
            "text": "March",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.511722,
            "count": 1
          },
          {
            "text": "business segments",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.510569,
            "count": 1
          },
          {
            "text": "factors",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.507149,
            "count": 1
          },
          {
            "text": "properties",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.505896,
            "count": 1
          },
          {
            "text": "stocks",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.504863,
            "count": 1
          },
          {
            "text": "Brazil",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.504863,
            "count": 1
          },
          {
            "text": "Canada",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.504863,
            "count": 1
          },
          {
            "text": "Gold Mine Complex",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.502978,
            "count": 1
          },
          {
            "text": "Centamin",
            "sentiment": {
              "score": 0.691957,
              "label": "positive"
            },
            "relevance": 0.488075,
            "count": 1
          },
          {
            "text": "Iron Quadrangle",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.470501,
            "count": 1
          },
          {
            "text": "Cote d’Ivoire",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.465846,
            "count": 1
          },
          {
            "text": "state of Minas Gerais",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.454795,
            "count": 1
          },
          {
            "text": "CaetÃ",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.418447,
            "count": 1
          },
          {
            "text": "Toronto",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.409254,
            "count": 1
          },
          {
            "text": "Corporate",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.408255,
            "count": 1
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "215019b9ef4f490a47d434a597582833a1170622",
        "filename": "1563577120241.zip-55f815fdbdfd4289bb62e4fdbba657be.xml",
        "file_type": "json"
      },
      "title": "Jaguar Mining (OTCMKTS:JAGGF) vs. Centamin (OTCMKTS:CELTF) Critical Survey",
      "forum_title": "Mayfield Recorder"
    },
    {
      "id": "0Qs1AN4w-fgdyOfhLdyPbuNVt0vg4ykPjL_8f1gD0poL50G2VNpuRf63vP-LJs56",
      "result_metadata": {
        "score": 20.252453
      },
      "author": "ACCESSWIRE",
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Health Strengthens Company",
            "relevance": 0.33,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 Million",
            "relevance": 0.33,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 Million",
            "relevance": 0.33,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0,
            "label": "neutral"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger",
              "keywords": [
                {
                  "text": "Debt Incurred"
                },
                {
                  "text": "Merger"
                },
                {
                  "text": "Effect"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$10.5 Million"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
            "object": {
              "text": "to Approximately $4.4 Million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$4.4 Million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Reducing",
                "tense": "present"
              },
              "text": "Reducing",
              "normalized": "Reducing"
            }
          }
        ],
        "concepts": [],
        "categories": [
          {
            "score": 0.987001,
            "label": "/business and industrial/company/merger and acquisition"
          }
        ],
        "relations": [],
        "keywords": [
          {
            "text": "Jaguar Health Strengthens Company's Balance Sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.744408,
            "count": 1
          },
          {
            "text": "Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.585918,
            "count": 1
          },
          {
            "text": "Effect",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.558755,
            "count": 1
          },
          {
            "text": "Merger",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.548529,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-15T15:36:56Z",
      "url": "http://business.wapakdailynews.com/wapakdailynews/news/read/38557999/jaguar_health_strengthens_company&",
      "host": "business.wapakdailynews.com",
      "text": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
      "country": "US",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-15T08:00:00-05:00",
      "enriched_text": {
        "entities": [
          {
            "count": 8,
            "sentiment": {
              "score": 0.460269,
              "label": "positive"
            },
            "text": "Jaguar",
            "relevance": 0.900038,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AwardWinner"
              ],
              "name": "Jaguar Cars",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
            }
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0.545547,
              "label": "positive"
            },
            "text": "Jaguar Health",
            "relevance": 0.627505,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0.456422,
              "label": "positive"
            },
            "text": "Jaguar Health, Inc.",
            "relevance": 0.540856,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.353787,
              "label": "positive"
            },
            "text": "Jaguar Animal Health",
            "relevance": 0.43755,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.591163,
              "label": "positive"
            },
            "text": "Jaguar Health Inc",
            "relevance": 0.426615,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Animal Health, Inc.",
            "relevance": 0.407863,
            "type": "Company"
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Mytesi",
            "relevance": 0.401244,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo Pharmaceuticals, Inc.",
            "relevance": 0.382565,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo",
            "relevance": 0.264009,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "StateOrCounty"
              ]
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": -0.679083,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.243406,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Napo",
            "relevance": 0.240332,
            "type": "Organization"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "U.S. Securities and Exchange Commission",
            "relevance": 0.233332,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency",
                "GovernmentalBody"
              ],
              "name": "U.S. Securities and Exchange Commission",
              "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Mytesi ®",
            "relevance": 0.225876,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "president and chief executive officer",
            "relevance": 0.223953,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.553674,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.223613,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "upper respiratory tract infection",
            "relevance": 0.22222,
            "type": "HealthCondition",
            "disambiguation": {
              "subtype": [
                "DiseaseOrMedicalCondition",
                "RiskFactor",
                "Symptom"
              ],
              "name": "Upper respiratory tract infection",
              "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Crofelemer",
            "relevance": 0.220337,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Chicago Venture Partners L.P.",
            "relevance": 0.21957,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "SAN FRANCISCO",
            "relevance": 0.215597,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Lisa Conte",
            "relevance": 0.212261,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Peter Hodge",
            "relevance": 0.202897,
            "type": "Person",
            "disambiguation": {
              "subtype": [],
              "name": "Peter Hodge",
              "dbpedia_resource": "http://dbpedia.org/resource/Peter_Hodge"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.353209,
              "label": "negative"
            },
            "text": "FDA",
            "relevance": 0.202518,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency"
              ],
              "name": "Food and Drug Administration",
              "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Amazon",
            "relevance": 0.175116,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.1%",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 million",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$2.3 million",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 million",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$6.4 million",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "one-year",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$5.58",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.5%",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.9%",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "5.7%",
            "relevance": 0.175116,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "8-K",
            "relevance": 0.175116,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": -0.320429,
            "label": "negative"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Maturity Date of Remaining Merger-related Debt",
              "keywords": [
                {
                  "text": "Maturity Date"
                },
                {
                  "text": "Merger-related Debt"
                }
              ]
            },
            "sentence": "Maturity Date of Remaining Merger-related Debt is December 31, 2020",
            "object": {
              "text": "December 31"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                },
                {
                  "text": "merger"
                },
                {
                  "text": "debt"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health, Inc."
                }
              ]
            },
            "sentence": " SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "action": {
              "verb": {
                "text": "announce",
                "tense": "past"
              },
              "text": "announced",
              "normalized": "announce"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "object": {
              "text": "reduced debt incurred to effect the 2017 merger of Jaguar Animal Health",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                },
                {
                  "text": "merger"
                },
                {
                  "text": "debt"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health, Inc."
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "object": {
              "text": "debt incurred to effect the 2017 merger of Jaguar Animal Health",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                },
                {
                  "text": "merger"
                },
                {
                  "text": "debt"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health, Inc."
                }
              ]
            },
            "action": {
              "verb": {
                "text": "reduce",
                "tense": "past"
              },
              "text": "has reduced",
              "normalized": "have reduce"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "object": {
              "text": "from approximately $10.5 million (the \"Original Debt\")",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$10.5 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "effect",
                "tense": "future"
              },
              "text": "to effect",
              "normalized": "to effect"
            }
          },
          {
            "subject": {
              "text": "The Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " The Company accomplished this reduction in indebtedness through the issuance of approximately 1,119,440 shares of common stock, at a weighted average price of approximately $5.58 per share, to Chicago Venture Partners L.P. (\"CVP\") pursuant to exchange agreements entered into between the Company and CVP from May 29, 2019 through July 12, 2019.",
            "object": {
              "text": "this reduction",
              "keywords": [
                {
                  "text": "reduction"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "accomplish",
                "tense": "past"
              },
              "text": "accomplished",
              "normalized": "accomplish"
            }
          },
          {
            "subject": {
              "text": "the Merger",
              "keywords": [
                {
                  "text": "Merger"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "effective July 31"
            },
            "action": {
              "verb": {
                "text": "become",
                "tense": "past"
              },
              "text": "became",
              "normalized": "become"
            }
          },
          {
            "subject": {
              "text": "Jaguar Animal Health's name",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "action": {
              "verb": {
                "text": "change",
                "tense": "past"
              },
              "text": "changed",
              "normalized": "change"
            }
          },
          {
            "subject": {
              "text": "Inc. and Napo Pharmaceuticals, Inc.",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "Inc."
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "operating as a wholly-owned subsidiary of Jaguar focused on human health",
              "keywords": [
                {
                  "text": "wholly-owned subsidiary"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "operating"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "begin",
                "tense": "past"
              },
              "text": "began",
              "normalized": "begin"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer)",
              "keywords": [
                {
                  "text": "follow-on indications"
                },
                {
                  "text": "ongoing commercialization"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "development"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "focus",
                "tense": "past"
              },
              "text": "focused",
              "normalized": "focus"
            }
          },
          {
            "subject": {
              "text": "We"
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "we"
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "important assets"
                },
                {
                  "text": "pipeline opportunities"
                },
                {
                  "text": "value recognition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "continue",
                "tense": "present"
              },
              "text": "continue",
              "normalized": "continue"
            }
          },
          {
            "subject": {
              "text": "our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "Lisa Conte"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                },
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "pipeline opportunities",
              "keywords": [
                {
                  "text": "pipeline opportunities"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "Lisa Conte, president and chief executive officer of Jaguar,",
              "keywords": [
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "Lisa Conte"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "president"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "deep pipeline"
                },
                {
                  "text": "pipeline opportunities"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "state",
                "tense": "past"
              },
              "text": "stated",
              "normalized": "state"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31",
              "keywords": [
                {
                  "text": "one-year extension"
                },
                {
                  "text": "Original Debt"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "a one-year extension",
              "keywords": [
                {
                  "text": "one-year extension"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "past"
              },
              "text": "has received",
              "normalized": "have receive"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "previously scheduled to mature on December 31, 2019"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "action": {
              "verb": {
                "text": "schedule",
                "tense": "past"
              },
              "text": "scheduled",
              "normalized": "schedule"
            }
          },
          {
            "subject": {
              "text": "The extension of the maturity date",
              "keywords": [
                {
                  "text": "maturity date"
                },
                {
                  "text": "extension"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "part of a larger restructuring of the Original Debt",
              "keywords": [
                {
                  "text": "larger restructuring"
                },
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "the acquisition of the Original Debt by CVP",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "Original Debt"
                },
                {
                  "text": "acquisition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "follow",
                "tense": "present"
              },
              "text": "following",
              "normalized": "follow"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " As consideration for such restructuring, which included among other things the extension of the maturity date by means of an exchange of the Original Debt for new secured debt with a maturity date of December 31, 2020, Jaguar paid CVP a fee of approximately $2.3 million in the form of additional debt (the \"Additional Debt\").",
            "object": {
              "text": "CVP a fee of approximately $2.3 million",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "fee"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$2.3 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "pay",
                "tense": "past"
              },
              "text": "paid",
              "normalized": "pay"
            }
          },
          {
            "subject": {
              "text": "The Additional Debt",
              "keywords": [
                {
                  "text": "Additional Debt"
                }
              ]
            },
            "sentence": " The Additional Debt is not included in the Original Debt.",
            "object": {
              "text": "in the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "past",
                "negated": true
              },
              "text": "included",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "The details of this transaction",
              "keywords": [
                {
                  "text": "transaction"
                },
                {
                  "text": "details"
                }
              ]
            },
            "sentence": " The details of this transaction are further described in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "object": {
              "text": "on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019",
              "keywords": [
                {
                  "text": "U.S. Securities"
                },
                {
                  "text": "Form 8-K"
                },
                {
                  "text": "Exchange Commission"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "U.S. Securities and Exchange Commission",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency",
                      "GovernmentalBody"
                    ],
                    "name": "U.S. Securities and Exchange Commission",
                    "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
                  }
                },
                {
                  "type": "Quantity",
                  "text": "8-K"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "describe",
                "tense": "past"
              },
              "text": "are further described",
              "normalized": "be further describe"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "object": {
              "text": "all of the approximately $6.4 million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$6.4 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "extinguish",
                "tense": "past"
              },
              "text": "extinguished",
              "normalized": "extinguish"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "action": {
              "verb": {
                "text": "issue",
                "tense": "past"
              },
              "text": "issued",
              "normalized": "issue"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "a commercial stage pharmaceuticals company focused on developing novel",
              "keywords": [
                {
                  "text": "commercial stage pharmaceuticals"
                },
                {
                  "text": "company"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "novel, sustainably derived gastrointestinal products on a global basis",
              "keywords": [
                {
                  "text": "gastrointestinal products"
                },
                {
                  "text": "global basis"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "develop",
                "tense": "future"
              },
              "text": "developing",
              "normalized": "develop"
            }
          },
          {
            "subject": {
              "text": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc.,",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "wholly-owned subsidiary"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "object": {
              "text": "proprietary human gastrointestinal pharmaceuticals",
              "keywords": [
                {
                  "text": "gastrointestinal pharmaceuticals"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "commercialize",
                "tense": "present"
              },
              "text": "commercializing",
              "normalized": "commercialize"
            }
          },
          {
            "subject": {
              "text": "plants",
              "keywords": [
                {
                  "text": "plants"
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "action": {
              "verb": {
                "text": "use",
                "tense": "past"
              },
              "text": "used",
              "normalized": "use"
            }
          },
          {
            "subject": {
              "text": "Our Mytesi ® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "approved by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "sentence": " Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "Our Mytesi ® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "approve",
                "tense": "past"
              },
              "text": "is approved",
              "normalized": "be approve"
            }
          },
          {
            "subject": {
              "text": "Mytesi (crofelemer)",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "object": {
              "text": "an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea",
              "keywords": [
                {
                  "text": "noninfectious diarrhea"
                },
                {
                  "text": "symptomatic relief"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "not indicated for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "indicate",
                "tense": "past",
                "negated": true
              },
              "text": "indicated",
              "normalized": "indicate"
            }
          },
          {
            "subject": {
              "text": "infectious etiologies of diarrhea",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "diarrhea"
                }
              ]
            },
            "sentence": " Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "action": {
              "verb": {
                "text": "Rule",
                "tense": "present"
              },
              "text": "Rule",
              "normalized": "Rule"
            }
          },
          {
            "subject": {
              "text": "patients with infectious etiologies",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "patients"
                }
              ]
            },
            "sentence": " If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen.",
            "object": {
              "text": "the appropriate therapy and their disease",
              "keywords": [
                {
                  "text": "appropriate therapy"
                },
                {
                  "text": "disease"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "future",
                "negated": true
              },
              "text": "receive",
              "normalized": "receive"
            }
          },
          {
            "subject": {
              "text": "a rate greater than placebo",
              "keywords": [
                {
                  "text": "placebo"
                },
                {
                  "text": "rate"
                }
              ]
            },
            "sentence": " In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).",
            "object": {
              "text": "upper respiratory tract infection",
              "keywords": [
                {
                  "text": "respiratory tract infection"
                }
              ],
              "entities": [
                {
                  "type": "HealthCondition",
                  "text": "upper respiratory tract infection",
                  "disambiguation": {
                    "subtype": [
                      "DiseaseOrMedicalCondition",
                      "RiskFactor",
                      "Symptom"
                    ],
                    "name": "Upper respiratory tract infection",
                    "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "were",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Crofelemer, the active ingredient in Mytesi,",
              "keywords": [
                {
                  "text": "active ingredient"
                },
                {
                  "text": "Crofelemer"
                },
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Crofelemer"
                },
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest.",
            "object": {
              "text": "a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest",
              "keywords": [
                {
                  "text": "red bark sap"
                },
                {
                  "text": "medicinal Croton"
                },
                {
                  "text": "Amazon rainforest"
                },
                {
                  "text": "drug"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Amazon"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "established a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "establish",
                "tense": "past"
              },
              "text": "has established",
              "normalized": "have establish"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a high degree of quality and ecological integrity",
              "keywords": [
                {
                  "text": "ecological integrity"
                },
                {
                  "text": "high degree"
                },
                {
                  "text": "quality"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "ensure",
                "tense": "future"
              },
              "text": "to ensure",
              "normalized": "to ensure"
            }
          },
          {
            "subject": {
              "text": "Certain statements in this press release",
              "keywords": [
                {
                  "text": "Certain statements"
                },
                {
                  "text": "press release"
                }
              ],
              "entities": []
            },
            "sentence": " Certain statements in this press release constitute \"forward-looking statements.\"",
            "object": {
              "text": "\"forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "constitute",
                "tense": "present"
              },
              "text": "constitute",
              "normalized": "constitute"
            }
          },
          {
            "subject": {
              "text": "statements regarding the Company's planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "statements"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " These include statements regarding the Company's planned clinical and commercial milestones.",
            "object": {
              "text": "These"
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "statements",
              "keywords": [
                {
                  "text": "statements"
                }
              ]
            },
            "sentence": " These include statements regarding the Company's planned clinical and commercial milestones.",
            "object": {
              "text": "the Company's planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "action": {
              "verb": {
                "text": "regard",
                "tense": "present"
              },
              "text": "regarding",
              "normalized": "regard"
            }
          },
          {
            "subject": {
              "text": "you"
            },
            "sentence": " In some cases, you can identify forward-looking statements by terms such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"aim,\" \"anticipate,\" \"could,\" \"intend,\" \"target,\" \"project,\" \"contemplate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential\" or \"continue\" or the negative of these terms or other similar expressions.",
            "object": {
              "text": "forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "identify",
                "tense": "future"
              },
              "text": "can identify",
              "normalized": "can identify"
            }
          },
          {
            "subject": {
              "text": "The forward-looking statements in this release",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "release"
                }
              ],
              "entities": []
            },
            "sentence": " The forward-looking statements in this release are only predictions.",
            "object": {
              "text": "only predictions",
              "keywords": [
                {
                  "text": "predictions"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Jaguar has based these forward-looking statements largely on its current expectations and projections about future events.",
            "object": {
              "text": "based these forward-looking statements largely on its current expectations and projections about future events",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "current expectations"
                },
                {
                  "text": "future events"
                },
                {
                  "text": "projections"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "These forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "sentence": " These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control.",
            "action": {
              "verb": {
                "text": "speak",
                "tense": "present"
              },
              "text": "speak",
              "normalized": "speak"
            }
          },
          {
            "subject": {
              "text": "These forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "sentence": " These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control.",
            "object": {
              "text": "subject to a number of risks, uncertainties and assumptions",
              "keywords": [
                {
                  "text": "uncertainties"
                },
                {
                  "text": "assumptions"
                },
                {
                  "text": "risks"
                },
                {
                  "text": "number"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.",
            "object": {
              "text": "not plan",
              "keywords": [
                {
                  "text": "plan"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "do",
                "tense": "present"
              },
              "text": "does",
              "normalized": "do"
            }
          }
        ],
        "concepts": [
          {
            "text": "Medicine",
            "relevance": 0.949148,
            "dbpedia_resource": "http://dbpedia.org/resource/Medicine"
          },
          {
            "text": "AIDS",
            "relevance": 0.697528,
            "dbpedia_resource": "http://dbpedia.org/resource/AIDS"
          },
          {
            "text": "Subsidiary",
            "relevance": 0.620152,
            "dbpedia_resource": "http://dbpedia.org/resource/Subsidiary"
          },
          {
            "text": "Antiretroviral drug",
            "relevance": 0.586115,
            "dbpedia_resource": "http://dbpedia.org/resource/Antiretroviral_drug"
          },
          {
            "text": "Respiratory system",
            "relevance": 0.556281,
            "dbpedia_resource": "http://dbpedia.org/resource/Respiratory_system"
          },
          {
            "text": "HIV",
            "relevance": 0.553508,
            "dbpedia_resource": "http://dbpedia.org/resource/HIV"
          },
          {
            "text": "Clinical trial",
            "relevance": 0.528021,
            "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"
          },
          {
            "text": "Health",
            "relevance": 0.526224,
            "dbpedia_resource": "http://dbpedia.org/resource/Health"
          },
          {
            "text": "Loan",
            "relevance": 0.519977,
            "dbpedia_resource": "http://dbpedia.org/resource/Loan"
          },
          {
            "text": "Upper respiratory tract infection",
            "relevance": 0.505968,
            "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
          },
          {
            "text": "Debt",
            "relevance": 0.504033,
            "dbpedia_resource": "http://dbpedia.org/resource/Debt"
          },
          {
            "text": "Maturity",
            "relevance": 0.495893,
            "dbpedia_resource": "http://dbpedia.org/resource/Maturity_(finance)"
          },
          {
            "text": "Jaguar",
            "relevance": 0.483748,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar"
          },
          {
            "text": "Etiology",
            "relevance": 0.482543,
            "dbpedia_resource": "http://dbpedia.org/resource/Etiology"
          },
          {
            "text": "Pharmacology",
            "relevance": 0.475223,
            "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"
          },
          {
            "text": "Pharmacy",
            "relevance": 0.458848,
            "dbpedia_resource": "http://dbpedia.org/resource/Pharmacy"
          },
          {
            "text": "Gastroenteritis",
            "relevance": 0.451673,
            "dbpedia_resource": "http://dbpedia.org/resource/Gastroenteritis"
          },
          {
            "text": "Rolling",
            "relevance": 0.451205,
            "dbpedia_resource": "http://dbpedia.org/resource/Rolling_(finance)"
          }
        ],
        "categories": [
          {
            "score": 0.973501,
            "label": "/health and fitness/disease/aids and hiv"
          },
          {
            "score": 0.71769,
            "label": "/health and fitness/disease/epidemic"
          },
          {
            "score": 0.691478,
            "label": "/business and industrial/company"
          }
        ],
        "relations": [
          {
            "type": "hasAttribute",
            "sentence": "Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.935375,
            "arguments": [
              {
                "text": "CA Jaguar Health, Inc.",
                "location": [
                  83,
                  105
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "JAGX",
                "location": [
                  116,
                  120
                ],
                "entities": [
                  {
                    "type": "Ticker",
                    "text": "JAGX"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.84494,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  1373,
                  1379
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  1361,
                  1369
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.824225,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  3609,
                  3615
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3597,
                  3605
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.504364,
            "arguments": [
              {
                "text": "people",
                "location": [
                  1738,
                  1744
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "people"
                  }
                ]
              },
              {
                "text": "HIV/AIDS",
                "location": [
                  1757,
                  1765
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "HIV/AIDS"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.608738,
            "arguments": [
              {
                "text": "chief executive officer",
                "location": [
                  1911,
                  1934
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Lisa Conte"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1938,
                  1944
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "score": 0.969167,
            "arguments": [
              {
                "text": "June 3, 2019",
                "location": [
                  1967,
                  1979
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "June 3, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  1957,
                  1966
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.558802,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  2189,
                  2202
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2217,
                  2228
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.435512,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  2253,
                  2256
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2217,
                  2228
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.811688,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  2236,
                  2249
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "CVP",
                "location": [
                  2253,
                  2256
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The details of this transaction are further described in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "score": 0.984349,
            "arguments": [
              {
                "text": "Securities and Exchange Commission",
                "location": [
                  2761,
                  2795
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Securities and Exchange Commission",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  2756,
                  2760
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Original Debt"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.990022,
            "arguments": [
              {
                "text": "Jaguar",
                "location": [
                  2816,
                  2822
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  2823,
                  2832
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.985113,
            "arguments": [
              {
                "text": "May 29, 2019",
                "location": [
                  2833,
                  2845
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "May 29, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  2823,
                  2832
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.986658,
            "arguments": [
              {
                "text": "today",
                "location": [
                  298,
                  303
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "today"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  288,
                  297
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.898709,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  2851,
                  2858
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "$6.4 million",
                "location": [
                  2906,
                  2918
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$6.4 million",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.979945,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  3010,
                  3017
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3029,
                  3035
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.88192,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  3039,
                  3042
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3029,
                  3035
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.842766,
            "arguments": [
              {
                "text": "July 2017",
                "location": [
                  3046,
                  3055
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "July 2017"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3029,
                  3035
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.526381,
            "arguments": [
              {
                "text": "March 2018",
                "location": [
                  3064,
                  3074
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "March 2018"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3029,
                  3035
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "score": 0.532118,
            "arguments": [
              {
                "text": "subsidiary",
                "location": [
                  3279,
                  3289
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  3291,
                  3317
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.613956,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  3495,
                  3503
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "Our",
                "location": [
                  3491,
                  3494
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Our"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.996698,
            "arguments": [
              {
                "text": "FDA",
                "location": [
                  3549,
                  3552
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "FDA",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  3544,
                  3548
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Original Debt"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "For more information about Napo, visit napopharma.com .",
            "score": 0.572924,
            "arguments": [
              {
                "text": "Napo",
                "location": [
                  3748,
                  3752
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "napopharma.com",
                "location": [
                  3760,
                  3774
                ],
                "entities": [
                  {
                    "type": "Web",
                    "text": "napopharma.com"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi ® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.927523,
            "arguments": [
              {
                "text": "patients",
                "location": [
                  3904,
                  3912
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "patients"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3886,
                  3894
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.462331,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  313,
                  320
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  366,
                  372
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Source: Jaguar Health, Inc. Contact: Peter Hodge Jaguar Health, Inc. phodge@jaguar.health Jaguar-JAGX SOURCE: Jaguar Health, Inc.  //www.accesswire.com/551917/Jaguar-Health-Strengthens-Companys-Balance-Sheet-by-Reducing-Approximately-105-Million-of-Debt-Incurred-to-Effect-2017-Merger-to-Approximately-44-Million Related Stocks: Jaguar Health Inc",
            "score": 0.767148,
            "arguments": [
              {
                "text": "Peter Hodge\nJaguar",
                "location": [
                  6078,
                  6096
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Peter Hodge\nJaguar"
                  }
                ]
              },
              {
                "text": "Health, Inc.\nphodge@jaguar.health\nJaguar-JAGX\nSOURCE",
                "location": [
                  6097,
                  6149
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Health, Inc.\nphodge@jaguar.health\nJaguar-JAGX\nSOURCE",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Source: Jaguar Health, Inc. Contact: Peter Hodge Jaguar Health, Inc. phodge@jaguar.health Jaguar-JAGX SOURCE: Jaguar Health, Inc.  //www.accesswire.com/551917/Jaguar-Health-Strengthens-Companys-Balance-Sheet-by-Reducing-Approximately-105-Million-of-Debt-Incurred-to-Effect-2017-Merger-to-Approximately-44-Million Related Stocks: Jaguar Health Inc",
            "score": 0.503687,
            "arguments": [
              {
                "text": "Jaguar Health, Inc.\n //",
                "location": [
                  6151,
                  6174
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "www.accesswire.com/551917/Jaguar",
                "location": [
                  6174,
                  6206
                ],
                "entities": [
                  {
                    "type": "Web",
                    "text": "www.accesswire.com/551917/Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.772237,
            "arguments": [
              {
                "text": "2017",
                "location": [
                  361,
                  365
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "2017"
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  366,
                  372
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.620033,
            "arguments": [
              {
                "text": "Jaguar Animal Health, Inc.",
                "location": [
                  376,
                  402
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Animal Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  366,
                  372
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "participantIn",
            "sentence": "Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.30416,
            "arguments": [
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  407,
                  433
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  366,
                  372
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. ( NASDAQ: JAGX ) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.766986,
            "arguments": [
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  407,
                  433
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "$10.5 million",
                "location": [
                  468,
                  481
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$10.5 million",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.489579,
            "arguments": [
              {
                "text": "subsidiary",
                "location": [
                  1115,
                  1125
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1129,
                  1135
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.747773,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  1244,
                  1252
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  1361,
                  1369
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.581568,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  3495,
                  3503
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3597,
                  3605
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi ® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.895097,
            "arguments": [
              {
                "text": "Mytesi ®\nMytesi",
                "location": [
                  3783,
                  3798
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3886,
                  3894
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Mytesi is not indicated for the treatment of infectious diarrhea.",
            "score": 0.643525,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  3960,
                  3966
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4016,
                  4024
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "score": 0.930052,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  4085,
                  4091
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4060,
                  4068
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "CA Jaguar Health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.725308,
            "count": 1
          },
          {
            "text": "pharmaceutical company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.600286,
            "count": 1
          },
          {
            "text": "Napo Pharmaceuticals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.594951,
            "count": 3
          },
          {
            "text": "merger of Jaguar Animal Health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.584126,
            "count": 1
          },
          {
            "text": "clinical studies",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.572499,
            "count": 1
          },
          {
            "text": "development of follow",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.553805,
            "count": 1
          },
          {
            "text": "commercial stage",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.553768,
            "count": 1
          },
          {
            "text": "Jaguar Animal Health's name",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.551478,
            "count": 1
          },
          {
            "text": "SAN FRANCISCO",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.548662,
            "count": 1
          },
          {
            "text": "gastrointestinal products",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.546669,
            "count": 2
          },
          {
            "text": "human health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.544261,
            "count": 1
          },
          {
            "text": "shares of common stock",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.54244,
            "count": 1
          },
          {
            "text": "press release",
            "sentiment": {
              "score": -0.607008,
              "label": "negative"
            },
            "relevance": 0.54099,
            "count": 1
          },
          {
            "text": "Company",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.539935,
            "count": 8
          },
          {
            "text": "active ingredient",
            "sentiment": {
              "score": -0.938438,
              "label": "negative"
            },
            "relevance": 0.538422,
            "count": 1
          },
          {
            "text": "pipeline opportunities",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.537369,
            "count": 1
          },
          {
            "text": "treatment of infectious diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.534273,
            "count": 1
          },
          {
            "text": "Jaguar Health",
            "sentiment": {
              "score": 0.363999,
              "mixed": "1",
              "label": "positive"
            },
            "relevance": 0.531619,
            "count": 4
          },
          {
            "text": "commercial product",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.531288,
            "count": 1
          },
          {
            "text": "Original Debt",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.530737,
            "count": 3
          },
          {
            "text": "Company's balance sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529629,
            "count": 1
          },
          {
            "text": "average price",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529337,
            "count": 1
          },
          {
            "text": "upper respiratory tract infection",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529289,
            "count": 1
          },
          {
            "text": "promissory notes",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529173,
            "count": 1
          },
          {
            "text": "subsidiary of Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.528808,
            "count": 1
          },
          {
            "text": "infectious etiologies of diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.527921,
            "count": 1
          },
          {
            "text": "symptomatic relief of noninfectious diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.526689,
            "count": 3
          },
          {
            "text": "class anti-secretory agent",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.526343,
            "count": 1
          },
          {
            "text": "adult patients",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.525881,
            "count": 1
          },
          {
            "text": "extension of the maturity date",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.525214,
            "count": 2
          },
          {
            "text": "part of a larger restructuring of the Original Debt",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.524402,
            "count": 1
          },
          {
            "text": "Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.523598,
            "count": 6
          },
          {
            "text": "one-year extension",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.522207,
            "count": 1
          },
          {
            "text": "Statements",
            "sentiment": {
              "score": -0.607008,
              "label": "negative"
            },
            "relevance": 0.522191,
            "count": 9
          },
          {
            "text": "such restructuring",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.522095,
            "count": 1
          },
          {
            "text": "effective July",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.521321,
            "count": 1
          },
          {
            "text": "commercial milestones",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519857,
            "count": 2
          },
          {
            "text": "details of this transaction",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519248,
            "count": 1
          },
          {
            "text": "further reduction of the Company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.518149,
            "count": 1
          },
          {
            "text": "Exchange Commission",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517836,
            "count": 1
          },
          {
            "text": "drug product",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.516964,
            "count": 1
          },
          {
            "text": "plan",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.516588,
            "count": 1
          },
          {
            "text": "chief executive officer of Jaguar",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.516106,
            "count": 1
          },
          {
            "text": "applicable law",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.515813,
            "count": 1
          },
          {
            "text": "global marketplace",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.515492,
            "count": 1
          },
          {
            "text": "global basis",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514371,
            "count": 2
          },
          {
            "text": "future events",
            "sentiment": {
              "score": 0.859669,
              "label": "positive"
            },
            "relevance": 0.513946,
            "count": 2
          },
          {
            "text": "ongoing commercialization",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.513733,
            "count": 1
          },
          {
            "text": "common adverse reactions",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.513083,
            "count": 1
          },
          {
            "text": "means of an exchange of the Original Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.513015,
            "count": 1
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "cb35b83310945a5e1f95337d8a0504bf06fcc527",
        "filename": "1563205016652.zip-963cf997f95e7735785a872d42332e46.xml",
        "file_type": "json"
      },
      "external_links": [
        "http://pr.report/4KhQR-nx",
        "http://ads.financialcontent.com/www/delivery/ajs.php",
        "https://www.accesswire.com/img.ashx?id=551917",
        "https://www.accesswire.com/551917/Jaguar-Health-Strengthens-Companys-Balance-Sheet-by-Reducing-Approximately-105-Million-of-Debt-Incurred-to-Effect-2017-Merger-to-Approximately-44-Million",
        "http://mailto:phodge@jaguar.health",
        "http://pr.report/6kwvcahl",
        "http://pr.report/gT3iZsMS"
      ],
      "title": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
      "forum_title": "Stock Market News | NSDQ, NYSE, and AMEX Stock Market News, Market News Categories, Market Indicators | The Wapakoneta Daily News"
    },
    {
      "id": "vhFNsr5O2DI5ObLhNyOisxOLLklkuaUzrQAI0xQmy6h7iytVLxYxEUOl9bhWibR-",
      "result_metadata": {
        "score": 20.171064
      },
      "author": "ACCESSWIRE",
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Health Strengthens Company",
            "relevance": 0.33,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 Million",
            "relevance": 0.33,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 Million",
            "relevance": 0.33,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": 0,
            "label": "neutral"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger",
              "keywords": [
                {
                  "text": "Debt Incurred"
                },
                {
                  "text": "Merger"
                },
                {
                  "text": "Effect"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$10.5 Million"
                }
              ]
            },
            "sentence": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
            "object": {
              "text": "to Approximately $4.4 Million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$4.4 Million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Reducing",
                "tense": "present"
              },
              "text": "Reducing",
              "normalized": "Reducing"
            }
          }
        ],
        "concepts": [],
        "categories": [
          {
            "score": 0.987001,
            "label": "/business and industrial/company/merger and acquisition"
          }
        ],
        "relations": [],
        "keywords": [
          {
            "text": "Jaguar Health Strengthens Company's Balance Sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.744408,
            "count": 1
          },
          {
            "text": "Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.585918,
            "count": 1
          },
          {
            "text": "Effect",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.558755,
            "count": 1
          },
          {
            "text": "Merger",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.548529,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-15T14:14:03Z",
      "url": "http://www.baystreet.ca/viewarticle.aspx?id=551917",
      "host": "baystreet.ca",
      "text": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
      "country": "CA",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-15T08:00:00-05:00",
      "enriched_text": {
        "entities": [
          {
            "count": 8,
            "sentiment": {
              "score": 0.460269,
              "label": "positive"
            },
            "text": "Jaguar",
            "relevance": 0.877738,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AwardWinner"
              ],
              "name": "Jaguar Cars",
              "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
            }
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0.545547,
              "label": "positive"
            },
            "text": "Jaguar Health",
            "relevance": 0.606352,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0.456422,
              "label": "positive"
            },
            "text": "Jaguar Health, Inc.",
            "relevance": 0.523065,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.353787,
              "label": "positive"
            },
            "text": "Jaguar Animal Health",
            "relevance": 0.423408,
            "type": "Company"
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Mytesi",
            "relevance": 0.401358,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguar Animal Health, Inc.",
            "relevance": 0.394719,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo Pharmaceuticals, Inc.",
            "relevance": 0.383405,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Napo",
            "relevance": 0.264198,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "StateOrCounty"
              ]
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": -0.679083,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.243302,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Napo",
            "relevance": 0.240352,
            "type": "Organization"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "U.S. Securities and Exchange Commission",
            "relevance": 0.233351,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency",
                "GovernmentalBody"
              ],
              "name": "U.S. Securities and Exchange Commission",
              "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Mytesi ®",
            "relevance": 0.225776,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "president and chief executive officer",
            "relevance": 0.223997,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.553674,
              "label": "negative"
            },
            "text": "Mytesi",
            "relevance": 0.223475,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "upper respiratory tract infection",
            "relevance": 0.222084,
            "type": "HealthCondition",
            "disambiguation": {
              "subtype": [
                "DiseaseOrMedicalCondition",
                "RiskFactor",
                "Symptom"
              ],
              "name": "Upper respiratory tract infection",
              "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.740518,
              "label": "positive"
            },
            "text": "Crofelemer",
            "relevance": 0.220124,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Peter Hodge",
            "relevance": 0.220014,
            "type": "Person",
            "disambiguation": {
              "subtype": [],
              "name": "Peter Hodge",
              "dbpedia_resource": "http://dbpedia.org/resource/Peter_Hodge"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Chicago Venture Partners L.P.",
            "relevance": 0.219593,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "SAN FRANCISCO",
            "relevance": 0.215585,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Lisa Conte",
            "relevance": 0.212265,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.353209,
              "label": "negative"
            },
            "text": "FDA",
            "relevance": 0.202351,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "GovernmentAgency"
              ],
              "name": "Food and Drug Administration",
              "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Amazon",
            "relevance": 0.174836,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.1%",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$10.5 million",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$2.3 million",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$4.4 million",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$6.4 million",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "one-year",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "$5.58",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.5%",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "3.9%",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "5.7%",
            "relevance": 0.174836,
            "type": "Quantity"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "8-K",
            "relevance": 0.174836,
            "type": "Quantity"
          }
        ],
        "sentiment": {
          "document": {
            "score": -0.320429,
            "label": "negative"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "[ACCESSWIRE]Maturity Date of Remaining Merger-related Debt",
              "keywords": [
                {
                  "text": "Remaining Merger-related Debt"
                },
                {
                  "text": "Maturity Date"
                },
                {
                  "text": "ACCESSWIRE"
                }
              ]
            },
            "sentence": "[ACCESSWIRE] Maturity Date of Remaining Merger-related Debt is December 31, 2020",
            "object": {
              "text": "December 31"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                },
                {
                  "text": "merger"
                },
                {
                  "text": "debt"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health, Inc."
                }
              ]
            },
            "sentence": " SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "action": {
              "verb": {
                "text": "announce",
                "tense": "past"
              },
              "text": "announced",
              "normalized": "announce"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "object": {
              "text": "reduced debt incurred to effect the 2017 merger of Jaguar Animal Health",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                },
                {
                  "text": "merger"
                },
                {
                  "text": "debt"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health, Inc."
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "object": {
              "text": "debt incurred to effect the 2017 merger of Jaguar Animal Health",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                },
                {
                  "text": "merger"
                },
                {
                  "text": "debt"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health, Inc."
                }
              ]
            },
            "action": {
              "verb": {
                "text": "reduce",
                "tense": "past"
              },
              "text": "has reduced",
              "normalized": "have reduce"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "object": {
              "text": "from approximately $10.5 million (the \"Original Debt\")",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$10.5 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "effect",
                "tense": "future"
              },
              "text": "to effect",
              "normalized": "to effect"
            }
          },
          {
            "subject": {
              "text": "The Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " The Company accomplished this reduction in indebtedness through the issuance of approximately 1,119,440 shares of common stock, at a weighted average price of approximately $5.58 per share, to Chicago Venture Partners L.P. (\"CVP\") pursuant to exchange agreements entered into between the Company and CVP from May 29, 2019 through July 12, 2019.",
            "object": {
              "text": "this reduction",
              "keywords": [
                {
                  "text": "reduction"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "accomplish",
                "tense": "past"
              },
              "text": "accomplished",
              "normalized": "accomplish"
            }
          },
          {
            "subject": {
              "text": "the Merger",
              "keywords": [
                {
                  "text": "Merger"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "effective July 31"
            },
            "action": {
              "verb": {
                "text": "become",
                "tense": "past"
              },
              "text": "became",
              "normalized": "become"
            }
          },
          {
            "subject": {
              "text": "Jaguar Animal Health's name",
              "keywords": [
                {
                  "text": "Jaguar Animal Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Animal Health"
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "action": {
              "verb": {
                "text": "change",
                "tense": "past"
              },
              "text": "changed",
              "normalized": "change"
            }
          },
          {
            "subject": {
              "text": "Inc. and Napo Pharmaceuticals, Inc.",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "Inc."
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "operating as a wholly-owned subsidiary of Jaguar focused on human health",
              "keywords": [
                {
                  "text": "wholly-owned subsidiary"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "operating"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "begin",
                "tense": "past"
              },
              "text": "began",
              "normalized": "begin"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer)",
              "keywords": [
                {
                  "text": "follow-on indications"
                },
                {
                  "text": "ongoing commercialization"
                },
                {
                  "text": "human health"
                },
                {
                  "text": "development"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "focus",
                "tense": "past"
              },
              "text": "focused",
              "normalized": "focus"
            }
          },
          {
            "subject": {
              "text": "We"
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "we"
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "important assets"
                },
                {
                  "text": "pipeline opportunities"
                },
                {
                  "text": "value recognition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "continue",
                "tense": "present"
              },
              "text": "continue",
              "normalized": "continue"
            }
          },
          {
            "subject": {
              "text": "our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "Lisa Conte"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                },
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "pipeline opportunities",
              "keywords": [
                {
                  "text": "pipeline opportunities"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "Lisa Conte, president and chief executive officer of Jaguar,",
              "keywords": [
                {
                  "text": "chief executive officer"
                },
                {
                  "text": "Lisa Conte"
                },
                {
                  "text": "Jaguar"
                },
                {
                  "text": "president"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Lisa Conte"
                },
                {
                  "type": "JobTitle",
                  "text": "president and chief executive officer"
                },
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " \"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "object": {
              "text": "as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent",
              "keywords": [
                {
                  "text": "potential follow-on opportunities"
                },
                {
                  "text": "first-in-class anti-secretory agent"
                },
                {
                  "text": "deep pipeline"
                },
                {
                  "text": "pipeline opportunities"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "state",
                "tense": "past"
              },
              "text": "stated",
              "normalized": "state"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31",
              "keywords": [
                {
                  "text": "one-year extension"
                },
                {
                  "text": "Original Debt"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "a one-year extension",
              "keywords": [
                {
                  "text": "one-year extension"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "one-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "past"
              },
              "text": "has received",
              "normalized": "have receive"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "object": {
              "text": "previously scheduled to mature on December 31, 2019"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "action": {
              "verb": {
                "text": "schedule",
                "tense": "past"
              },
              "text": "scheduled",
              "normalized": "schedule"
            }
          },
          {
            "subject": {
              "text": "The extension of the maturity date",
              "keywords": [
                {
                  "text": "maturity date"
                },
                {
                  "text": "extension"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "part of a larger restructuring of the Original Debt",
              "keywords": [
                {
                  "text": "larger restructuring"
                },
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "sentence": " The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "object": {
              "text": "the acquisition of the Original Debt by CVP",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "Original Debt"
                },
                {
                  "text": "acquisition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "follow",
                "tense": "present"
              },
              "text": "following",
              "normalized": "follow"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AwardWinner"
                    ],
                    "name": "Jaguar Cars",
                    "dbpedia_resource": "http://dbpedia.org/resource/Jaguar_Cars"
                  }
                }
              ]
            },
            "sentence": " As consideration for such restructuring, which included among other things the extension of the maturity date by means of an exchange of the Original Debt for new secured debt with a maturity date of December 31, 2020, Jaguar paid CVP a fee of approximately $2.3 million in the form of additional debt (the \"Additional Debt\").",
            "object": {
              "text": "CVP a fee of approximately $2.3 million",
              "keywords": [
                {
                  "text": "CVP"
                },
                {
                  "text": "fee"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$2.3 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "pay",
                "tense": "past"
              },
              "text": "paid",
              "normalized": "pay"
            }
          },
          {
            "subject": {
              "text": "The Additional Debt",
              "keywords": [
                {
                  "text": "Additional Debt"
                }
              ]
            },
            "sentence": " The Additional Debt is not included in the Original Debt.",
            "object": {
              "text": "in the Original Debt",
              "keywords": [
                {
                  "text": "Original Debt"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "past",
                "negated": true
              },
              "text": "included",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "The details of this transaction",
              "keywords": [
                {
                  "text": "transaction"
                },
                {
                  "text": "details"
                }
              ]
            },
            "sentence": " The details of this transaction are further described in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "object": {
              "text": "on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019",
              "keywords": [
                {
                  "text": "U.S. Securities"
                },
                {
                  "text": "Form 8-K"
                },
                {
                  "text": "Exchange Commission"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "U.S. Securities and Exchange Commission",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency",
                      "GovernmentalBody"
                    ],
                    "name": "U.S. Securities and Exchange Commission",
                    "dbpedia_resource": "http://dbpedia.org/resource/U.S._Securities_and_Exchange_Commission"
                  }
                },
                {
                  "type": "Quantity",
                  "text": "8-K"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "describe",
                "tense": "past"
              },
              "text": "are further described",
              "normalized": "be further describe"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "object": {
              "text": "all of the approximately $6.4 million",
              "entities": [
                {
                  "type": "Quantity",
                  "text": "$6.4 million"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "extinguish",
                "tense": "past"
              },
              "text": "extinguished",
              "normalized": "extinguish"
            }
          },
          {
            "subject": {
              "text": "the Company",
              "keywords": [
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "action": {
              "verb": {
                "text": "issue",
                "tense": "past"
              },
              "text": "issued",
              "normalized": "issue"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "a commercial stage pharmaceuticals company focused on developing novel",
              "keywords": [
                {
                  "text": "commercial stage pharmaceuticals"
                },
                {
                  "text": "company"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar Health, Inc.",
              "keywords": [
                {
                  "text": "Jaguar Health"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar Health, Inc."
                }
              ]
            },
            "sentence": " Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis.",
            "object": {
              "text": "novel, sustainably derived gastrointestinal products on a global basis",
              "keywords": [
                {
                  "text": "gastrointestinal products"
                },
                {
                  "text": "global basis"
                },
                {
                  "text": "novel"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "develop",
                "tense": "future"
              },
              "text": "developing",
              "normalized": "develop"
            }
          },
          {
            "subject": {
              "text": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc.,",
              "keywords": [
                {
                  "text": "Napo Pharmaceuticals"
                },
                {
                  "text": "wholly-owned subsidiary"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Napo Pharmaceuticals, Inc."
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "object": {
              "text": "proprietary human gastrointestinal pharmaceuticals",
              "keywords": [
                {
                  "text": "gastrointestinal pharmaceuticals"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "commercialize",
                "tense": "present"
              },
              "text": "commercializing",
              "normalized": "commercialize"
            }
          },
          {
            "subject": {
              "text": "plants",
              "keywords": [
                {
                  "text": "plants"
                }
              ]
            },
            "sentence": " Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "action": {
              "verb": {
                "text": "use",
                "tense": "past"
              },
              "text": "used",
              "normalized": "use"
            }
          },
          {
            "subject": {
              "text": "Our Mytesi ® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "approved by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "by the U.S. FDA",
              "keywords": [
                {
                  "text": "U.S. FDA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "FDA",
                  "disambiguation": {
                    "subtype": [
                      "GovernmentAgency"
                    ],
                    "name": "Food and Drug Administration",
                    "dbpedia_resource": "http://dbpedia.org/resource/Food_and_Drug_Administration"
                  }
                }
              ]
            },
            "sentence": " Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "object": {
              "text": "Our Mytesi ® (crofelemer) product",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                },
                {
                  "text": "product"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "approve",
                "tense": "past"
              },
              "text": "is approved",
              "normalized": "be approve"
            }
          },
          {
            "subject": {
              "text": "Mytesi (crofelemer)",
              "keywords": [
                {
                  "text": "Mytesi"
                },
                {
                  "text": "crofelemer"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "object": {
              "text": "an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea",
              "keywords": [
                {
                  "text": "noninfectious diarrhea"
                },
                {
                  "text": "symptomatic relief"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "not indicated for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "for the treatment of infectious diarrhea",
              "keywords": [
                {
                  "text": "infectious diarrhea"
                },
                {
                  "text": "treatment"
                }
              ]
            },
            "sentence": " Mytesi is not indicated for the treatment of infectious diarrhea.",
            "object": {
              "text": "Mytesi",
              "keywords": [
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Mytesi"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "indicate",
                "tense": "past",
                "negated": true
              },
              "text": "indicated",
              "normalized": "indicate"
            }
          },
          {
            "subject": {
              "text": "infectious etiologies of diarrhea",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "diarrhea"
                }
              ]
            },
            "sentence": " Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "action": {
              "verb": {
                "text": "Rule",
                "tense": "present"
              },
              "text": "Rule",
              "normalized": "Rule"
            }
          },
          {
            "subject": {
              "text": "patients with infectious etiologies",
              "keywords": [
                {
                  "text": "infectious etiologies"
                },
                {
                  "text": "patients"
                }
              ]
            },
            "sentence": " If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen.",
            "object": {
              "text": "the appropriate therapy and their disease",
              "keywords": [
                {
                  "text": "appropriate therapy"
                },
                {
                  "text": "disease"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "receive",
                "tense": "future",
                "negated": true
              },
              "text": "receive",
              "normalized": "receive"
            }
          },
          {
            "subject": {
              "text": "a rate greater than placebo",
              "keywords": [
                {
                  "text": "placebo"
                },
                {
                  "text": "rate"
                }
              ]
            },
            "sentence": " In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).",
            "object": {
              "text": "upper respiratory tract infection",
              "keywords": [
                {
                  "text": "respiratory tract infection"
                }
              ],
              "entities": [
                {
                  "type": "HealthCondition",
                  "text": "upper respiratory tract infection",
                  "disambiguation": {
                    "subtype": [
                      "DiseaseOrMedicalCondition",
                      "RiskFactor",
                      "Symptom"
                    ],
                    "name": "Upper respiratory tract infection",
                    "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "were",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Crofelemer, the active ingredient in Mytesi,",
              "keywords": [
                {
                  "text": "active ingredient"
                },
                {
                  "text": "Crofelemer"
                },
                {
                  "text": "Mytesi"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Crofelemer"
                },
                {
                  "type": "Company",
                  "text": "Mytesi"
                }
              ]
            },
            "sentence": " Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest.",
            "object": {
              "text": "a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest",
              "keywords": [
                {
                  "text": "red bark sap"
                },
                {
                  "text": "medicinal Croton"
                },
                {
                  "text": "Amazon rainforest"
                },
                {
                  "text": "drug"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Amazon"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "established a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a sustainable harvesting program",
              "keywords": [
                {
                  "text": "sustainable harvesting program"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "establish",
                "tense": "past"
              },
              "text": "has established",
              "normalized": "have establish"
            }
          },
          {
            "subject": {
              "text": "Napo",
              "keywords": [
                {
                  "text": "Napo"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "Napo"
                }
              ]
            },
            "sentence": " Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.",
            "object": {
              "text": "a high degree of quality and ecological integrity",
              "keywords": [
                {
                  "text": "ecological integrity"
                },
                {
                  "text": "high degree"
                },
                {
                  "text": "quality"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "ensure",
                "tense": "future"
              },
              "text": "to ensure",
              "normalized": "to ensure"
            }
          },
          {
            "subject": {
              "text": "Certain statements in this press release",
              "keywords": [
                {
                  "text": "Certain statements"
                },
                {
                  "text": "press release"
                }
              ],
              "entities": []
            },
            "sentence": " Certain statements in this press release constitute \"forward-looking statements.\"",
            "object": {
              "text": "\"forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "constitute",
                "tense": "present"
              },
              "text": "constitute",
              "normalized": "constitute"
            }
          },
          {
            "subject": {
              "text": "statements regarding the Company's planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "statements"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "sentence": " These include statements regarding the Company's planned clinical and commercial milestones.",
            "object": {
              "text": "These"
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "include",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "statements",
              "keywords": [
                {
                  "text": "statements"
                }
              ]
            },
            "sentence": " These include statements regarding the Company's planned clinical and commercial milestones.",
            "object": {
              "text": "the Company's planned clinical and commercial milestones",
              "keywords": [
                {
                  "text": "commercial milestones"
                },
                {
                  "text": "Company"
                }
              ],
              "entities": []
            },
            "action": {
              "verb": {
                "text": "regard",
                "tense": "present"
              },
              "text": "regarding",
              "normalized": "regard"
            }
          },
          {
            "subject": {
              "text": "you"
            },
            "sentence": " In some cases, you can identify forward-looking statements by terms such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"aim,\" \"anticipate,\" \"could,\" \"intend,\" \"target,\" \"project,\" \"contemplate,\" \"believe,\" \"estimate,\" \"predict,\" \"potential\" or \"continue\" or the negative of these terms or other similar expressions.",
            "object": {
              "text": "forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "identify",
                "tense": "future"
              },
              "text": "can identify",
              "normalized": "can identify"
            }
          },
          {
            "subject": {
              "text": "The forward-looking statements in this release",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "release"
                }
              ],
              "entities": []
            },
            "sentence": " The forward-looking statements in this release are only predictions.",
            "object": {
              "text": "only predictions",
              "keywords": [
                {
                  "text": "predictions"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Jaguar has based these forward-looking statements largely on its current expectations and projections about future events.",
            "object": {
              "text": "based these forward-looking statements largely on its current expectations and projections about future events",
              "keywords": [
                {
                  "text": "forward-looking statements"
                },
                {
                  "text": "current expectations"
                },
                {
                  "text": "future events"
                },
                {
                  "text": "projections"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "has",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "These forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "sentence": " These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control.",
            "action": {
              "verb": {
                "text": "speak",
                "tense": "present"
              },
              "text": "speak",
              "normalized": "speak"
            }
          },
          {
            "subject": {
              "text": "These forward-looking statements",
              "keywords": [
                {
                  "text": "forward-looking statements"
                }
              ]
            },
            "sentence": " These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control.",
            "object": {
              "text": "subject to a number of risks, uncertainties and assumptions",
              "keywords": [
                {
                  "text": "uncertainties"
                },
                {
                  "text": "assumptions"
                },
                {
                  "text": "risks"
                },
                {
                  "text": "number"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "are",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.",
            "object": {
              "text": "not plan",
              "keywords": [
                {
                  "text": "plan"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "do",
                "tense": "present"
              },
              "text": "does",
              "normalized": "do"
            }
          }
        ],
        "concepts": [
          {
            "text": "Medicine",
            "relevance": 0.96253,
            "dbpedia_resource": "http://dbpedia.org/resource/Medicine"
          },
          {
            "text": "AIDS",
            "relevance": 0.749257,
            "dbpedia_resource": "http://dbpedia.org/resource/AIDS"
          },
          {
            "text": "Subsidiary",
            "relevance": 0.668659,
            "dbpedia_resource": "http://dbpedia.org/resource/Subsidiary"
          },
          {
            "text": "Antiretroviral drug",
            "relevance": 0.630212,
            "dbpedia_resource": "http://dbpedia.org/resource/Antiretroviral_drug"
          },
          {
            "text": "Respiratory system",
            "relevance": 0.601464,
            "dbpedia_resource": "http://dbpedia.org/resource/Respiratory_system"
          },
          {
            "text": "HIV",
            "relevance": 0.595274,
            "dbpedia_resource": "http://dbpedia.org/resource/HIV"
          },
          {
            "text": "Health",
            "relevance": 0.565066,
            "dbpedia_resource": "http://dbpedia.org/resource/Health"
          },
          {
            "text": "Clinical trial",
            "relevance": 0.560939,
            "dbpedia_resource": "http://dbpedia.org/resource/Clinical_trial"
          },
          {
            "text": "Loan",
            "relevance": 0.55896,
            "dbpedia_resource": "http://dbpedia.org/resource/Loan"
          },
          {
            "text": "Upper respiratory tract infection",
            "relevance": 0.547053,
            "dbpedia_resource": "http://dbpedia.org/resource/Upper_respiratory_tract_infection"
          },
          {
            "text": "Debt",
            "relevance": 0.541992,
            "dbpedia_resource": "http://dbpedia.org/resource/Debt"
          },
          {
            "text": "Maturity",
            "relevance": 0.532655,
            "dbpedia_resource": "http://dbpedia.org/resource/Maturity_(finance)"
          },
          {
            "text": "Jaguar",
            "relevance": 0.5196,
            "dbpedia_resource": "http://dbpedia.org/resource/Jaguar"
          },
          {
            "text": "Etiology",
            "relevance": 0.518316,
            "dbpedia_resource": "http://dbpedia.org/resource/Etiology"
          },
          {
            "text": "Pharmacology",
            "relevance": 0.512442,
            "dbpedia_resource": "http://dbpedia.org/resource/Pharmacology"
          },
          {
            "text": "Gastroenteritis",
            "relevance": 0.485162,
            "dbpedia_resource": "http://dbpedia.org/resource/Gastroenteritis"
          },
          {
            "text": "Rolling",
            "relevance": 0.484655,
            "dbpedia_resource": "http://dbpedia.org/resource/Rolling_(finance)"
          }
        ],
        "categories": [
          {
            "score": 0.974089,
            "label": "/health and fitness/disease/aids and hiv"
          },
          {
            "score": 0.721115,
            "label": "/health and fitness/disease/epidemic"
          },
          {
            "score": 0.693402,
            "label": "/business and industrial/company"
          }
        ],
        "relations": [
          {
            "type": "hasAttribute",
            "sentence": "[ACCESSWIRE] Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.935375,
            "arguments": [
              {
                "text": "CA Jaguar Health, Inc.",
                "location": [
                  96,
                  118
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "JAGX",
                "location": [
                  128,
                  132
                ],
                "entities": [
                  {
                    "type": "Ticker",
                    "text": "JAGX"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.84494,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  1384,
                  1390
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  1372,
                  1380
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.824225,
            "arguments": [
              {
                "text": "adults",
                "location": [
                  3620,
                  3626
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "adults"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3608,
                  3616
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.504364,
            "arguments": [
              {
                "text": "people",
                "location": [
                  1749,
                  1755
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "people"
                  }
                ]
              },
              {
                "text": "HIV/AIDS",
                "location": [
                  1768,
                  1776
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "HIV/AIDS"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "\"We are pleased about this further reduction of the Company's liabilities as we continue to focus on our planned clinical and commercial milestones and value recognition for our important assets and pipeline opportunities, which include our commercial product, Mytesi, launched directly into the specialty market for people living with HIV/AIDS, and our deep pipeline of potential follow-on opportunities for this first-in-class anti-secretory agent, crofelemer,\" Lisa Conte, president and chief executive officer of Jaguar, stated.",
            "score": 0.608738,
            "arguments": [
              {
                "text": "chief executive officer",
                "location": [
                  1922,
                  1945
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Lisa Conte"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1949,
                  1955
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As announced June 3, 2019, the Company has received a one-year extension on the Original Debt, which was previously scheduled to mature on December 31, 2019.",
            "score": 0.969167,
            "arguments": [
              {
                "text": "June 3, 2019",
                "location": [
                  1978,
                  1990
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "June 3, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  1968,
                  1977
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.558802,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  2200,
                  2213
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2228,
                  2239
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.435512,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  2264,
                  2267
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "acquisition",
                "location": [
                  2228,
                  2239
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The extension of the maturity date was part of a larger restructuring of the Original Debt following the acquisition of the Original Debt by CVP.",
            "score": 0.811688,
            "arguments": [
              {
                "text": "Original Debt",
                "location": [
                  2247,
                  2260
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "CVP",
                "location": [
                  2264,
                  2267
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The details of this transaction are further described in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on June 3, 2019.",
            "score": 0.984349,
            "arguments": [
              {
                "text": "Securities and Exchange Commission",
                "location": [
                  2772,
                  2806
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Securities and Exchange Commission",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  2767,
                  2771
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Original Debt"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.990022,
            "arguments": [
              {
                "text": "Jaguar",
                "location": [
                  2827,
                  2833
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  2834,
                  2843
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.985113,
            "arguments": [
              {
                "text": "May 29, 2019",
                "location": [
                  2844,
                  2856
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "May 29, 2019"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  2834,
                  2843
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "[ACCESSWIRE] Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.986658,
            "arguments": [
              {
                "text": "today",
                "location": [
                  309,
                  314
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "today"
                  }
                ]
              },
              {
                "text": "announced",
                "location": [
                  299,
                  308
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announced"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.898709,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  2862,
                  2869
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "$6.4 million",
                "location": [
                  2917,
                  2929
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$6.4 million",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.979945,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  3021,
                  3028
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3040,
                  3046
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.88192,
            "arguments": [
              {
                "text": "CVP",
                "location": [
                  3050,
                  3053
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "CVP"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3040,
                  3046
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.842766,
            "arguments": [
              {
                "text": "July 2017",
                "location": [
                  3057,
                  3066
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "July 2017"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3040,
                  3046
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "As Jaguar announced May 29, 2019, the Company recently extinguished all of the approximately $6.4 million in secured promissory notes that were outstanding as of December 31, 2018, which notes the Company originally issued to CVP in July 2017 through March 2018.",
            "score": 0.526381,
            "arguments": [
              {
                "text": "March 2018",
                "location": [
                  3075,
                  3085
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "March 2018"
                  }
                ]
              },
              {
                "text": "issued",
                "location": [
                  3040,
                  3046
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "issued"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.",
            "score": 0.532118,
            "arguments": [
              {
                "text": "subsidiary",
                "location": [
                  3290,
                  3300
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  3302,
                  3328
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.613956,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  3506,
                  3514
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "Our",
                "location": [
                  3502,
                  3505
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Our"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.996698,
            "arguments": [
              {
                "text": "FDA",
                "location": [
                  3560,
                  3563
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "FDA",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "U.S.",
                "location": [
                  3555,
                  3559
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Original Debt"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "For more information about Napo, visit napopharma.com .",
            "score": 0.572924,
            "arguments": [
              {
                "text": "Napo",
                "location": [
                  3759,
                  3763
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "napopharma.com",
                "location": [
                  3771,
                  3785
                ],
                "entities": [
                  {
                    "type": "Web",
                    "text": "napopharma.com"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi ® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.927523,
            "arguments": [
              {
                "text": "patients",
                "location": [
                  3915,
                  3923
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "patients"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3897,
                  3905
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "[ACCESSWIRE] Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.462331,
            "arguments": [
              {
                "text": "Company",
                "location": [
                  324,
                  331
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  377,
                  383
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Source: Jaguar Health, Inc. Contact: Peter Hodge Jaguar Health, Inc. phodge@jaguar.health Jaguar-JAGX SOURCE: Jaguar Health, Inc.  //www.accesswire.com/551917/Jaguar-Health-Strengthens-Companys-Balance-Sheet-by-Reducing-Approximately-105-Million-of-Debt-Incurred-to-Effect-2017-Merger-to-Approximately-44-Million",
            "score": 0.763364,
            "arguments": [
              {
                "text": "Peter Hodge\nJaguar",
                "location": [
                  6089,
                  6107
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Peter Hodge\nJaguar"
                  }
                ]
              },
              {
                "text": "Health, Inc.\nphodge@jaguar.health\nJaguar-JAGX\nSOURCE",
                "location": [
                  6108,
                  6160
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Health, Inc.\nphodge@jaguar.health\nJaguar-JAGX\nSOURCE",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Source: Jaguar Health, Inc. Contact: Peter Hodge Jaguar Health, Inc. phodge@jaguar.health Jaguar-JAGX SOURCE: Jaguar Health, Inc.  //www.accesswire.com/551917/Jaguar-Health-Strengthens-Companys-Balance-Sheet-by-Reducing-Approximately-105-Million-of-Debt-Incurred-to-Effect-2017-Merger-to-Approximately-44-Million",
            "score": 0.500591,
            "arguments": [
              {
                "text": "Jaguar Health, Inc.\n //",
                "location": [
                  6162,
                  6185
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "www.accesswire.com/551917/Jaguar",
                "location": [
                  6185,
                  6217
                ],
                "entities": [
                  {
                    "type": "Web",
                    "text": "www.accesswire.com/551917/Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "[ACCESSWIRE] Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.772237,
            "arguments": [
              {
                "text": "2017",
                "location": [
                  372,
                  376
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "2017"
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  377,
                  383
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "[ACCESSWIRE] Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.620033,
            "arguments": [
              {
                "text": "Jaguar Animal Health, Inc.",
                "location": [
                  387,
                  413
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Animal Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  377,
                  383
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "participantIn",
            "sentence": "[ACCESSWIRE] Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.30416,
            "arguments": [
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  418,
                  444
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "merger",
                "location": [
                  377,
                  383
                ],
                "entities": [
                  {
                    "type": "EventBusiness",
                    "text": "merger"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "[ACCESSWIRE] Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA Jaguar Health, Inc. (NASDAQ: JAGX) (\"Jaguar\" or the \"Company\"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has reduced debt incurred to effect the 2017 merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (the \"Merger\") from approximately $10.5 million (the \"Original Debt\") to approximately $4.4 million, thereby strengthening the Company's balance sheet.",
            "score": 0.766986,
            "arguments": [
              {
                "text": "Napo Pharmaceuticals, Inc.",
                "location": [
                  418,
                  444
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Napo Pharmaceuticals, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "$10.5 million",
                "location": [
                  479,
                  492
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$10.5 million",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.489579,
            "arguments": [
              {
                "text": "subsidiary",
                "location": [
                  1126,
                  1136
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Original Debt"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  1140,
                  1146
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Jaguar Health, Inc.\nJaguar Health, Inc.",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Following the Merger, which became effective July 31, 2017, Jaguar Animal Health's name changed to Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. began operating as a wholly-owned subsidiary of Jaguar focused on human health and the ongoing commercialization of, and development of follow-on indications for, Mytesi ® (crofelemer), the Company's FDA-approved drug product indicated for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.747773,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  1255,
                  1263
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  1372,
                  1380
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Our Mytesi ® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.",
            "score": 0.581568,
            "arguments": [
              {
                "text": "Mytesi ®",
                "location": [
                  3506,
                  3514
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3608,
                  3616
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "About Mytesi ® Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).",
            "score": 0.895097,
            "arguments": [
              {
                "text": "Mytesi ®\nMytesi",
                "location": [
                  3794,
                  3809
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  3897,
                  3905
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Mytesi is not indicated for the treatment of infectious diarrhea.",
            "score": 0.643525,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  3971,
                  3977
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4027,
                  4035
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Rule out infectious etiologies of diarrhea before starting Mytesi.",
            "score": 0.930052,
            "arguments": [
              {
                "text": "Mytesi",
                "location": [
                  4096,
                  4102
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Mytesi ®\nMytesi"
                  }
                ]
              },
              {
                "text": "diarrhea",
                "location": [
                  4071,
                  4079
                ],
                "entities": [
                  {
                    "type": "HealthCondition",
                    "text": "infection"
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "CA Jaguar Health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.72604,
            "count": 1
          },
          {
            "text": "pharmaceutical company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.600034,
            "count": 1
          },
          {
            "text": "Napo Pharmaceuticals",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.59558,
            "count": 3
          },
          {
            "text": "merger of Jaguar Animal Health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.58497,
            "count": 1
          },
          {
            "text": "clinical studies",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.57222,
            "count": 1
          },
          {
            "text": "development of follow",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.554391,
            "count": 1
          },
          {
            "text": "commercial stage",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.553751,
            "count": 1
          },
          {
            "text": "Jaguar Animal Health's name",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.551951,
            "count": 1
          },
          {
            "text": "SAN FRANCISCO",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.550466,
            "count": 1
          },
          {
            "text": "gastrointestinal products",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.546638,
            "count": 2
          },
          {
            "text": "human health",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.544662,
            "count": 1
          },
          {
            "text": "press release",
            "sentiment": {
              "score": -0.607008,
              "label": "negative"
            },
            "relevance": 0.541144,
            "count": 1
          },
          {
            "text": "Company",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.539828,
            "count": 8
          },
          {
            "text": "active ingredient",
            "sentiment": {
              "score": -0.938438,
              "label": "negative"
            },
            "relevance": 0.538376,
            "count": 1
          },
          {
            "text": "shares of common stock",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.537673,
            "count": 1
          },
          {
            "text": "pipeline opportunities",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.537412,
            "count": 1
          },
          {
            "text": "treatment of infectious diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.534194,
            "count": 1
          },
          {
            "text": "Jaguar Health",
            "sentiment": {
              "score": 0.363999,
              "mixed": "1",
              "label": "positive"
            },
            "relevance": 0.531742,
            "count": 4
          },
          {
            "text": "commercial product",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.53131,
            "count": 1
          },
          {
            "text": "Original Debt",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.531163,
            "count": 3
          },
          {
            "text": "Company's balance sheet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529537,
            "count": 1
          },
          {
            "text": "subsidiary of Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529319,
            "count": 1
          },
          {
            "text": "promissory notes",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529242,
            "count": 1
          },
          {
            "text": "upper respiratory tract infection",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.52922,
            "count": 1
          },
          {
            "text": "average price",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.529196,
            "count": 1
          },
          {
            "text": "infectious etiologies of diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.527841,
            "count": 1
          },
          {
            "text": "symptomatic relief of noninfectious diarrhea",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.526578,
            "count": 3
          },
          {
            "text": "class anti-secretory agent",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.526493,
            "count": 1
          },
          {
            "text": "adult patients",
            "sentiment": {
              "score": 0.713733,
              "label": "positive"
            },
            "relevance": 0.525875,
            "count": 1
          },
          {
            "text": "extension of the maturity date",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.525571,
            "count": 2
          },
          {
            "text": "part of a larger restructuring of the Original Debt",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.524622,
            "count": 1
          },
          {
            "text": "Jaguar",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.523673,
            "count": 6
          },
          {
            "text": "one-year extension",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.522382,
            "count": 1
          },
          {
            "text": "Statements",
            "sentiment": {
              "score": -0.607008,
              "label": "negative"
            },
            "relevance": 0.522228,
            "count": 9
          },
          {
            "text": "effective July",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.522187,
            "count": 1
          },
          {
            "text": "such restructuring",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.522089,
            "count": 1
          },
          {
            "text": "commercial milestones",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519792,
            "count": 2
          },
          {
            "text": "details of this transaction",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519092,
            "count": 1
          },
          {
            "text": "Exchange Commission",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517866,
            "count": 1
          },
          {
            "text": "further reduction of the Company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517768,
            "count": 1
          },
          {
            "text": "drug product",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.516854,
            "count": 1
          },
          {
            "text": "plan",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.516588,
            "count": 1
          },
          {
            "text": "chief executive officer of Jaguar",
            "sentiment": {
              "score": 0.959829,
              "label": "positive"
            },
            "relevance": 0.516359,
            "count": 1
          },
          {
            "text": "applicable law",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.516107,
            "count": 1
          },
          {
            "text": "global marketplace",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.51548,
            "count": 1
          },
          {
            "text": "global basis",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.514351,
            "count": 2
          },
          {
            "text": "future events",
            "sentiment": {
              "score": 0.859669,
              "label": "positive"
            },
            "relevance": 0.514028,
            "count": 2
          },
          {
            "text": "ongoing commercialization",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.513707,
            "count": 1
          },
          {
            "text": "means of an exchange of the Original Debt",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.513094,
            "count": 1
          },
          {
            "text": "commercial stage pharmaceuticals company",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.512903,
            "count": 1
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "7826e97c177d7d80b2dd3e7bfc0c9329fcb7fce3",
        "filename": "1563200043309.zip-51152c9e57d5cb8141b54d790a5a5c00.xml",
        "file_type": "json"
      },
      "external_links": [
        "http://pr.report/4KhQR-nx",
        "https://www.accesswire.com/img.ashx?id=551917",
        "https://ads.investingchannel.com/adtags/BayStreet/equities/300x250.js",
        "https://www.accesswire.com/551917/Jaguar-Health-Strengthens-Companys-Balance-Sheet-by-Reducing-Approximately-105-Million-of-Debt-Incurred-to-Effect-2017-Merger-to-Approximately-44-Million",
        "http://pr.report/6kwvcahl",
        "http://pr.report/gT3iZsMS"
      ],
      "title": "Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million",
      "forum_title": "Baystreet.ca - ACCESSWIRE"
    },
    {
      "id": "kXhcP9uXqHtIIWYPsY5A642q4FGiVuNM-t3zH8-r0bIdup4A6TCarfnc6VVDPqiH",
      "result_metadata": {
        "score": 20.164728
      },
      "author": "Editorial Staff",
      "enriched_title": {
        "entities": [
          {
            "count": 1,
            "sentiment": {
              "score": 0.60104,
              "label": "positive"
            },
            "text": "France",
            "relevance": 0.33,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "Country"
              ]
            }
          }
        ],
        "sentiment": {
          "document": {
            "score": 0.704128,
            "label": "positive"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "France",
              "keywords": [
                {
                  "text": "France"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "France",
                  "disambiguation": {
                    "subtype": [
                      "Country"
                    ]
                  }
                }
              ]
            },
            "sentence": "France Finally Kickstarts Scorpion Land Vehicle Acquisition",
            "object": {
              "text": "Scorpion Land Vehicle Acquisition",
              "keywords": [
                {
                  "text": "Scorpion Land Vehicle"
                },
                {
                  "text": "Acquisition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Kickstarts",
                "tense": "present"
              },
              "text": "Kickstarts",
              "normalized": "Kickstarts"
            }
          }
        ],
        "concepts": [
          {
            "text": "Vehicle",
            "relevance": 0.886784,
            "dbpedia_resource": "http://dbpedia.org/resource/Vehicle"
          }
        ],
        "categories": [
          {
            "score": 0.999921,
            "label": "/automotive and vehicles/vehicle brands"
          },
          {
            "score": 0.999187,
            "label": "/business and industrial/company/merger and acquisition"
          }
        ],
        "relations": [
          {
            "type": "partOf",
            "sentence": "France Finally Kickstarts Scorpion Land Vehicle Acquisition",
            "score": 0.530354,
            "arguments": [
              {
                "text": "Kickstarts Scorpion Land Vehicle Acquisition",
                "location": [
                  15,
                  59
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Kickstarts Scorpion Land Vehicle Acquisition"
                  }
                ]
              },
              {
                "text": "France",
                "location": [
                  0,
                  6
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "France",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "Kickstarts Scorpion Land Vehicle Acquisition",
            "sentiment": {
              "score": 0.704128,
              "label": "positive"
            },
            "relevance": 0.968539,
            "count": 1
          },
          {
            "text": "France",
            "sentiment": {
              "score": 0.704128,
              "label": "positive"
            },
            "relevance": 0.899735,
            "count": 1
          }
        ]
      },
      "crawl_date": "2019-07-17T12:34:07Z",
      "url": "http://www.defenseindustrydaily.com/france-scorpion-land-vehicles-028975/",
      "host": "defenseindustrydaily.com",
      "text": "The same group is also developing the Jaguar, a combat vehicle designed to share common equipment with the Griffon.",
      "main_image_url": "https://media.defenceindustrydaily.com/images/LAND_Griffon_Concept.jpg",
      "country": "US",
      "source_type": "mainstream",
      "language": "en",
      "publication_date": "2019-07-17T03:58:00Z",
      "enriched_text": {
        "entities": [
          {
            "count": 14,
            "sentiment": {
              "score": -0.624039,
              "label": "negative"
            },
            "text": "France",
            "relevance": 0.889997,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "Region",
                "AdministrativeDivision",
                "GovernmentalJurisdiction",
                "FilmDirector",
                "Country"
              ],
              "name": "France",
              "dbpedia_resource": "http://dbpedia.org/resource/France"
            }
          },
          {
            "count": 5,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Scorpion",
            "relevance": 0.773509,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Ronn Motor Company",
              "dbpedia_resource": "http://dbpedia.org/resource/Ronn_Motor_Company"
            }
          },
          {
            "count": 7,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "French Army",
            "relevance": 0.755258,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "ArmedForce"
              ],
              "name": "French Army",
              "dbpedia_resource": "http://dbpedia.org/resource/French_Army"
            }
          },
          {
            "count": 8,
            "sentiment": {
              "score": 0.34928,
              "label": "positive"
            },
            "text": "Thales",
            "relevance": 0.716752,
            "type": "Company"
          },
          {
            "count": 7,
            "sentiment": {
              "score": -0.170851,
              "label": "negative"
            },
            "text": "DGA",
            "relevance": 0.633442,
            "type": "Organization"
          },
          {
            "count": 6,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Nexter",
            "relevance": 0.591112,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Nexter",
              "dbpedia_resource": "http://dbpedia.org/resource/Nexter"
            }
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Renault Trucks Defense",
            "relevance": 0.554883,
            "type": "Company"
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0.495611,
              "label": "positive"
            },
            "text": "Jaguar",
            "relevance": 0.475873,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "French Army’s Griffon",
            "relevance": 0.471938,
            "type": "Organization"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Nexter",
            "relevance": 0.417407,
            "type": "Person"
          },
          {
            "count": 3,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "EBRCs",
            "relevance": 0.397649,
            "type": "Company"
          },
          {
            "count": 5,
            "sentiment": {
              "score": 0.302481,
              "label": "positive"
            },
            "text": "Belgium",
            "relevance": 0.397381,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "Country"
              ]
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "French government",
            "relevance": 0.392435,
            "type": "Organization"
          },
          {
            "count": 4,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "VABs",
            "relevance": 0.372624,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "VBMR",
            "relevance": 0.372256,
            "type": "Organization"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Land Forces",
            "relevance": 0.369632,
            "type": "Organization"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0.431048,
              "label": "positive"
            },
            "text": "MBDA",
            "relevance": 0.366184,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "MBDA",
              "dbpedia_resource": "http://dbpedia.org/resource/MBDA"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Defense Industry",
            "relevance": 0.362004,
            "type": "Company"
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "VBMRs",
            "relevance": 0.346162,
            "type": "Company"
          },
          {
            "count": 3,
            "sentiment": {
              "score": -0.572786,
              "label": "negative"
            },
            "text": "RTD",
            "relevance": 0.345803,
            "type": "Organization"
          },
          {
            "count": 2,
            "sentiment": {
              "score": -0.513316,
              "label": "negative"
            },
            "text": "Paris",
            "relevance": 0.340004,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "AdministrativeDivision",
                "FrenchDepartment",
                "GovernmentalJurisdiction",
                "OlympicBiddingCity",
                "OlympicHostCity",
                "PlaceWithNeighborhoods",
                "City"
              ],
              "name": "Paris",
              "dbpedia_resource": "http://dbpedia.org/resource/Paris"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "French",
            "relevance": 0.332993,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 2,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "official",
            "relevance": 0.330918,
            "type": "JobTitle"
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.475993,
              "label": "negative"
            },
            "text": "NATO",
            "relevance": 0.321789,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "Location",
                "MembershipOrganization"
              ],
              "name": "NATO",
              "dbpedia_resource": "http://dbpedia.org/resource/NATO"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Véhicules Blindés Légers",
            "relevance": 0.318868,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Renault",
            "relevance": 0.307715,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AutomobileCompany",
                "AwardWinner"
              ],
              "name": "Renault",
              "dbpedia_resource": "http://dbpedia.org/resource/Renault"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Leclerc XL",
            "relevance": 0.302547,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Préférence nationale",
            "relevance": 0.301901,
            "type": "Facility"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.403942,
              "label": "positive"
            },
            "text": "Safran",
            "relevance": 0.301042,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Safran",
              "dbpedia_resource": "http://dbpedia.org/resource/Safran"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "VAB",
            "relevance": 0.290122,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Leclerc tank",
            "relevance": 0.289708,
            "type": "GeographicFeature"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.645679,
              "label": "positive"
            },
            "text": "Arquus",
            "relevance": 0.289354,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Système",
            "relevance": 0.28918,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Véhicules de l’avant",
            "relevance": 0.289063,
            "type": "Location",
            "disambiguation": {
              "subtype": [
                "City"
              ]
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Arquus",
            "relevance": 0.287604,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0.428217,
              "label": "positive"
            },
            "text": "Les Echos",
            "relevance": 0.287494,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "TFEU",
            "relevance": 0.283049,
            "type": "Organization"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Armed Forces Ministry",
            "relevance": 0.280189,
            "type": "Organization"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Renault Trucks",
            "relevance": 0.273525,
            "type": "Company",
            "disambiguation": {
              "subtype": [],
              "name": "Renault Trucks",
              "dbpedia_resource": "http://dbpedia.org/resource/Renault_Trucks"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jaguars",
            "relevance": 0.270772,
            "type": "Organization",
            "disambiguation": {
              "subtype": [
                "SportsTeam",
                "FootballTeam",
                "ProfessionalSportsTeam"
              ],
              "name": "Jacksonville Jaguars",
              "dbpedia_resource": "http://dbpedia.org/resource/Jacksonville_Jaguars"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": -0.469012,
              "label": "negative"
            },
            "text": "Galix",
            "relevance": 0.269904,
            "type": "Company"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "Jane",
            "relevance": 0.269767,
            "type": "Person"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "RCWS",
            "relevance": 0.269623,
            "type": "Organization"
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "BAE",
            "relevance": 0.268083,
            "type": "Company",
            "disambiguation": {
              "subtype": [
                "AircraftManufacturer"
              ],
              "name": "BAE Systems",
              "dbpedia_resource": "http://dbpedia.org/resource/BAE_Systems"
            }
          },
          {
            "count": 1,
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "text": "CTA International",
            "relevance": 0.262089,
            "type": "Company"
          }
        ],
        "sentiment": {
          "document": {
            "score": -0.31435,
            "label": "negative"
          }
        },
        "semantic_roles": [
          {
            "subject": {
              "text": "France",
              "keywords": [
                {
                  "text": "France"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "France",
                  "disambiguation": {
                    "subtype": [
                      "Region",
                      "AdministrativeDivision",
                      "Country",
                      "GovernmentalJurisdiction",
                      "FilmDirector",
                      "Country"
                    ],
                    "name": "France",
                    "dbpedia_resource": "http://dbpedia.org/resource/France"
                  }
                }
              ]
            },
            "sentence": "France Finally Kickstarts Scorpion Land Vehicle Acquisition Jul 17, 2019 04:58 UTC by Defense Industry Daily staff Latest update [?]",
            "object": {
              "text": "Scorpion Land Vehicle Acquisition",
              "keywords": [
                {
                  "text": "Scorpion Land Vehicle"
                },
                {
                  "text": "Acquisition"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "Kickstarts",
                "tense": "present"
              },
              "text": "Kickstarts",
              "normalized": "Kickstarts"
            }
          },
          {
            "subject": {
              "text": "by the French defense procurement agency (DGA)",
              "keywords": [
                {
                  "text": "French defense procurement"
                },
                {
                  "text": "DGA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "DGA"
                }
              ]
            },
            "sentence": " The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium includes 60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR).",
            "object": {
              "text": "The CaMo contract",
              "keywords": [
                {
                  "text": "CaMo contract"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "award",
                "tense": "past"
              },
              "text": "awarded",
              "normalized": "award"
            }
          },
          {
            "subject": {
              "text": "60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR)",
              "keywords": [
                {
                  "text": "multi-role armored vehicles"
                },
                {
                  "text": "Jaguar reconnaissance"
                },
                {
                  "text": "combat vehicles"
                },
                {
                  "text": "Griffon"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "EBRCs"
                },
                {
                  "type": "Organization",
                  "text": "VBMR"
                }
              ]
            },
            "sentence": " The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium includes 60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR).",
            "object": {
              "text": "The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium",
              "keywords": [
                {
                  "text": "French defense procurement"
                },
                {
                  "text": "CaMo contract"
                },
                {
                  "text": "DGA"
                },
                {
                  "text": "behalf"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "DGA"
                },
                {
                  "type": "Location",
                  "text": "Belgium",
                  "disambiguation": {
                    "subtype": [
                      "Country"
                    ]
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "includes",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "communications, onboard computing and decision support solutions, and perimeter vision, self-protection and navigation systems",
              "keywords": [
                {
                  "text": "perimeter vision"
                },
                {
                  "text": "navigation systems"
                },
                {
                  "text": "support solutions"
                },
                {
                  "text": "decision"
                }
              ],
              "entities": []
            },
            "sentence": " As with France’s Scorpion program, under this contract Thales is in charge of common combat vetronics, including communications, onboard computing and decision support solutions, and perimeter vision, self-protection and navigation systems.",
            "object": {
              "text": "common combat vetronics",
              "keywords": [
                {
                  "text": "common combat"
                },
                {
                  "text": "vetronics"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "including",
              "normalized": "include"
            }
          },
          {
            "subject": {
              "text": "the whole story with recent events",
              "keywords": [
                {
                  "text": "recent events"
                },
                {
                  "text": "story"
                }
              ]
            },
            "sentence": " Keep reading for the whole story with recent events put in context Griffon",
            "object": {
              "text": "in context Griffon",
              "keywords": [
                {
                  "text": "context Griffon"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "put",
                "tense": "past"
              },
              "text": "put",
              "normalized": "put"
            }
          },
          {
            "subject": {
              "text": "France",
              "keywords": [
                {
                  "text": "France"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "France",
                  "disambiguation": {
                    "subtype": [
                      "Region",
                      "AdministrativeDivision",
                      "Country",
                      "GovernmentalJurisdiction",
                      "FilmDirector",
                      "Country"
                    ],
                    "name": "France",
                    "dbpedia_resource": "http://dbpedia.org/resource/France"
                  }
                }
              ]
            },
            "sentence": " In 2009 France was planning to start delivering by 2015 new multirole armored vehicles to replace a variety of aging infantry vehicles starting, within a large modernization program called Scorpion.",
            "object": {
              "text": "to start delivering by 2015 new multirole armored vehicles to replace a variety of aging infantry vehicles starting",
              "keywords": [
                {
                  "text": "multirole armored vehicles"
                },
                {
                  "text": "infantry vehicles"
                },
                {
                  "text": "variety"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "plan",
                "tense": "past"
              },
              "text": "planning",
              "normalized": "plan"
            }
          },
          {
            "subject": {
              "text": "a large modernization program",
              "keywords": [
                {
                  "text": "large modernization program"
                }
              ]
            },
            "sentence": " In 2009 France was planning to start delivering by 2015 new multirole armored vehicles to replace a variety of aging infantry vehicles starting, within a large modernization program called Scorpion.",
            "object": {
              "text": "Scorpion",
              "keywords": [
                {
                  "text": "Scorpion"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Scorpion",
                  "disambiguation": {
                    "subtype": [],
                    "name": "Ronn Motor Company",
                    "dbpedia_resource": "http://dbpedia.org/resource/Ronn_Motor_Company"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "call",
                "tense": "past"
              },
              "text": "called",
              "normalized": "call"
            }
          },
          {
            "subject": {
              "text": "a number of rosy assumptions",
              "keywords": [
                {
                  "text": "rosy assumptions"
                },
                {
                  "text": "number"
                }
              ]
            },
            "sentence": " But the 2010-14 multiyear budget relied on a number of rosy assumptions that were soon disproved by reality, and the Scorpion program was one of the mismatch’s casualties, along with plans to start working on a second aircraft carrier .",
            "object": {
              "text": "soon disproved by reality",
              "keywords": [
                {
                  "text": "reality"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "were",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "by reality",
              "keywords": [
                {
                  "text": "reality"
                }
              ]
            },
            "sentence": " But the 2010-14 multiyear budget relied on a number of rosy assumptions that were soon disproved by reality, and the Scorpion program was one of the mismatch’s casualties, along with plans to start working on a second aircraft carrier .",
            "object": {
              "text": "a number of rosy assumptions",
              "keywords": [
                {
                  "text": "rosy assumptions"
                },
                {
                  "text": "number"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "disprove",
                "tense": "past"
              },
              "text": "disproved",
              "normalized": "disprove"
            }
          },
          {
            "subject": {
              "text": "the Scorpion program",
              "keywords": [
                {
                  "text": "Scorpion program"
                }
              ]
            },
            "sentence": " But the 2010-14 multiyear budget relied on a number of rosy assumptions that were soon disproved by reality, and the Scorpion program was one of the mismatch’s casualties, along with plans to start working on a second aircraft carrier .",
            "object": {
              "text": "one of the mismatch’s casualties",
              "keywords": [
                {
                  "text": "mismatch"
                },
                {
                  "text": "casualties"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "was",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Promises"
            },
            "sentence": " Promises were made again in the next 5-year budget plan, while maintenance costs kept increasing to sustain vehicles offering an underwhelming mix of limited protection, autonomy, and mobility.",
            "object": {
              "text": "made again in the next 5-year budget plan",
              "keywords": [
                {
                  "text": "5-year budget plan"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "5-year"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "past"
              },
              "text": "were",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "Promises"
            },
            "sentence": " Promises were made again in the next 5-year budget plan, while maintenance costs kept increasing to sustain vehicles offering an underwhelming mix of limited protection, autonomy, and mobility.",
            "action": {
              "verb": {
                "text": "make",
                "tense": "past"
              },
              "text": "were made",
              "normalized": "be make"
            }
          },
          {
            "subject": {
              "text": "maintenance costs",
              "keywords": [
                {
                  "text": "maintenance costs"
                }
              ]
            },
            "sentence": " Promises were made again in the next 5-year budget plan, while maintenance costs kept increasing to sustain vehicles offering an underwhelming mix of limited protection, autonomy, and mobility.",
            "object": {
              "text": "increasing to sustain vehicles offering an underwhelming mix of limited protection, autonomy, and mobility",
              "keywords": [
                {
                  "text": "underwhelming mix"
                },
                {
                  "text": "limited protection"
                },
                {
                  "text": "autonomy"
                },
                {
                  "text": "mobility"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "keep",
                "tense": "past"
              },
              "text": "kept",
              "normalized": "keep"
            }
          },
          {
            "subject": {
              "text": "maintenance costs",
              "keywords": [
                {
                  "text": "maintenance costs"
                }
              ]
            },
            "sentence": " Promises were made again in the next 5-year budget plan, while maintenance costs kept increasing to sustain vehicles offering an underwhelming mix of limited protection, autonomy, and mobility.",
            "object": {
              "text": "vehicles offering an underwhelming mix of limited protection, autonomy, and mobility",
              "keywords": [
                {
                  "text": "underwhelming mix"
                },
                {
                  "text": "limited protection"
                },
                {
                  "text": "autonomy"
                },
                {
                  "text": "mobility"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "sustain",
                "tense": "future"
              },
              "text": "kept increasing to sustain",
              "normalized": "keep increase to sustain"
            }
          },
          {
            "subject": {
              "text": "Scorpion",
              "keywords": [
                {
                  "text": "Scorpion"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Scorpion",
                  "disambiguation": {
                    "subtype": [],
                    "name": "Ronn Motor Company",
                    "dbpedia_resource": "http://dbpedia.org/resource/Ronn_Motor_Company"
                  }
                }
              ]
            },
            "sentence": " French defense manufacturers also started to sound the alarm as Scorpion became increasingly vital to prevent factory closures.",
            "object": {
              "text": "increasingly vital to prevent factory closures",
              "keywords": [
                {
                  "text": "factory closures"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "become",
                "tense": "past"
              },
              "text": "became",
              "normalized": "become"
            }
          },
          {
            "subject": {
              "text": "French defense manufacturers",
              "keywords": [
                {
                  "text": "French defense manufacturers"
                }
              ]
            },
            "sentence": " French defense manufacturers also started to sound the alarm as Scorpion became increasingly vital to prevent factory closures.",
            "object": {
              "text": "factory closures",
              "keywords": [
                {
                  "text": "factory closures"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "prevent",
                "tense": "future"
              },
              "text": "to prevent",
              "normalized": "to prevent"
            }
          },
          {
            "subject": {
              "text": "The French DGA defense procurement agency",
              "keywords": [
                {
                  "text": "DGA defense procurement"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "DGA"
                }
              ]
            },
            "sentence": " The French DGA defense procurement agency paid heed to their plea and issued a tender limited to national manufacturers.",
            "object": {
              "text": "a tender limited",
              "keywords": [
                {
                  "text": "tender"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "issue",
                "tense": "past"
              },
              "text": "issued",
              "normalized": "issue"
            }
          },
          {
            "subject": {
              "text": "a tender",
              "keywords": [
                {
                  "text": "tender"
                }
              ]
            },
            "sentence": " The French DGA defense procurement agency paid heed to their plea and issued a tender limited to national manufacturers.",
            "object": {
              "text": "to national manufacturers",
              "keywords": [
                {
                  "text": "national manufacturers"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "limit",
                "tense": "past"
              },
              "text": "limited",
              "normalized": "limit"
            }
          },
          {
            "subject": {
              "text": "the ministry of defense",
              "keywords": [
                {
                  "text": "ministry"
                },
                {
                  "text": "defense"
                }
              ]
            },
            "sentence": " By the end of 2014 the ministry of defense finally initiated the 1st procurement tranche of a program expected to last beyond 2025.",
            "action": {
              "verb": {
                "text": "initiate",
                "tense": "past"
              },
              "text": "initiated",
              "normalized": "initiate"
            }
          },
          {
            "subject": {
              "text": "the expected turnaround from prototype to delivery in 4 to 6 years",
              "keywords": [
                {
                  "text": "turnaround"
                },
                {
                  "text": "prototype"
                },
                {
                  "text": "delivery"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "6 years"
                }
              ]
            },
            "sentence": " On one hand, the expected turnaround from prototype to delivery in 4 to 6 years is tight and will put pressure on contractors, though they started some early conceptual work in 2010.",
            "object": {
              "text": "tight"
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "pressure",
              "keywords": [
                {
                  "text": "pressure"
                }
              ]
            },
            "sentence": " On one hand, the expected turnaround from prototype to delivery in 4 to 6 years is tight and will put pressure on contractors, though they started some early conceptual work in 2010.",
            "object": {
              "text": "on contractors",
              "keywords": [
                {
                  "text": "contractors"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "put",
                "tense": "future"
              },
              "text": "will put",
              "normalized": "will put"
            }
          },
          {
            "subject": {
              "text": "they"
            },
            "sentence": " On one hand, the expected turnaround from prototype to delivery in 4 to 6 years is tight and will put pressure on contractors, though they started some early conceptual work in 2010.",
            "object": {
              "text": "some early conceptual work",
              "keywords": [
                {
                  "text": "early conceptual work"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "start",
                "tense": "past"
              },
              "text": "started",
              "normalized": "start"
            }
          },
          {
            "subject": {
              "text": "this"
            },
            "sentence": " On the other hand this still amounts to a late and light production schedule for the rest of the decade.",
            "object": {
              "text": "to a late and light production schedule",
              "keywords": [
                {
                  "text": "light production schedule"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "amount",
                "tense": "present"
              },
              "text": "amounts",
              "normalized": "amount"
            }
          },
          {
            "subject": {
              "text": "This major program",
              "keywords": [
                {
                  "text": "major program"
                }
              ]
            },
            "sentence": " This major program intends to rationalize a hodgepodge of aging land vehicles and systems while preserving France’s industrial base.",
            "object": {
              "text": "to rationalize a hodgepodge of aging land vehicles and systems",
              "keywords": [
                {
                  "text": "hodgepodge"
                },
                {
                  "text": "land vehicles"
                },
                {
                  "text": "systems"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "intend",
                "tense": "present"
              },
              "text": "intends",
              "normalized": "intend"
            }
          },
          {
            "subject": {
              "text": "This major program",
              "keywords": [
                {
                  "text": "major program"
                }
              ]
            },
            "sentence": " This major program intends to rationalize a hodgepodge of aging land vehicles and systems while preserving France’s industrial base.",
            "object": {
              "text": "a hodgepodge of aging land vehicles and systems",
              "keywords": [
                {
                  "text": "hodgepodge"
                },
                {
                  "text": "land vehicles"
                },
                {
                  "text": "systems"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "rationalize",
                "tense": "future"
              },
              "text": "intends to rationalize",
              "normalized": "intend to rationalize"
            }
          },
          {
            "subject": {
              "text": "This major program",
              "keywords": [
                {
                  "text": "major program"
                }
              ]
            },
            "sentence": " This major program intends to rationalize a hodgepodge of aging land vehicles and systems while preserving France’s industrial base.",
            "object": {
              "text": "France’s industrial base",
              "keywords": [
                {
                  "text": "industrial base"
                },
                {
                  "text": "France"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "France",
                  "disambiguation": {
                    "subtype": [
                      "Region",
                      "AdministrativeDivision",
                      "Country",
                      "GovernmentalJurisdiction",
                      "FilmDirector",
                      "Country"
                    ],
                    "name": "France",
                    "dbpedia_resource": "http://dbpedia.org/resource/France"
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "preserve",
                "tense": "present"
              },
              "text": "preserving",
              "normalized": "preserve"
            }
          },
          {
            "subject": {
              "text": "The 2 main vehicles",
              "keywords": [
                {
                  "text": "main vehicles"
                }
              ]
            },
            "sentence": " The 2 main vehicles in this program share a common chassis and will offer protection from mines and IEDs and ballistic threats at NATO’s STANAG 4569 Level 4.",
            "object": {
              "text": "protection",
              "keywords": [
                {
                  "text": "protection"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "offer",
                "tense": "future"
              },
              "text": "will offer",
              "normalized": "will offer"
            }
          },
          {
            "subject": {
              "text": "VBMRs",
              "keywords": [
                {
                  "text": "VBMRs"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "VBMRs"
                }
              ]
            },
            "sentence": " Dubbed “Griffon”, VBMRs will replace Véhicules de l’avant blindé (VAB) 4×4 infantry carriers acquired starting in 1976 and upgraded in the late 90s.",
            "object": {
              "text": "Véhicules de l’avant blindé (VAB) 4×4 infantry carriers acquired starting in 1976 and upgraded in the late 90s",
              "keywords": [
                {
                  "text": "infantry carriers"
                },
                {
                  "text": "late 90s"
                },
                {
                  "text": "l’avant blindé"
                },
                {
                  "text": "Véhicules"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "Véhicules de l’avant",
                  "disambiguation": {
                    "subtype": [
                      "City"
                    ]
                  }
                },
                {
                  "type": "Company",
                  "text": "VABs"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "replace",
                "tense": "future"
              },
              "text": "will replace",
              "normalized": "will replace"
            }
          },
          {
            "subject": {
              "text": "4×4 infantry carriers",
              "keywords": [
                {
                  "text": "infantry carriers"
                }
              ]
            },
            "sentence": " Dubbed “Griffon”, VBMRs will replace Véhicules de l’avant blindé (VAB) 4×4 infantry carriers acquired starting in 1976 and upgraded in the late 90s.",
            "action": {
              "verb": {
                "text": "acquire",
                "tense": "past"
              },
              "text": "acquired",
              "normalized": "acquire"
            }
          },
          {
            "subject": {
              "text": "carriers",
              "keywords": [
                {
                  "text": "carriers"
                }
              ]
            },
            "sentence": " Dubbed “Griffon”, VBMRs will replace Véhicules de l’avant blindé (VAB) 4×4 infantry carriers acquired starting in 1976 and upgraded in the late 90s.",
            "action": {
              "verb": {
                "text": "start",
                "tense": "present"
              },
              "text": "starting",
              "normalized": "start"
            }
          },
          {
            "subject": {
              "text": "The 6×6 designs",
              "keywords": [
                {
                  "text": "designs"
                }
              ]
            },
            "sentence": " The 6×6 designs will weight between 20 and 24 tons, with a remotely-operated 7.62mm or 12.7mm machine gun or a 40mm grenade launcher.",
            "object": {
              "text": "between 20 and 24 tons",
              "keywords": [
                {
                  "text": "tons"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "24 tons"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "weight",
                "tense": "future"
              },
              "text": "will weight",
              "normalized": "will weight"
            }
          },
          {
            "subject": {
              "text": "Deliveries",
              "keywords": [
                {
                  "text": "Deliveries"
                }
              ]
            },
            "sentence": " Deliveries should reach 780 units by 2025.",
            "object": {
              "text": "780 units",
              "keywords": [
                {
                  "text": "units"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "reach",
                "tense": "future"
              },
              "text": "should reach",
              "normalized": "should reach"
            }
          },
          {
            "subject": {
              "text": "The infantry transport version",
              "keywords": [
                {
                  "text": "infantry transport version"
                }
              ]
            },
            "sentence": " The infantry transport version will carry 8 troops in addition to the crew of 2.",
            "object": {
              "text": "8 troops",
              "keywords": [
                {
                  "text": "troops"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "carry",
                "tense": "future"
              },
              "text": "will carry",
              "normalized": "will carry"
            }
          },
          {
            "subject": {
              "text": "reconnaissance et de combat (EBRC)",
              "keywords": [
                {
                  "text": "reconnaissance et"
                },
                {
                  "text": "combat"
                },
                {
                  "text": "EBRC"
                }
              ]
            },
            "sentence": " 248 engins blindés de reconnaissance et de combat (EBRC)",
            "object": {
              "text": "248 engins blindés",
              "keywords": [
                {
                  "text": "engins blindés"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "de",
                "tense": "present"
              },
              "text": "de",
              "normalized": "de"
            }
          },
          {
            "subject": {
              "text": "EBRCs",
              "keywords": [
                {
                  "text": "EBRCs"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "EBRCs"
                }
              ]
            },
            "sentence": " Dubbed “Jaguar”, EBRCs will replace AMX10RC and Sagaie light tanks, as well as VABs in their HOT antitank configuration, to perform combat and reconnaissance missions.",
            "object": {
              "text": "AMX10RC and Sagaie light tanks",
              "keywords": [
                {
                  "text": "Sagaie light tanks"
                },
                {
                  "text": "AMX10RC"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "replace",
                "tense": "future"
              },
              "text": "will replace",
              "normalized": "will replace"
            }
          },
          {
            "subject": {
              "text": "These legacy vehicles",
              "keywords": [
                {
                  "text": "legacy"
                },
                {
                  "text": "vehicles"
                }
              ]
            },
            "sentence": " These legacy vehicles lost mobility and autonomy with upgrades, but their design remains vulnerable to current threats, and they have become expensive to maintain given their average age.",
            "object": {
              "text": "mobility and autonomy",
              "keywords": [
                {
                  "text": "autonomy"
                },
                {
                  "text": "mobility"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "lose",
                "tense": "past"
              },
              "text": "lost",
              "normalized": "lose"
            }
          },
          {
            "subject": {
              "text": "they"
            },
            "sentence": " These legacy vehicles lost mobility and autonomy with upgrades, but their design remains vulnerable to current threats, and they have become expensive to maintain given their average age.",
            "object": {
              "text": "become expensive"
            },
            "action": {
              "verb": {
                "text": "have",
                "tense": "present"
              },
              "text": "have",
              "normalized": "have"
            }
          },
          {
            "subject": {
              "text": "they"
            },
            "sentence": " These legacy vehicles lost mobility and autonomy with upgrades, but their design remains vulnerable to current threats, and they have become expensive to maintain given their average age.",
            "object": {
              "text": "expensive"
            },
            "action": {
              "verb": {
                "text": "become",
                "tense": "past"
              },
              "text": "have become",
              "normalized": "have become"
            }
          },
          {
            "subject": {
              "text": "VABs for instance",
              "keywords": [
                {
                  "text": "instance"
                },
                {
                  "text": "VABs"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "VABs"
                }
              ]
            },
            "sentence": " VABs for instance grew from an initial 13 tons to about 16 tons in the latest Ultima configuration.",
            "object": {
              "text": "from an initial 13 tons",
              "keywords": [
                {
                  "text": "tons"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "13 tons"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "grow",
                "tense": "past"
              },
              "text": "grew",
              "normalized": "grow"
            }
          },
          {
            "subject": {
              "text": "Jaguar",
              "keywords": [
                {
                  "text": "Jaguar"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                }
              ]
            },
            "sentence": " Jaguar is a 6×6 wheeled 25-ton design with a crew of 3.",
            "object": {
              "text": "a 6×6 wheeled 25-ton design",
              "keywords": [
                {
                  "text": "25-ton design"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Jaguar"
                },
                {
                  "type": "Quantity",
                  "text": "25-ton"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "be",
                "tense": "present"
              },
              "text": "is",
              "normalized": "be"
            }
          },
          {
            "subject": {
              "text": "it"
            },
            "sentence": " For armament it will be fitted with a 40mm cannon jointly developed by Nexter and BAE with a 1,500m reach, a remote-controlled 7.62mm machine gun, and MBDA’s MMP (3,500, reach).",
            "object": {
              "text": "For armament",
              "keywords": [
                {
                  "text": "armament"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "fit",
                "tense": "future"
              },
              "text": "will be fitted",
              "normalized": "will be fit"
            }
          },
          {
            "subject": {
              "text": "by Nexter and BAE",
              "keywords": [
                {
                  "text": "BAE"
                },
                {
                  "text": "Nexter"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "Nexter",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "Company"
                    ],
                    "name": "Nexter",
                    "dbpedia_resource": "http://dbpedia.org/resource/Nexter"
                  }
                },
                {
                  "type": "Company",
                  "text": "BAE",
                  "disambiguation": {
                    "subtype": [
                      "Organization",
                      "AircraftManufacturer"
                    ],
                    "name": "BAE Systems",
                    "dbpedia_resource": "http://dbpedia.org/resource/BAE_Systems"
                  }
                }
              ]
            },
            "sentence": " For armament it will be fitted with a 40mm cannon jointly developed by Nexter and BAE with a 1,500m reach, a remote-controlled 7.62mm machine gun, and MBDA’s MMP (3,500, reach).",
            "object": {
              "text": "a 40mm cannon",
              "keywords": [
                {
                  "text": "40mm"
                },
                {
                  "text": "cannon"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "40mm"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "develop",
                "tense": "past"
              },
              "text": "developed",
              "normalized": "develop"
            }
          },
          {
            "subject": {
              "text": "Deliveries",
              "keywords": [
                {
                  "text": "Deliveries"
                }
              ]
            },
            "sentence": " Deliveries should reach 110 units by 2025.",
            "object": {
              "text": "110 units",
              "keywords": [
                {
                  "text": "units"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "reach",
                "tense": "future"
              },
              "text": "should reach",
              "normalized": "should reach"
            }
          },
          {
            "subject": {
              "text": "4-ton Véhicules Blindés Légers (Light armored vehicles",
              "keywords": [
                {
                  "text": "4-ton Véhicules Blindés"
                },
                {
                  "text": "Légers"
                },
                {
                  "text": "Light"
                },
                {
                  "text": "vehicles"
                }
              ],
              "entities": [
                {
                  "type": "Person",
                  "text": "Véhicules Blindés Légers"
                },
                {
                  "type": "Quantity",
                  "text": "4-ton"
                }
              ]
            },
            "sentence": " This 10-ton 4×4 design will replace 4-ton Véhicules Blindés Légers (Light armored vehicles) procured since 1990.",
            "object": {
              "text": "This 10-ton 4×4 design",
              "keywords": [
                {
                  "text": "design"
                }
              ],
              "entities": [
                {
                  "type": "Quantity",
                  "text": "10-ton"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "replace",
                "tense": "future"
              },
              "text": "will replace",
              "normalized": "will replace"
            }
          },
          {
            "subject": {
              "text": "Deliveries between 2021 and 2025",
              "keywords": [
                {
                  "text": "Deliveries"
                }
              ]
            },
            "sentence": " Deliveries between 2021 and 2025 should reach 200 vehicles.",
            "object": {
              "text": "200 vehicles",
              "keywords": [
                {
                  "text": "vehicles"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "reach",
                "tense": "future"
              },
              "text": "should reach",
              "normalized": "should reach"
            }
          },
          {
            "subject": {
              "text": "6 separate legacy systems",
              "keywords": [
                {
                  "text": "separate legacy systems"
                }
              ]
            },
            "sentence": " This common communications platform will replace 6 separate legacy systems, starting in 2016.",
            "object": {
              "text": "This common communications platform",
              "keywords": [
                {
                  "text": "common communications platform"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "replace",
                "tense": "future"
              },
              "text": "will replace",
              "normalized": "will replace"
            }
          },
          {
            "subject": {
              "text": "This"
            },
            "sentence": " This looks somewhat like an extraneous graft in this program, so that France doesn’t give up entirely on what’s left of its battle tank fleet.",
            "object": {
              "text": "an extraneous graft",
              "keywords": [
                {
                  "text": "extraneous graft"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "look",
                "tense": "present"
              },
              "text": "looks",
              "normalized": "look"
            }
          },
          {
            "subject": {
              "text": "France",
              "keywords": [
                {
                  "text": "France"
                }
              ],
              "entities": [
                {
                  "type": "Location",
                  "text": "France",
                  "disambiguation": {
                    "subtype": [
                      "Region",
                      "AdministrativeDivision",
                      "Country",
                      "GovernmentalJurisdiction",
                      "FilmDirector",
                      "Country"
                    ],
                    "name": "France",
                    "dbpedia_resource": "http://dbpedia.org/resource/France"
                  }
                }
              ]
            },
            "sentence": " This looks somewhat like an extraneous graft in this program, so that France doesn’t give up entirely on what’s left of its battle tank fleet.",
            "object": {
              "text": "n’t give up entirely on what’s left of its battle tank fleet",
              "keywords": [
                {
                  "text": "battle tank fleet"
                },
                {
                  "text": "n’t"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "do",
                "tense": "present"
              },
              "text": "does",
              "normalized": "do"
            }
          },
          {
            "subject": {
              "text": "by the French defense procurement agency (DGA)",
              "keywords": [
                {
                  "text": "French defense procurement"
                },
                {
                  "text": "DGA"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "DGA"
                }
              ]
            },
            "sentence": " The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium includes 60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR).",
            "object": {
              "text": "The CaMo contract",
              "keywords": [
                {
                  "text": "CaMo contract"
                }
              ]
            },
            "action": {
              "verb": {
                "text": "award",
                "tense": "past"
              },
              "text": "awarded",
              "normalized": "award"
            }
          },
          {
            "subject": {
              "text": "60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR)",
              "keywords": [
                {
                  "text": "multi-role armored vehicles"
                },
                {
                  "text": "Jaguar reconnaissance"
                },
                {
                  "text": "combat vehicles"
                },
                {
                  "text": "Griffon"
                }
              ],
              "entities": [
                {
                  "type": "Company",
                  "text": "EBRCs"
                },
                {
                  "type": "Organization",
                  "text": "VBMR"
                }
              ]
            },
            "sentence": " The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium includes 60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR).",
            "object": {
              "text": "The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium",
              "keywords": [
                {
                  "text": "French defense procurement"
                },
                {
                  "text": "CaMo contract"
                },
                {
                  "text": "DGA"
                },
                {
                  "text": "behalf"
                }
              ],
              "entities": [
                {
                  "type": "Organization",
                  "text": "DGA"
                },
                {
                  "type": "Location",
                  "text": "Belgium",
                  "disambiguation": {
                    "subtype": [
                      "Country"
                    ]
                  }
                }
              ]
            },
            "action": {
              "verb": {
                "text": "include",
                "tense": "present"
              },
              "text": "includes",
              "normalized": "include"
            }
          }
        ],
        "concepts": [
          {
            "text": "Armoured personnel carrier",
            "relevance": 0.988118,
            "dbpedia_resource": "http://dbpedia.org/resource/Armoured_personnel_carrier"
          },
          {
            "text": "Vehicle armour",
            "relevance": 0.801784,
            "dbpedia_resource": "http://dbpedia.org/resource/Vehicle_armour"
          },
          {
            "text": "Armoured fighting vehicle",
            "relevance": 0.764899,
            "dbpedia_resource": "http://dbpedia.org/resource/Armoured_fighting_vehicle"
          },
          {
            "text": "Tank",
            "relevance": 0.716142,
            "dbpedia_resource": "http://dbpedia.org/resource/Tank"
          },
          {
            "text": "Infantry fighting vehicle",
            "relevance": 0.679163,
            "dbpedia_resource": "http://dbpedia.org/resource/Infantry_fighting_vehicle"
          },
          {
            "text": "Vehicle",
            "relevance": 0.595057,
            "dbpedia_resource": "http://dbpedia.org/resource/Vehicle"
          },
          {
            "text": "Armoured recovery vehicle",
            "relevance": 0.541116,
            "dbpedia_resource": "http://dbpedia.org/resource/Armoured_recovery_vehicle"
          }
        ],
        "categories": [
          {
            "score": 0.952935,
            "label": "/automotive and vehicles/vehicle brands"
          },
          {
            "score": 0.86044,
            "label": "/law, govt and politics/armed forces/air force"
          },
          {
            "score": 0.812436,
            "label": "/business and industrial/business operations"
          }
        ],
        "relations": [
          {
            "type": "employedBy",
            "sentence": "France Finally Kickstarts Scorpion Land Vehicle Acquisition Jul 17, 2019 04:58 UTC by Defense Industry Daily staff Latest update [?",
            "score": 0.734994,
            "arguments": [
              {
                "text": "Jul",
                "location": [
                  60,
                  63
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Jul"
                  }
                ]
              },
              {
                "text": "Kickstarts Scorpion Land Vehicle Acquisition",
                "location": [
                  15,
                  59
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Kickstarts Scorpion Land Vehicle Acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The French DGA defense procurement agency paid heed to their plea and issued a tender limited to national manufacturers.",
            "score": 0.858008,
            "arguments": [
              {
                "text": "defense",
                "location": [
                  1579,
                  1586
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Defense Industry Daily staff Latest"
                  }
                ]
              },
              {
                "text": "DGA",
                "location": [
                  1575,
                  1578
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "DGA",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "By the end of 2014 the ministry of defense finally initiated the 1st procurement tranche of a program expected to last beyond 2025.",
            "score": 0.666831,
            "arguments": [
              {
                "text": "ministry",
                "location": [
                  1708,
                  1716
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Armed Forces Ministry",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "defense",
                "location": [
                  1720,
                  1727
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Defense Industry Daily staff Latest"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "Jaguar is a 6×6 wheeled 25-ton design with a crew of 3.",
            "score": 0.81274,
            "arguments": [
              {
                "text": "crew",
                "location": [
                  3789,
                  3793
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "infantry"
                  }
                ]
              },
              {
                "text": "ton",
                "location": [
                  3771,
                  3774
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Ambulance"
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "200 overhauled Leclerc XL tanks This looks somewhat like an extraneous graft in this program, so that France doesn't give up entirely on what's left of its battle tank fleet.",
            "score": 0.546594,
            "arguments": [
              {
                "text": "its",
                "location": [
                  4514,
                  4517
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "its"
                  }
                ]
              },
              {
                "text": "fleet",
                "location": [
                  4530,
                  4535
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "fleet"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Contracts and Events July 17/19: Scorpion Role-Model for Belgium According to Thales , Belgium selected the company for onboard intelligence and data capabilities of its Land Forces.",
            "score": 0.491607,
            "arguments": [
              {
                "text": "Scorpion",
                "location": [
                  4570,
                  4578
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "multi-billion Scorpion"
                  }
                ]
              },
              {
                "text": "Thales",
                "location": [
                  4615,
                  4621
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Thales",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Contracts and Events July 17/19: Scorpion Role-Model for Belgium According to Thales , Belgium selected the company for onboard intelligence and data capabilities of its Land Forces.",
            "score": 0.46618,
            "arguments": [
              {
                "text": "company",
                "location": [
                  4645,
                  4652
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Kickstarts Scorpion Land Vehicle Acquisition"
                  }
                ]
              },
              {
                "text": "Belgium",
                "location": [
                  4624,
                  4631
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Belgium",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Contracts and Events July 17/19: Scorpion Role-Model for Belgium According to Thales , Belgium selected the company for onboard intelligence and data capabilities of its Land Forces.",
            "score": 0.907528,
            "arguments": [
              {
                "text": "Land Forces",
                "location": [
                  4707,
                  4718
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Land Forces"
                  }
                ]
              },
              {
                "text": "its",
                "location": [
                  4703,
                  4706
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Kickstarts Scorpion Land Vehicle Acquisition"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium includes 60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR).",
            "score": 0.602264,
            "arguments": [
              {
                "text": "defense",
                "location": [
                  4760,
                  4767
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Defense Industry Daily staff Latest"
                  }
                ]
              },
              {
                "text": "awarded",
                "location": [
                  4738,
                  4745
                ],
                "entities": [
                  {
                    "type": "EntertainmentAward",
                    "text": "awarded"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "July 10/18: Mk 3 in full production French defense manufacturer Arquus is now in full production if its Mk 3 6×6 Vehicule de l'Avant Blinde (VAB).",
            "score": 0.845752,
            "arguments": [
              {
                "text": "defense manufacturer",
                "location": [
                  5211,
                  5231
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Arquus Hornet"
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  5204,
                  5210
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "June 19/18: Hornet RCWS unveiled Jane's reports that France's Arquus Hornet remote controlled weapon system (RCWS).",
            "score": 0.72623,
            "arguments": [
              {
                "text": "Arquus Hornet",
                "location": [
                  5871,
                  5884
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Arquus Hornet"
                  }
                ]
              },
              {
                "text": "France",
                "location": [
                  5862,
                  5868
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "July 10/18: Mk 3 in full production French defense manufacturer Arquus is now in full production if its Mk 3 6×6 Vehicule de l'Avant Blinde (VAB).",
            "score": 0.398527,
            "arguments": [
              {
                "text": "Avant Blinde",
                "location": [
                  5295,
                  5307
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Avant Blinde"
                  }
                ]
              },
              {
                "text": "VAB",
                "location": [
                  5309,
                  5312
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "VAB Hot"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "France Finally Kickstarts Scorpion Land Vehicle Acquisition Jul 17, 2019 04:58 UTC by Defense Industry Daily staff Latest update [?",
            "score": 0.574603,
            "arguments": [
              {
                "text": "Defense Industry Daily staff Latest",
                "location": [
                  86,
                  121
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Defense Industry Daily staff Latest"
                  }
                ]
              },
              {
                "text": "UTC",
                "location": [
                  79,
                  82
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "UTC"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "It is equipped with a remote weapons station that can also be found on the French Army's Griffon armored personnel carriers.",
            "score": 0.326313,
            "arguments": [
              {
                "text": "weapons",
                "location": [
                  5516,
                  5523
                ],
                "entities": [
                  {
                    "type": "Weapon",
                    "text": "weapons"
                  }
                ]
              },
              {
                "text": "station",
                "location": [
                  5524,
                  5531
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "station"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "It is equipped with a remote weapons station that can also be found on the French Army's Griffon armored personnel carriers.",
            "score": 0.981214,
            "arguments": [
              {
                "text": "Army",
                "location": [
                  5569,
                  5573
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  5562,
                  5568
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The newly developed system will equip the future French Army's fleet of armored fighting vehicles.",
            "score": 0.981771,
            "arguments": [
              {
                "text": "Army",
                "location": [
                  5981,
                  5985
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  5974,
                  5980
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The vehicle is a key element in the French Army's $12 billion Scorpion modernization program.",
            "score": 0.982041,
            "arguments": [
              {
                "text": "Army",
                "location": [
                  7032,
                  7036
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  7025,
                  7031
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "November 28/17: Tender Award French government-owned weapons manufacturer Nexter has won out against a unit of Swedish-owned Volvo—Renault Trucks Defense (RTD)—in a tender to design and produce a light multirole reconnaissance vehicle, dubbed \"Light VBMR,\" for the French Army.",
            "score": 0.967092,
            "arguments": [
              {
                "text": "Army",
                "location": [
                  8166,
                  8170
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  8159,
                  8165
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The vehicle is being procured as part of the French Army's Scorpion program , where Nexter are already involved as joint prime contractor for the Jaguar combat reconnaissance vehicle and Griffon multirole troop carrier.",
            "score": 0.949591,
            "arguments": [
              {
                "text": "Army",
                "location": [
                  8351,
                  8355
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  8344,
                  8350
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The Griffon featured in the parade was one of two prototype vehicles undergoing certification tests by the French Army and Direction Générale de l'Armement (DGA)—its procurement office—with four more currently on order with manufacturers Nexter, Renault Trucks Defense and Thales.",
            "score": 0.954874,
            "arguments": [
              {
                "text": "Army",
                "location": [
                  9901,
                  9905
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  9894,
                  9900
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Paris is likely to use the Griffon to replace the VAB Hot personnel carriers currently used by the French Army, while the Jaguar will replace the army's wheeled light tanks.",
            "score": 0.888064,
            "arguments": [
              {
                "text": "Army",
                "location": [
                  11065,
                  11069
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  11058,
                  11064
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "productOf",
            "sentence": "It is equipped with a remote weapons station that can also be found on the French Army's Griffon armored personnel carriers.",
            "score": 0.846855,
            "arguments": [
              {
                "text": "Griffon",
                "location": [
                  5576,
                  5583
                ],
                "entities": [
                  {
                    "type": "Product",
                    "text": "Griffon multirole"
                  }
                ]
              },
              {
                "text": "Army",
                "location": [
                  5569,
                  5573
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "June 19/18: Hornet RCWS unveiled Jane's reports that France's Arquus Hornet remote controlled weapon system (RCWS).",
            "score": 0.710505,
            "arguments": [
              {
                "text": "June",
                "location": [
                  5809,
                  5813
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "June"
                  }
                ]
              },
              {
                "text": "unveiled",
                "location": [
                  5833,
                  5841
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "unveiled"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "June 19/18: Hornet RCWS unveiled Jane's reports that France's Arquus Hornet remote controlled weapon system (RCWS).",
            "score": 0.616274,
            "arguments": [
              {
                "text": "19/18",
                "location": [
                  5814,
                  5819
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "19/18"
                  }
                ]
              },
              {
                "text": "unveiled",
                "location": [
                  5833,
                  5841
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "unveiled"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "June 19/18: Hornet RCWS unveiled Jane's reports that France's Arquus Hornet remote controlled weapon system (RCWS).",
            "score": 0.996575,
            "arguments": [
              {
                "text": "Hornet RCWS",
                "location": [
                  5821,
                  5832
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Hornet RCWS"
                  }
                ]
              },
              {
                "text": "unveiled",
                "location": [
                  5833,
                  5841
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "unveiled"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "June 19/18: Hornet RCWS unveiled Jane's reports that France's Arquus Hornet remote controlled weapon system (RCWS).",
            "score": 0.945868,
            "arguments": [
              {
                "text": "Jane",
                "location": [
                  5842,
                  5846
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Jane"
                  }
                ]
              },
              {
                "text": "reports",
                "location": [
                  5849,
                  5856
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "reports"
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "June 19/18: Hornet RCWS unveiled Jane's reports that France's Arquus Hornet remote controlled weapon system (RCWS).",
            "score": 0.536649,
            "arguments": [
              {
                "text": "France",
                "location": [
                  5862,
                  5868
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "weapon",
                "location": [
                  5903,
                  5909
                ],
                "entities": [
                  {
                    "type": "Weapon",
                    "text": "weapon"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "June 19/18: Hornet RCWS unveiled Jane's reports that France's Arquus Hornet remote controlled weapon system (RCWS).",
            "score": 0.622985,
            "arguments": [
              {
                "text": "Arquus Hornet",
                "location": [
                  5871,
                  5884
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Arquus Hornet"
                  }
                ]
              },
              {
                "text": "RCWS",
                "location": [
                  5918,
                  5922
                ],
                "entities": [
                  {
                    "type": "Ticker",
                    "text": "RCWS"
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "The newly developed system will equip the future French Army's fleet of armored fighting vehicles.",
            "score": 0.773217,
            "arguments": [
              {
                "text": "Army",
                "location": [
                  5981,
                  5985
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "fleet",
                "location": [
                  5988,
                  5993
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "fleet"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium includes 60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR).",
            "score": 0.602264,
            "arguments": [
              {
                "text": "defense",
                "location": [
                  323,
                  330
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Defense Industry Daily staff Latest"
                  }
                ]
              },
              {
                "text": "awarded",
                "location": [
                  301,
                  308
                ],
                "entities": [
                  {
                    "type": "EntertainmentAward",
                    "text": "awarded"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "Arquus is already a protected vehicle and integrated support market leader, and a major player in the Scorpion program .",
            "score": 0.379425,
            "arguments": [
              {
                "text": "leader",
                "location": [
                  6092,
                  6098
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "leader"
                  }
                ]
              },
              {
                "text": "Arquus",
                "location": [
                  6024,
                  6030
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Arquus Hornet"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "France is ordering more Light-VBMR reconnaissance vehicles.",
            "score": 0.611827,
            "arguments": [
              {
                "text": "France",
                "location": [
                  6811,
                  6817
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "ordering",
                "location": [
                  6821,
                  6829
                ],
                "entities": [
                  {
                    "type": "EventLegal",
                    "text": "ordering"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "The 15-ton vehicle is designed to carry 10 troops and can be deployed in several configurations.",
            "score": 0.414004,
            "arguments": [
              {
                "text": "ton",
                "location": [
                  7321,
                  7324
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Ambulance"
                  }
                ]
              },
              {
                "text": "vehicle",
                "location": [
                  7325,
                  7332
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The 15-ton vehicle is designed to carry 10 troops and can be deployed in several configurations.",
            "score": 0.859747,
            "arguments": [
              {
                "text": "troops",
                "location": [
                  7357,
                  7363
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "members"
                  }
                ]
              },
              {
                "text": "vehicle",
                "location": [
                  7325,
                  7332
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The vehicle is armed with a remote controlled 7.62mm machine gun, a minigun at the rear and self-protection with a Galix smoke dispenser and can be airlifted by C-130 and A400M transport aircraft.",
            "score": 0.601342,
            "arguments": [
              {
                "text": "gun",
                "location": [
                  7620,
                  7623
                ],
                "entities": [
                  {
                    "type": "Weapon",
                    "text": "gun"
                  }
                ]
              },
              {
                "text": "vehicle",
                "location": [
                  7563,
                  7570
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "November 28/17: Tender Award French government-owned weapons manufacturer Nexter has won out against a unit of Swedish-owned Volvo—Renault Trucks Defense (RTD)—in a tender to design and produce a light multirole reconnaissance vehicle, dubbed \"Light VBMR,\" for the French Army.",
            "score": 0.465925,
            "arguments": [
              {
                "text": "weapons manufacturer",
                "location": [
                  7947,
                  7967
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Nexter",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  7923,
                  7929
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "November 28/17: Tender Award French government-owned weapons manufacturer Nexter has won out against a unit of Swedish-owned Volvo—Renault Trucks Defense (RTD)—in a tender to design and produce a light multirole reconnaissance vehicle, dubbed \"Light VBMR,\" for the French Army.",
            "score": 0.301608,
            "arguments": [
              {
                "text": "Swedish-owned Volvo",
                "location": [
                  8005,
                  8024
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Swedish-owned Volvo"
                  }
                ]
              },
              {
                "text": "Renault Trucks Defense",
                "location": [
                  8025,
                  8047
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Renault Trucks Defense and Thales"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "November 28/17: Tender Award French government-owned weapons manufacturer Nexter has won out against a unit of Swedish-owned Volvo—Renault Trucks Defense (RTD)—in a tender to design and produce a light multirole reconnaissance vehicle, dubbed \"Light VBMR,\" for the French Army.",
            "score": 0.526762,
            "arguments": [
              {
                "text": "Swedish-owned Volvo",
                "location": [
                  8005,
                  8024
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Swedish-owned Volvo"
                  }
                ]
              },
              {
                "text": "vehicle",
                "location": [
                  8121,
                  8128
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The winning firm was informed unofficially last week ahead of the eventual official announcement by the Armed Forces Ministry.",
            "score": 0.843627,
            "arguments": [
              {
                "text": "Armed Forces Ministry",
                "location": [
                  8276,
                  8297
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Armed Forces Ministry",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "announcement",
                "location": [
                  8256,
                  8268
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announcement"
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "The vehicle is being procured as part of the French Army's Scorpion program , where Nexter are already involved as joint prime contractor for the Jaguar combat reconnaissance vehicle and Griffon multirole troop carrier.",
            "score": 0.467067,
            "arguments": [
              {
                "text": "troop",
                "location": [
                  8504,
                  8509
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "troop"
                  }
                ]
              },
              {
                "text": "carrier",
                "location": [
                  8510,
                  8517
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Ambulance"
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "Thales supplies the Contact system and is an industrial partner with Nexter and Renault Trucks Defense on the Griffon troop carrier as well as the Jaguar reconnaissance and combat vehicle being developed under the Scorpion program.",
            "score": 0.594569,
            "arguments": [
              {
                "text": "troop",
                "location": [
                  9532,
                  9537
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "troop"
                  }
                ]
              },
              {
                "text": "carrier",
                "location": [
                  9538,
                  9545
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Ambulance"
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "July 26/17: France placed its new Griffon multirole troop carrier on public display during this year's Bastille Day celebrations on July 14.",
            "score": 0.590509,
            "arguments": [
              {
                "text": "troop",
                "location": [
                  9698,
                  9703
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "troop"
                  }
                ]
              },
              {
                "text": "carrier",
                "location": [
                  9704,
                  9711
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Ambulance"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium includes 60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR).",
            "score": 0.928508,
            "arguments": [
              {
                "text": "defense",
                "location": [
                  323,
                  330
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Defense Industry Daily staff Latest"
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  316,
                  322
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The CaMo contract awarded by the French defense procurement agency (DGA) on behalf of Belgium includes 60 Jaguar reconnaissance and combat vehicles (EBRC) and 382 Griffon multi-role armored vehicles (VBMR).",
            "score": 0.928508,
            "arguments": [
              {
                "text": "defense",
                "location": [
                  4760,
                  4767
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Defense Industry Daily staff Latest"
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  4753,
                  4759
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Despite having earlier highlighted the strategic importance of winning the competition, an RTD exec said that losing the Light VBMR deal \"is a pity, but not catastrophic.",
            "score": 0.964511,
            "arguments": [
              {
                "text": "RTD exec",
                "location": [
                  8610,
                  8618
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Renault Trucks Defense and Thales"
                  }
                ]
              },
              {
                "text": "said",
                "location": [
                  8619,
                  8623
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "said"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "The two vehicles will replace some 3,000 ageing VAB troop carriers.",
            "score": 0.759329,
            "arguments": [
              {
                "text": "troop carriers",
                "location": [
                  8870,
                  8884
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "troop carriers"
                  }
                ]
              },
              {
                "text": "vehicles",
                "location": [
                  8826,
                  8834
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Ambulance"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The comments were made to Parliament by former chief of staff Army Gen. Pierre de Villiers prior to his resignation on July 19.",
            "score": 0.498972,
            "arguments": [
              {
                "text": "Parliament",
                "location": [
                  9065,
                  9075
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Parliament",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "comments",
                "location": [
                  9043,
                  9051
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "comments"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "The comments were made to Parliament by former chief of staff Army Gen. Pierre de Villiers prior to his resignation on July 19.",
            "score": 0.572315,
            "arguments": [
              {
                "text": "chief of staff",
                "location": [
                  9086,
                  9100
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Pierre"
                  }
                ]
              },
              {
                "text": "Army",
                "location": [
                  9101,
                  9105
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "The comments were made to Parliament by former chief of staff Army Gen. Pierre de Villiers prior to his resignation on July 19.",
            "score": 0.721532,
            "arguments": [
              {
                "text": "Gen.",
                "location": [
                  9106,
                  9110
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Pierre"
                  }
                ]
              },
              {
                "text": "Army",
                "location": [
                  9101,
                  9105
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "The comments were made to Parliament by former chief of staff Army Gen. Pierre de Villiers prior to his resignation on July 19.",
            "score": 0.527612,
            "arguments": [
              {
                "text": "his",
                "location": [
                  9139,
                  9142
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Pierre"
                  }
                ]
              },
              {
                "text": "resignation",
                "location": [
                  9143,
                  9154
                ],
                "entities": [
                  {
                    "type": "EventPersonnel",
                    "text": "resignation"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "The comments were made to Parliament by former chief of staff Army Gen. Pierre de Villiers prior to his resignation on July 19.",
            "score": 0.949109,
            "arguments": [
              {
                "text": "July 19",
                "location": [
                  9158,
                  9165
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "July 19"
                  }
                ]
              },
              {
                "text": "resignation",
                "location": [
                  9143,
                  9154
                ],
                "entities": [
                  {
                    "type": "EventPersonnel",
                    "text": "resignation"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "\"If we do not receive the required funding, we will need to postpone this program, with all the consequences that will entail,\" he said, adding that Contact—a key software-defined radio used on the program's vehicles—is expected to be a casualty.",
            "score": 0.968409,
            "arguments": [
              {
                "text": "he",
                "location": [
                  9295,
                  9297
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Pierre"
                  }
                ]
              },
              {
                "text": "said",
                "location": [
                  9298,
                  9302
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "adding"
                  }
                ]
              }
            ]
          },
          {
            "type": "productOf",
            "sentence": "Thales supplies the Contact system and is an industrial partner with Nexter and Renault Trucks Defense on the Griffon troop carrier as well as the Jaguar reconnaissance and combat vehicle being developed under the Scorpion program.",
            "score": 0.552823,
            "arguments": [
              {
                "text": "Griffon",
                "location": [
                  9524,
                  9531
                ],
                "entities": [
                  {
                    "type": "Product",
                    "text": "Griffon multirole"
                  }
                ]
              },
              {
                "text": "Renault Trucks Defense",
                "location": [
                  9494,
                  9516
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Renault Trucks Defense and Thales"
                  }
                ]
              }
            ]
          },
          {
            "type": "participantIn",
            "sentence": "Thales supplies the Contact system and is an industrial partner with Nexter and Renault Trucks Defense on the Griffon troop carrier as well as the Jaguar reconnaissance and combat vehicle being developed under the Scorpion program.",
            "score": 0.758599,
            "arguments": [
              {
                "text": "Renault Trucks Defense",
                "location": [
                  9494,
                  9516
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Renault Trucks Defense and Thales"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  9561,
                  9567
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "participantIn",
            "sentence": "The same group is also developing the Jaguar, a combat vehicle designed to share common equipment with the Griffon.",
            "score": 0.693133,
            "arguments": [
              {
                "text": "group",
                "location": [
                  10077,
                  10082
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Renault Trucks Defense and Thales"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  10106,
                  10112
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "productOf",
            "sentence": "July 26/17: France placed its new Griffon multirole troop carrier on public display during this year's Bastille Day celebrations on July 14.",
            "score": 0.828458,
            "arguments": [
              {
                "text": "Griffon multirole",
                "location": [
                  9680,
                  9697
                ],
                "entities": [
                  {
                    "type": "Product",
                    "text": "Griffon multirole"
                  }
                ]
              },
              {
                "text": "its",
                "location": [
                  9672,
                  9675
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "its"
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "As with France's Scorpion program, under this contract Thales is in charge of common combat vetronics, including communications, onboard computing and decision support solutions, and perimeter vision, self-protection and navigation systems.",
            "score": 0.429822,
            "arguments": [
              {
                "text": "Scorpion",
                "location": [
                  507,
                  515
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "multi-billion Scorpion"
                  }
                ]
              },
              {
                "text": "France",
                "location": [
                  498,
                  504
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "As with France's Scorpion program, under this contract Thales is in charge of common combat vetronics, including communications, onboard computing and decision support solutions, and perimeter vision, self-protection and navigation systems.",
            "score": 0.429822,
            "arguments": [
              {
                "text": "Scorpion",
                "location": [
                  4944,
                  4952
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "multi-billion Scorpion"
                  }
                ]
              },
              {
                "text": "France",
                "location": [
                  4935,
                  4941
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "managerOf",
            "sentence": "August 9/17: France's Scorpion modernization program is likely to suffer a funding hit as Paris looks to skim $1 billion off this year's defense budget.",
            "score": 0.521209,
            "arguments": [
              {
                "text": "Scorpion",
                "location": [
                  8908,
                  8916
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "multi-billion Scorpion"
                  }
                ]
              },
              {
                "text": "France",
                "location": [
                  8899,
                  8905
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "July 26/17: France placed its new Griffon multirole troop carrier on public display during this year's Bastille Day celebrations on July 14.",
            "score": 0.472822,
            "arguments": [
              {
                "text": "its",
                "location": [
                  9672,
                  9675
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "its"
                  }
                ]
              },
              {
                "text": "carrier",
                "location": [
                  9704,
                  9711
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Ambulance"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "The Griffon featured in the parade was one of two prototype vehicles undergoing certification tests by the French Army and Direction Générale de l'Armement (DGA)—its procurement office—with four more currently on order with manufacturers Nexter, Renault Trucks Defense and Thales.",
            "score": 0.40028,
            "arguments": [
              {
                "text": "Nexter",
                "location": [
                  10025,
                  10031
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Nexter",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "manufacturers",
                "location": [
                  10011,
                  10024
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "manufacturers",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "The Griffon featured in the parade was one of two prototype vehicles undergoing certification tests by the French Army and Direction Générale de l'Armement (DGA)—its procurement office—with four more currently on order with manufacturers Nexter, Renault Trucks Defense and Thales.",
            "score": 0.35611,
            "arguments": [
              {
                "text": "Renault Trucks Defense and Thales",
                "location": [
                  10033,
                  10066
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Renault Trucks Defense and Thales"
                  }
                ]
              },
              {
                "text": "manufacturers",
                "location": [
                  10011,
                  10024
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "manufacturers",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "Both vehicles are being developed under France's Project Scorpion —a $6.8 billion multi-company modernization effort that aims to replace all of France's frontline fighting vehicles with improved platforms linked with a new and unified communications and battlefield management system (BMS).",
            "score": 0.859613,
            "arguments": [
              {
                "text": "company",
                "location": [
                  10272,
                  10279
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Kickstarts Scorpion Land Vehicle Acquisition"
                  }
                ]
              },
              {
                "text": "$6.8 billion",
                "location": [
                  10253,
                  10265
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$6.8 billion",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "ownerOf",
            "sentence": "Both vehicles are being developed under France's Project Scorpion —a $6.8 billion multi-company modernization effort that aims to replace all of France's frontline fighting vehicles with improved platforms linked with a new and unified communications and battlefield management system (BMS).",
            "score": 0.574538,
            "arguments": [
              {
                "text": "France",
                "location": [
                  10329,
                  10335
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "vehicles",
                "location": [
                  10357,
                  10365
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Ambulance"
                  }
                ]
              }
            ]
          },
          {
            "type": "affiliatedWith",
            "sentence": "Thales, Nexter, and Renault Trucks Defense will deliver over 300 models of the Griffon , a 6×6 multi-role personnel carrier, and the 6×6 Jaguar, which is armed with a 40mm gun and anti-tank missiles.",
            "score": 0.448607,
            "arguments": [
              {
                "text": "carrier",
                "location": [
                  10736,
                  10743
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Renault Trucks Defense and Thales"
                  }
                ]
              },
              {
                "text": "personnel",
                "location": [
                  10726,
                  10735
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "personnel"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "Paris is likely to use the Griffon to replace the VAB Hot personnel carriers currently used by the French Army, while the Jaguar will replace the army's wheeled light tanks.",
            "score": 0.31726,
            "arguments": [
              {
                "text": "personnel",
                "location": [
                  11017,
                  11026
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "personnel"
                  }
                ]
              },
              {
                "text": "VAB Hot",
                "location": [
                  11009,
                  11016
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "VAB Hot"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "Paris is likely to use the Griffon to replace the VAB Hot personnel carriers currently used by the French Army, while the Jaguar will replace the army's wheeled light tanks.",
            "score": 0.550006,
            "arguments": [
              {
                "text": "carriers",
                "location": [
                  11027,
                  11035
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "personnel carriers"
                  }
                ]
              },
              {
                "text": "personnel",
                "location": [
                  11017,
                  11026
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "personnel"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "June 14/16: The French government has pledged $6.7 billion over 11 years for the Army's Scorpion modernization program , with more being sought by both the Army and industry members involved.",
            "score": 0.901509,
            "arguments": [
              {
                "text": "French government",
                "location": [
                  11149,
                  11166
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "pledged",
                "location": [
                  11171,
                  11178
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "pledged"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "June 14/16: The French government has pledged $6.7 billion over 11 years for the Army's Scorpion modernization program , with more being sought by both the Army and industry members involved.",
            "score": 0.407832,
            "arguments": [
              {
                "text": "French government",
                "location": [
                  11149,
                  11166
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "$6.7 billion",
                "location": [
                  11179,
                  11191
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$6.7 billion",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "Keep reading for the whole story with recent events put in context Griffon In 2009 France was planning to start delivering by 2015 new multirole armored vehicles to replace a variety of aging infantry vehicles starting, within a large modernization program called Scorpion.",
            "score": 0.451846,
            "arguments": [
              {
                "text": "vehicles",
                "location": [
                  884,
                  892
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Ambulance"
                  }
                ]
              },
              {
                "text": "vehicles",
                "location": [
                  932,
                  940
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "vehicles"
                  }
                ]
              }
            ]
          },
          {
            "type": "hasAttribute",
            "sentence": "June 14/16: The French government has pledged $6.7 billion over 11 years for the Army's Scorpion modernization program , with more being sought by both the Army and industry members involved.",
            "score": 0.526581,
            "arguments": [
              {
                "text": "Army",
                "location": [
                  11214,
                  11218
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "$6.7 billion",
                "location": [
                  11179,
                  11191
                ],
                "entities": [
                  {
                    "type": "Money",
                    "text": "$6.7 billion",
                    "disambiguation": {
                      "subtype": [
                        "Gainloss"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "June 14/16: The French government has pledged $6.7 billion over 11 years for the Army's Scorpion modernization program , with more being sought by both the Army and industry members involved.",
            "score": 0.673236,
            "arguments": [
              {
                "text": "Scorpion",
                "location": [
                  11221,
                  11229
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "multi-billion Scorpion"
                  }
                ]
              },
              {
                "text": "Army",
                "location": [
                  11214,
                  11218
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Army",
                    "disambiguation": {
                      "subtype": [
                        "Military"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "Aspects of the program include the delivery of 780 Griffon multirole troop carriers and 248 units of the light multirole Jaguar combat vehicle by 2020.",
            "score": 0.447413,
            "arguments": [
              {
                "text": "troop carriers",
                "location": [
                  11394,
                  11408
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "troop carriers"
                  }
                ]
              },
              {
                "text": "Griffon multirole",
                "location": [
                  11376,
                  11393
                ],
                "entities": [
                  {
                    "type": "Facility",
                    "text": "Griffon multirole"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Aspects of the program include the delivery of 780 Griffon multirole troop carriers and 248 units of the light multirole Jaguar combat vehicle by 2020.",
            "score": 0.809819,
            "arguments": [
              {
                "text": "2020",
                "location": [
                  11471,
                  11475
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "2020"
                  }
                ]
              },
              {
                "text": "Jaguar",
                "location": [
                  11446,
                  11452
                ],
                "entities": [
                  {
                    "type": "SportingEvent",
                    "text": "Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "affectedBy",
            "sentence": "Aspects of the program include the delivery of 780 Griffon multirole troop carriers and 248 units of the light multirole Jaguar combat vehicle by 2020.",
            "score": 0.35537,
            "arguments": [
              {
                "text": "vehicle",
                "location": [
                  11460,
                  11467
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Jaguar"
                  }
                ]
              },
              {
                "text": "combat",
                "location": [
                  11453,
                  11459
                ],
                "entities": [
                  {
                    "type": "EventViolence",
                    "text": "combat"
                  }
                ]
              }
            ]
          },
          {
            "type": "timeOf",
            "sentence": "Aspects of the program include the delivery of 780 Griffon multirole troop carriers and 248 units of the light multirole Jaguar combat vehicle by 2020.",
            "score": 0.858832,
            "arguments": [
              {
                "text": "2020",
                "location": [
                  11471,
                  11475
                ],
                "entities": [
                  {
                    "type": "Date",
                    "text": "2020"
                  }
                ]
              },
              {
                "text": "combat",
                "location": [
                  11453,
                  11459
                ],
                "entities": [
                  {
                    "type": "EventViolence",
                    "text": "combat"
                  }
                ]
              }
            ]
          },
          {
            "type": "employedBy",
            "sentence": "French Defense Minister Jean-Yves le Drian announces the phase 1 award in the Scorpion program, in line with commitments made in the 2014-19 defense budget planning law known as LPM.",
            "score": 0.73816,
            "arguments": [
              {
                "text": "Defense Minister",
                "location": [
                  11655,
                  11671
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Jean-Yves le Drian"
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  11648,
                  11654
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "French Defense Minister Jean-Yves le Drian announces the phase 1 award in the Scorpion program, in line with commitments made in the 2014-19 defense budget planning law known as LPM.",
            "score": 0.998526,
            "arguments": [
              {
                "text": "Jean-Yves le Drian",
                "location": [
                  11672,
                  11690
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Jean-Yves le Drian"
                  }
                ]
              },
              {
                "text": "announces",
                "location": [
                  11691,
                  11700
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "announces"
                  }
                ]
              }
            ]
          },
          {
            "type": "awardedTo",
            "sentence": "French Defense Minister Jean-Yves le Drian announces the phase 1 award in the Scorpion program, in line with commitments made in the 2014-19 defense budget planning law known as LPM.",
            "score": 0.666475,
            "arguments": [
              {
                "text": "award",
                "location": [
                  11713,
                  11718
                ],
                "entities": [
                  {
                    "type": "EntertainmentAward",
                    "text": "award"
                  }
                ]
              },
              {
                "text": "Scorpion",
                "location": [
                  11726,
                  11734
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "multi-billion Scorpion"
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Les Echos reports that the DGA procurement agency restricted its tender to French manufacturers, and cited article 346 of the European Union Treaty to exclude bids from other member states.",
            "score": 0.977536,
            "arguments": [
              {
                "text": "Les Echos",
                "location": [
                  12239,
                  12248
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Les Echos",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "reports",
                "location": [
                  12249,
                  12256
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "reports"
                  }
                ]
              }
            ]
          },
          {
            "type": "locatedAt",
            "sentence": "But the 2010-14 multiyear budget relied on a number of rosy assumptions that were soon disproved by reality, and the Scorpion program was one of the mismatch's casualties, along with plans to start working on a second aircraft carrier .",
            "score": 0.544323,
            "arguments": [
              {
                "text": "casualties",
                "location": [
                  1165,
                  1175
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "casualties"
                  }
                ]
              },
              {
                "text": "aircraft carrier",
                "location": [
                  1223,
                  1239
                ],
                "entities": [
                  {
                    "type": "Vehicle",
                    "text": "Jaguar"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Les Echos reports that the DGA procurement agency restricted its tender to French manufacturers, and cited article 346 of the European Union Treaty to exclude bids from other member states.",
            "score": 0.724922,
            "arguments": [
              {
                "text": "manufacturers",
                "location": [
                  12321,
                  12334
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "manufacturers",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "its",
                "location": [
                  12300,
                  12303
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "Renault Trucks Defense and Thales"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Les Echos reports that the DGA procurement agency restricted its tender to French manufacturers, and cited article 346 of the European Union Treaty to exclude bids from other member states.",
            "score": 0.825168,
            "arguments": [
              {
                "text": "manufacturers",
                "location": [
                  12321,
                  12334
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "manufacturers",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  12314,
                  12320
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "agentOf",
            "sentence": "Les Echos reports that the DGA procurement agency restricted its tender to French manufacturers, and cited article 346 of the European Union Treaty to exclude bids from other member states.",
            "score": 0.503249,
            "arguments": [
              {
                "text": "manufacturers",
                "location": [
                  12321,
                  12334
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "manufacturers",
                    "disambiguation": {
                      "subtype": [
                        "Commercial"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "cited",
                "location": [
                  12340,
                  12345
                ],
                "entities": [
                  {
                    "type": "EventCommunication",
                    "text": "cited"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "Les Echos reports that the DGA procurement agency restricted its tender to French manufacturers, and cited article 346 of the European Union Treaty to exclude bids from other member states.",
            "score": 0.231605,
            "arguments": [
              {
                "text": "member",
                "location": [
                  12414,
                  12420
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "Renault Trucks Defense and Thales"
                  }
                ]
              },
              {
                "text": "states",
                "location": [
                  12421,
                  12427
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "states"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "Readings and Sources French MINDEF - Official Scorpion presentation [PDF, in French] DGA - Scorpion [in French]",
            "score": 0.880915,
            "arguments": [
              {
                "text": "French MINDEF – Official Scorpion",
                "location": [
                  12838,
                  12871
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "French MINDEF – Official Scorpion"
                  }
                ]
              },
              {
                "text": "Sources",
                "location": [
                  12830,
                  12837
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Sources"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOfMany",
            "sentence": "Readings and Sources French MINDEF - Official Scorpion presentation [PDF, in French] DGA - Scorpion [in French]",
            "score": 0.669536,
            "arguments": [
              {
                "text": "Scorpion",
                "location": [
                  12908,
                  12916
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "multi-billion Scorpion"
                  }
                ]
              },
              {
                "text": "Sources",
                "location": [
                  12830,
                  12837
                ],
                "entities": [
                  {
                    "type": "Person",
                    "text": "Sources"
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "French defense manufacturers also started to sound the alarm as Scorpion became increasingly vital to prevent factory closures.",
            "score": 0.957669,
            "arguments": [
              {
                "text": "defense manufacturers",
                "location": [
                  1443,
                  1464
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "defense manufacturers"
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  1436,
                  1442
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          },
          {
            "type": "partOf",
            "sentence": "The French DGA defense procurement agency paid heed to their plea and issued a tender limited to national manufacturers.",
            "score": 0.944774,
            "arguments": [
              {
                "text": "DGA",
                "location": [
                  1575,
                  1578
                ],
                "entities": [
                  {
                    "type": "Organization",
                    "text": "DGA",
                    "disambiguation": {
                      "subtype": [
                        "Government"
                      ]
                    }
                  }
                ]
              },
              {
                "text": "French",
                "location": [
                  1568,
                  1574
                ],
                "entities": [
                  {
                    "type": "GeopoliticalEntity",
                    "text": "French government",
                    "disambiguation": {
                      "subtype": [
                        "Country"
                      ]
                    }
                  }
                ]
              }
            ]
          }
        ],
        "keywords": [
          {
            "text": "French defense procurement agency",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.640777,
            "count": 2
          },
          {
            "text": "France’s Scorpion program",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.604754,
            "count": 2
          },
          {
            "text": "combat vehicles",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.592759,
            "count": 2
          },
          {
            "text": "Defense Industry Daily staff",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.586851,
            "count": 1
          },
          {
            "text": "French defense manufacturers",
            "sentiment": {
              "score": -0.901526,
              "label": "negative"
            },
            "relevance": 0.574704,
            "count": 1
          },
          {
            "text": "Jaguar reconnaissance",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.566444,
            "count": 3
          },
          {
            "text": "Scorpion Role-Model",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.553337,
            "count": 2
          },
          {
            "text": "light production schedule",
            "sentiment": {
              "score": -0.594211,
              "label": "negative"
            },
            "relevance": 0.551403,
            "count": 1
          },
          {
            "text": "French DGA defense procurement agency",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.550211,
            "count": 1
          },
          {
            "text": "large modernization program",
            "sentiment": {
              "score": 0.566347,
              "label": "positive"
            },
            "relevance": 0.550139,
            "count": 1
          },
          {
            "text": "Hornet RCWS",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.546843,
            "count": 1
          },
          {
            "text": "French Army’s Griffon",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.54522,
            "count": 1
          },
          {
            "text": "Renault Trucks Defense",
            "sentiment": {
              "score": -0.592324,
              "label": "negative"
            },
            "relevance": 0.542004,
            "count": 6
          },
          {
            "text": "navigation systems",
            "sentiment": {
              "score": 0.566347,
              "label": "positive"
            },
            "relevance": 0.538578,
            "count": 2
          },
          {
            "text": "French defense manufacturer Arquus",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.536767,
            "count": 1
          },
          {
            "text": "context Griffon",
            "sentiment": {
              "score": 0.566347,
              "label": "positive"
            },
            "relevance": 0.536513,
            "count": 1
          },
          {
            "text": "troop transport",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.535084,
            "count": 1
          },
          {
            "text": "7.62mm",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.534801,
            "count": 1
          },
          {
            "text": "Véhicules de l’avant blindé",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.534165,
            "count": 1
          },
          {
            "text": "charge of common combat vetronics",
            "sentiment": {
              "score": 0.566347,
              "label": "positive"
            },
            "relevance": 0.531427,
            "count": 2
          },
          {
            "text": "next 5-year budget plan",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.531365,
            "count": 1
          },
          {
            "text": "new multirole",
            "sentiment": {
              "score": 0.566347,
              "label": "positive"
            },
            "relevance": 0.529563,
            "count": 1
          },
          {
            "text": "major program",
            "sentiment": {
              "score": 0.922854,
              "label": "positive"
            },
            "relevance": 0.528709,
            "count": 2
          },
          {
            "text": "Tender Award",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.528285,
            "count": 1
          },
          {
            "text": "Scorpion program",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.5276,
            "count": 5
          },
          {
            "text": "second aircraft carrier",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.527572,
            "count": 1
          },
          {
            "text": "infantry vehicles",
            "sentiment": {
              "score": 0.566347,
              "label": "positive"
            },
            "relevance": 0.527449,
            "count": 1
          },
          {
            "text": "French government",
            "sentiment": {
              "score": -0.592324,
              "label": "negative"
            },
            "relevance": 0.526955,
            "count": 3
          },
          {
            "text": "self-protection",
            "sentiment": {
              "score": 0.566347,
              "label": "positive"
            },
            "relevance": 0.524189,
            "count": 3
          },
          {
            "text": "12.7mm machine gun",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.523378,
            "count": 1
          },
          {
            "text": "French Army",
            "sentiment": {
              "score": 0.922854,
              "label": "positive"
            },
            "relevance": 0.523254,
            "count": 4
          },
          {
            "text": "CaMo contract",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.523065,
            "count": 2
          },
          {
            "text": "reconnaissance missions",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.522903,
            "count": 1
          },
          {
            "text": "Kickstarts Scorpion Land Vehicle Acquisition Jul",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.521675,
            "count": 1
          },
          {
            "text": "Scorpion Acquisition VAB Ultima",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.521639,
            "count": 1
          },
          {
            "text": "France’s Arquus Hornet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.521236,
            "count": 1
          },
          {
            "text": "Sagaie light tanks",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.52098,
            "count": 1
          },
          {
            "text": "Griffon",
            "sentiment": {
              "score": -0.591306,
              "label": "negative"
            },
            "relevance": 0.520255,
            "count": 6
          },
          {
            "text": "start of Scorpion",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.520081,
            "count": 1
          },
          {
            "text": "1st procurement tranche of a program",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519692,
            "count": 1
          },
          {
            "text": "current order",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519634,
            "count": 1
          },
          {
            "text": "personnel carriers",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519498,
            "count": 1
          },
          {
            "text": "Development of the Mk",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.519188,
            "count": 1
          },
          {
            "text": "maintenance costs",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.518727,
            "count": 1
          },
          {
            "text": "remote weapons station",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.518452,
            "count": 1
          },
          {
            "text": "future French Army’s fleet",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.518213,
            "count": 1
          },
          {
            "text": "multiyear budget",
            "sentiment": {
              "score": 0.566347,
              "label": "positive"
            },
            "relevance": 0.517656,
            "count": 1
          },
          {
            "text": "France",
            "sentiment": {
              "score": 0.566347,
              "label": "positive"
            },
            "relevance": 0.517649,
            "count": 5
          },
          {
            "text": "funding hit",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517541,
            "count": 1
          },
          {
            "text": "armored fighting vehicles",
            "sentiment": {
              "score": 0,
              "label": "neutral"
            },
            "relevance": 0.517447,
            "count": 1
          }
        ]
      },
      "extracted_metadata": {
        "sha1": "756f574316fb376198f576ad49375a4c92fa3e25",
        "filename": "1563366847410.zip-de60d1b69aa6ed301d68e9baadc72a62.xml",
        "file_type": "json"
      },
      "external_links": [
        "http://www.janes.com/article/81582/arquus-reveals-more-roles-for-its-latest-vab-mk-3",
        "http://www.janes.com/article/81119/eurosatory-2018-arquus-readies-hornet-rcws",
        "http://www.defense.gouv.fr/dga/equipement/terrestre/le-programme-scorpion",
        "http://www.defensenews.com/story/defense-news/2016/06/12/key-french-army-modernization-program-scrambles-funding/85602036/",
        "https://www.defensenews.com/land/2017/11/26/in-a-blow-to-rtd-france-selects-nexter-for-light-multirole-vehicle/",
        "https://www.defensenews.com/digital-show-dailies/eurosatory/2018/06/08/france-to-double-military-vehicle-order-asking-for-multiple-variants/",
        "http://www.upi.com/Defense-News/2017/04/25/France-orders-new-armored-vehicles-from-Nexter-Renault-Thales/7991493129636/?utm_source=sec&utm_campaign=sl&utm_medium=6",
        "http://www.lesechos.fr/16/01/2014/lesechos.fr/0203247703546_blindes---l-armee-lance-un-appel-d-offres-de-plus-de-2-milliards-d-euros.htm",
        "https://www.thalesgroup.com/en/group/press-release/belgium-chooses-thales-onboard-intelligence-and-future-data-capabilities-its",
        "http://www.defensenews.com/land/2017/07/14/french-army-unveils-griffon-multirole-troop-carrier/",
        "https://www.eda.europa.eu/procurement-gateway/information/codeda-regulationaba/article-346-of-the-tfeu",
        "http://www.defesanet.com.br/en/eurosatory/noticia/29592/Arquus---The-Hornet-Remote-Controlled-Weapons-Stations-Range/",
        "http://defense-update.com/20180212_vbmr-l.html",
        "https://www.armyrecognition.com/french_army_france_wheeled_armoured_vehicle_uk/griffon_vbmr_6x6_multi-role_armoured_vehicle_ebmr_scorpion_technical_data_sheet_specifications.html",
        "https://www.army-technology.com/projects/jaguar-armoured-reconnaissance-and-combat-vehicle/",
        "http://www.defense.gouv.fr/content/download/328171/4523035/file/plaquette%20de%20pre%CC%81sentation%20SCORPION2.pdf",
        "https://www.arquus-defense.com/vab-mk-3“",
        "http://www.armyrecognition.com/french_army_france_wheeled_armoured_vehicle_uk/griffon_vbmr_6x6_multi-role_armoured_vehicle_ebmr_scorpion_technical_data_sheet_specifications.html",
        "https://www.defensenews.com/global/europe/2017/08/07/french-military-chief-scorpion-program-will-suffer-under-budget-cuts/?utm_source=Sailthru&utm_medium=email&utm_campaign=DFN%20DNR%208.7.17&utm_term=Editorial%20-%20Daily%20News%20Roundup"
      ],
      "title": "France Finally Kickstarts Scorpion Land Vehicle Acquisition",
      "forum_title": "Defense Industry Daily"
    }
  ]
}